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SUMMARY 
J l is well accepted that disturbances in the central synaptic transmission lead to a variety of 
neurological disorders. Numerous investigators have shown alterations in the levels of 
neurotransmitters due to change in activity of the enzymes involved in their synthesis, uptake, 
release and degradation. Neurotransmitter receptors depending upon the availability of their 
specific neurotransmitters at the site, exhibit alterations in their numbers and affinity. Such 
modulations in the receptor sensitivity have been observed in neurological disorders like 
Parkinson's disease, post traumatic seizure, Huntington's chorea, Alzheimer's disease and 
psychiatric disturbances such as schizophrenia and depressive disorders. Altered receptor 
sensitivity has also been reported on exposure to xenobiotics including drugs or after surgical 
destruction of specific neurons. 
Most of the direct information about the role of neurotransmitters in diseased conditions has 
been obtained using postmortem brain samples which are not reliable since conditions of 
collection and preservation of such samples are not uniform and there is hardly any choice of 
age, sex, or stage of the disease. Several techniques have been employed to quantitate the 
neurotransmitter receptors. Although the recent advances have lead to development in non-
invasive imaging techniques such as PET, SPECT and NMR for the assay neurotransmitters 
and neurotransmitter receptors in live brain. There are some limitations including the high 
cost of operation as well as expertise for their operation and interpretation of the data. The 
neuroscientists have therefore been interested in developing and validating a peripheral 
neuronal model, which can be used for the study of the neurotransmitter parameters in 
neuropsychiatric and neurotoxicological conditions. 
Circulating blood components such as lymphocytes and blood platelets have been used to 
study the uptake and release of certain neurotransmitters and neurotransmitter receptors. 
Alterations in the binding of ^H-spiperone to lymphocytes in Parkinsonism and Wilson 
disease and that ^H-dihydroalprenolol in depressed patients have reported. Several 
similarities between platelets and neuron with respect to morphology, biochemistry and 
pharmacology have further strengthened their usefulness as peripheral model. As the changes 
are specific and parallel with those observed in the brain, the assay of platelet receptors 
appears to be a useful tool for these studies. Such studies have not only helped in 
understanding the disease process but also in monitoring the disease condition during the 
course of treatment and follow up. With demonstration of several neurotransmitters and their 
receptor sites and related enzymes, platelets can be considered as multi-neurotransmitter sites 
similar to neurons. The use of blood platelets as a model system for the synaptic apparatus 
can however, be justified only for those parameters where it can be shown that blood platelets 
and nervous tissue share almost identical characteristics. Although platelets appear to be 
fascinating model to study the functions of brain, the mechanism by which dopamine and 
serotonin receptors are modulated is not clearly understood. The response of neurotoxicant 
and specificity to platelets is also not clear. Changes in the biochemical parameters in platelet 
such as neurotransmitter receptors and enzymes have been reported in disease condition or on 
exposure to toxicants but their validation is required to establish the use of platelets as 
peripheral model. 
In view of the above, present study was aimed investigate the mechanism of modulation of 
platelet DA-D2 and 5-HT2A, study the effect of selected neurotoxicants (Manganese, 6-
Hydroxydopamine and cypermethrin) on platelet and brain neurotransmitter receptors and 
membrane function parameters. Study was also aimed to investigate the status of platelet DA-
D2 and monoamine oxidase activity in idiopathic Parkinson's disease cases and status of 
platelet 5-HT2A receptor in clinical cases of migraine
Studies on the Mechanism of IModulation of Dopamine-Da and Serotonin-5-
HT2A Receptors in Platelets 
Both in vivo and vitro studies on human and rat platelets were undertaken to investigate the 
possible mechanism of modulation of DA-D2 and 5-HT2A receptors using selective 
pharmacological agent acting on dopaminergic and serotonergic systems respectively. 
Rats treated with reserpine at a dose of 1 mg/kg /day for 5 days showed a significant increase 
in the binding of ^H-spiperone to platelet (36%) and striatal (47%) membranes, known to 
label DA-D2 receptors as compared to controls. Reserpine at a dose of 5 mg/kg (single 
exposure) caused a decrease in the binding of ^H-spiperone to platelet (33 %) and striatal (44 
%) membranes at 18 hours after the treatment. Scatchard analysis revealed that the increase 
in the binding of ^H-spiperone to platelet and striatal membranes following daily reserpine 
treatment for 5 days and the decrease in binding following a single exposure was due to 
change in the affinity (Kj) with no significant change in the receptor number (Bmax)-
Incubation of platelet rich plasma (PRP) with reserpine at both the concentrations, (1 |ig/ml 
and 2 |ig/ml) caused a decrease in the binding of ^H-spiperone to platelet membranes by 37% 
and 42% respectively. It was, however, interesting to note that PRP preparations pre-
incubated with pargyline followed by incubation with reserpine showed a higher degree of 
decrease in the binding of ^H-spiperone to platelet membranes in comparison to those 
incubated with reserpine alone. A decrease in platelet ^H-spiperone binding was observed 
following incubation of PRP with dopamine (5, 15, 37 and 65%) and mazindol (2, 16, 30 and 
45%) at concentrations- 0.5,1, 5 and lOnM respectively. 
Binding of ^H-ketanserin to platelet membrane knovra to label 5-HT2A receptors was found to 
be decreased following incubation of PRP with clomipramine (4, 20, 43 and 56%), 
fenfluramine (2, 42, 61, and 69%) and serotonin (46, 64, 68 and 83%) at concentrations - 0.5, 
1, 5 and 10 nM respectively. The results suggest that the availability of dopamine and 
serotonin at the site influence the sensitivity of DA-D2 and 5-HT2A receptors respectively in 
platelets as in the brain. 
Effect of Manganese, 6-Hydroxydopamine and Cypermethrin on Selected 
Biochemical Parameters in Brain and Platelets 
With the understanding that the environmental chemicals like manganese (Mn) may cause 
extrapyramidal symptoms like Parkinsonism, there has been considerable interest to 
understand the possible mechanism of Mn induced neurotoxicity. Although there are 
convincing evidences concerning the role of dopamine in Mn neurotoxicity, several 
investigators have shown involvement of oxygen free radicals in the neurotoxic effects of this 
metal. As the occupational workers in the metal industries and mining are at a greater risk to 
Mn induced neurotoxicity, there is an urgent need of a validated peripheral test system which 
could be utilised to monitor such neurotoxicological disorders. Since blood platelets have 
been shown to reflect changes of the CNS and are proposed as a peripheral model, the present 
study was undertaken to investigate whether neurotoxic effect of Mn are reflected in platelets. 
Exposure of Mn (10 or 15 mg/kg bw, i.p) in adult rats for 45 days caused a significant 
increase in membrane fluidity as evidenced by decreased fluorescence polarisation (platelets 
11 and 14%, striatum 9 and 13%), intracellular calcium (platelets - 25 and 38%, striatum - 28 
and 40%) and superoxide dismutase (platelets - 23 and 37%, striatum - 31 and 42%) activity 
both in platelets and striatum in comparison to controls. A significant decrease was observed 
in the reduced glutathione content (platelets - 22%, striatum - 25%) and catalase activity 
(platelets - 35%, striatum - 44%) following exposure to Mn at a dose of 15 mg/kg body 
weight. Exposure of Mn at both the doses for 15 days also caused an increase in the binding 
of ^H-spiperone to striatal and platelet membranes in comparison to controls. The results 
suggest that exposure to Mn may alter the membrane functions and also impair the 
antioxidant defense mechanism both in the platelets and brain. 
Selective lesioning with 6-OHDA into brain causes destruction of nigrostriatal dopamine 
containing neurons and lead to behavioural and biochemical deficits. Earlier studies have 
shown the involvement of free radical mediated neurotoxicity in 6-OHDA lesioned rats and 
their effect on membrane related functions. In order to investigate whether neurotoxic effects 
of 6-OHDA are reflected in platelets, the present study was undertaken on rats and effect on 
selected biochemical parameters studied both in corpus striatum and platelets. Rats lesioned 
with 6-OHDA exhibited a significant increase in striatal dopamine receptors (61%), lipid 
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peroxidation (38%) and intracellular calcium (83%) and a decrease in reduced glutathione 
levels and membrane fluidity as evidenced by an increase in fluorescence polarization (20%) 
in comparison to sheim. Interestingly, a significant increase in the binding of ^H-spiperone to 
platelet membranes (43%) was observed in the 6-OHDA lesioned rats however, marginal 
changes were observed in all other parameters in platelets in these rats. The results suggest 
that alterations in striatal dopamine receptors following bilateral lesioning be reflected in 
platelets. 
Cypermethrin, a type II synthetic and photostable pyrethroid of high bio-efficacy is widely 
used in agriculture for pest management. Several reports exhibit its adverse effects on the 
CNS and cardiovascular functions. As the pesticide has been shown to be persistent in the 
environment and detected in mammalian tissues, it can pose risk to human health. Keeping 
this in view, studies were carried out to understand the mechanism of neurotoxicity and 
investigate whether such changes are reflected in platelets on selected biochemical 
parameters to validate usefulness of platelets as a peripheral model. Effect of cypermethrin 
(15 or 30 mg/kg) was studied on membrane fluidity, intracellular calcium, monoamine 
oxidase activity and DA-D2 receptors both in the platelets and brain of rats after 10 and 21 
days of exposure. A decrease in fluorescence polarization (7 and 12%) and monoamine 
oxidase activity (34 and 62%) in platelets was observed like corpus striatum (fluorescence 
polarization 8 and 13%, monoamine oxidase activity 29 and 49%) following exposure to 
cypermethrin for 21 days at both the doses i.e. 15 and 30 mg/kg respectively in comparison to 
controls. These rats also exhibited an increase in intracellular calcium levels (platelets - 24 
and 40%; corpus striatum -29 and 54%) 21 days after exposure at both the doses. 
Cypermethrin treatment in rats for 21 days also caused a decrease in the binding of ^H-
spiperone to platelet (36 and 49%) and striatal membranes (36 and 46%). No significant 
change on these parameters was observed in rats 10 days after exposure to cypermethrin at 
both the doses. Saturation studies revealed that the decrease in binding both in platelets and 
corpus striatal membranes was due to decreased maximum number of binding sites (Bmax) 
without any significant change in the affinity (Kd). Interestingly, changes in these 
biochemical parameters were restored to control values at the lower dose (15 mg/kg) and 
persisted at the higher dose (30 mg/kg) of cypermethrin both in platelets and corpus striatum 
following cessation of treatment for 10 days in the 21 days cypermethrin exposed group. The 
results suggest that exposure to cypermethrin may alter the membrane functions and 
dopaminergic functions, which are evident both in platelets and brain. 
Status of Some Biochemical Parameters in Platelets of Idiopathic Parkinson's 
Disease and Migraine Patients 
Parkinson's disease (PD) is a crippling neurodegenerative disease, which results from 
degeneration of dopaminergic neurons responsible for dopamine loss in the striatum. Various 
studies have shown the alteration in the dopamine receptors and monoamine oxidase activity 
in the brain of PD patients. Platelets have been used as peripheral neuronal model to study the 
reflections of brain biochemistry in PD. In the present study of dopamine (DA-D2) receptors 
and monoamine oxidase activity were measured in platelets of PD patients. Binding of ^H-
spiperone to platelet membranes known to label DA-D2 receptors was assayed in clinical 
cases of PD (n=25) and control subjects (n=13). The binding characteristics: equilibrium 
dissociation constant (Kj) and maximum number binding sites (Bmax) determined by 
scatchard analysis revealed a significant increase in the Bmax and no change in the affinity in 
the cases of Parkinson's disease in comparison to controls. A significant increase in the 
activity of monoamine oxidase was observed in Parkinson's cases in comparison to controls. 
No significant change in these parameters was observed while the data were analysed with 
respect to age, sex and clinical variables viz. duration and stage of disease. Results suggest 
alterations in the DA-D2 receptors and monoamine oxidase activity in platelets in Parkinson's 
disease. 
There is increasing evidence about the role serotonin in the pathogenesis of migraine and 
much attention has been focussed on understanding the functioning of serotonin receptors as 
its agonists have been found to alleviate the migraine pain. Keeping in view that platelets 
serves as a peripheral neuronal model, binding of ^H-ketanserin to platelet membranes known 
to label 5-HT2A receptors was investigated in clinical cases of migraine (n=33) and control 
subjects (n=30). The binding characteristics: equilibrium dissociation constant (Kd) and 
maximum number binding sites (Bmax) determined by scatchard analysis revealed a 
significant decrease in the affinity and no change in the Bmax in the cases of migraine in 
comparison to controls. However no correlation was observed in Kd and Bmax with respect to 
clinical features of migraine like duration disease, time since last attack, headache index, 
family history and type of migraine. The results of the study suggest alteration in the 
sensitivity of platelet 5-HT2a receptors in migraine. 
Conclusions 
The results of present study indicate that the availability of serotonin and dopamine at the site 
influence the sensitivity of 5-HT2A and DA-D2 receptors respectively in platelets and brain. 
Results of mangEinese exposure show that neurotoxicity of manganese mediates through 
increased oxidative stress and altered membrane functions as indicated by increased 
superoxide dismutase activity, membrane fluidity, intracellular calcium levels and decrease in 
catalase activity and reduced glutathione levels in both platelets and platelets. Manganese 
exposure also caused a parallel increase in dopamine receptors in platelets and brain. 
Cypermethrin a commonly used pesticide appear to exert its neurotoxic effects by altering 
membrane functions, which in turn probably, decrease the density of dopamine receptors. 
Study also shows that changes at higher dose of cypermethrin were persistent. The changes 
observed in brain were also exhibited in platelets. 
A result of 6-Hydroxydopamine lesioning in striatum shows parallel increase in dopamine 
receptors in platelets and brain. 
Parallel changes in platelets and striatum strengthened the usefulness of platelets as neuronal 
model for monitoring the changes induced by exposure to these chemicals. 
Results of clinical studies show that platelet DA-D2 receptors and monoamine oxidase-B 
(MAO-B) activity is high in Indian cases of Parkinson's disease treated with L-dopa. Results 
of clinical studies also reveal that affinity of platelet 5-HT2A receptors decreased in migraine 
patients. These studies suggest that assay of platelet DA-D2 receptor and MAO-B activity in 
Parkinson's disease and 5-HT2A receptors in migraine could be useful in monitoring the 
disease condition. 
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PREFACE 
With the rapid industrialisation, a large number of chemicals of varied nature and properties 
are being introduced in the environment to which man gets exposed directly and indirectly. 
The chemicals being increasingly used are metals, solvents, monomers, and a variety of other 
synthetic compounds. Most of these chemicals have been found to affect the central nervous 
system (CNS) and cause transient neurobehavioral changes to chronic disorders leading to 
crippling disease. Several reports on the role of environmental chemicals like manganese, 
paraquat & rotenone in causing Parkinson's disease and aluminium & lead in Alzheimer's 
disease have aroused a great concern among the scientists over the associated health 
problems. 
The role of neurotransmitters, their receptors and cellular signalling in functioning of the 
central nervous system is well established and alterations in their levels have been reported to 
lead to neuropsychiatric disorders like Parkinson's disease, schizophrenia, mental retardation, 
depression and others. The intricate process of synaptic transmission involves several 
important steps viz. synthesis, release, degradation, uptake of neurotransmitters and their 
binding with receptors and subsequent translation of the message. Even slight alteration at 
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any step can affect transmission process and alter the receptor sensitivity. A variety of 
substances including biogenic amines, acetylcholine, GABA, glutamic acid, glycine and 
peptides have been recognised as neurotransmitters. These substances either interact with ion 
channels and receptors directly for fast neurotransmission or through second messengers and 
modulate the biological response. Several studies have reported behavioural alterations 
following exposure to neurotoxicants and also in neuropsychiatric conditions. The receptor 
response maintains homeostasis and are instrumental in maintaining/controlling normal 
behaviour and play an important role in the functioning of the brain. 
The studies on autopsied samples of brain have provided valuable information about the 
mechanism of neuropsychiatric disorders but the reliability of the data is uncertain due to 
associated difficulties, such as proper isolation and preservation of the tissues, which could 
significantly affect the biomolecules. Moreover, choice of age, sex and stage of the disease 
and monitoring of biochemical alterations with progression of disease or treatment follow-up 
in humans are not possible. Availability of the non-invasive techniques like PET, SPECT and 
NMR has made possible to study the neurotransmitter function in vivo but their availability is 
limiting factor due to high cost. Realising these problems neuroscientists are trying to 
characterise and validate parameters in the peripheral fluids of humans as surrogate markers 
of dysfunction, damage or interactions involving neural targets of toxicants which could be 
used as marker to study the CNS functions. A number of peripheral tissues and fluids have 
been used as models for CNS function in health and disease including, lacrimal fluids, saliva, 
sweat, urine, blood and blood components and cerebrospinal fluids. Study of cerebrospinal in 
patients after lumbar puncture poses ethical considerations and are not preferred while studies 
on blood and blood components and urine in different neurological, psychiatric and 
neurotoxicological disorders are possible without any problems. Such studies have helped in 
developing the effect and exposure related markers, development of effective therapeutic 
drugs and better management of the patients. 
Platelets have been extensively used as an effective model to understand the functioning of 
the brain. Due to several similarities between platelets and neurons with respect to 
morphology, biochemistry and pharmacology, platelets have been proposed as a peripheral 
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model for neurons. Initially, platelets were proposed as model for presynaptic nerve terminals 
on account of their ability to accumulate, store and release biogenic amines such as serotonin, 
noradrenaline and dopamine. Subsequently, receptor binding sites for neurotransmitters 
(serotonin, dopamine, adrenergic, glutamate) and drugs (tricyclic anti-depressants, 
benzodiazepine and phencyclidine) have been demonstrated on platelets. Parallel changes 
between platelet and brain dopamine and serotonin receptors following exposure to selected 
drugs and neurotoxicants acting on dopaminergic and serotonergic systems respectively have 
further strengthened the usefulness of platelets as a peripheral model. The 5-HT uptake 
mechanisms or 5-HT transporter is an important part of the 5-HT system which can be 
measured by the number of binding sites for antidepressant drugs located on the 5-HT-
transporter in the membranes of serotonergic neurons or platelets. Human platelet 5-HT 
uptake site is identical with the human 5-HT transporter and the same single copy gene 
encodes both proteins. 5-HT2A receptors in human platelets have been found to modulate 
platelet shape change and regulate platelet aggregation. It has been suggested that 5-HT2A 
receptors in platelets and brain are under genetic control. Interestingly, the nucleotide 
sequence of 5-HT2A C D N A in platelets was found to be identical to that reported for the 
human frontal cortex 5-HT2A receptors except a minor difference at nucleotide 102. 
The platelet neurotransmitter binding sites have been found to be altered in neuropsychiatric 
conditions. The 5-HT2a receptors has been proposed as an effective model for 5-Hr2A 
receptors in brain and could serve as the window to CNS disorders linked to 5-HT2A 
receptors such as anxiety, depression and schizophrenia. An increase in platelets 5-HT2A 
receptors has been reported in suicide attempters and their assay in platelets has been 
suggested as a peripheral marker to monitor the suicide episodes. Alteration in platelet 
dopamine receptors in schizophrenia and Parkinson's disease has been reported and their 
assay has been found to be useful in the management of these disorders. 
Although platelets appear to be a promising peripheral model for CNS, the mechanism by 
which dopamine and serotonin receptors are altered in platelets is not known. The response 
of certain neurotoxicants like metals and pesticides on platelet dopamine receptors and other 
oxidative stress related parameters are also not clearly understood. 
Keeping this in view, the present study was aimed to investigate, 
i. the possible mechanism of modulation of dopamine and serotonin receptors in platelets 
by altering the availability of dopamine and serotonin respectively at the site. 
ii. the effect of selected neurotoxicants viz. manganese, cypermethrin and 6-OHDA on 
dopamine receptors and other parameters related with oxidative stress and membrane 
function. 
iii. the status of 5-HT2a receptors in platelets of migraine and dopamine receptors and 
monoamine oxidase activity in Parkinson's disease to study their relationship in the 
respective diseases and assess their usefulness as a peripheral model. 
It is the sincere hope of the author that these studies would provide valuable information on 
the basic mechanism of alteration of neurotransmitter receptors in platelets and help in 
developing and validating markers for neurological and psychiatric disorders. These studies 
would also strengthen the usefulness of platelets as a peripheral model for CNS. 
VI 
C H A P T E R - 1 
REVIEW OF PERTINENT LITERATURE 
PLATELETS 
Platelets, an important constituent of blood play several important physiological functions, of 
which homeostasis is the most important one. Platelets have been proposed since long as a 
neuronal model. Several neuroscientists have used it in understanding the brain fijnctions in 
neurotoxicological and neuropsychiatric conditions. Several exhaustive reviews have appeared 
time to time on this subject (Pletscher 1978; 1988; Stahl 1985; 1988; Rehavi et al., 1988; Seth 
et al., 1994; Seth and Khanna, 1991; 1999; Mendelson, 2000). The candidate has therefore 
attempted to review the present status of platelets related with neuropsychiatric and 
neurotoxicological conditions. 
Platelet: Formation and Function 
Platelets are the smallest of blood cells and have a critical role in normal haemostasis and 
important contributors to thrombotic disorders. The development of megakaryocytes and 
production of platelets is a unique process. Megakaryocyte maturation involves nuclear 
duplication without cell division, resulting in giant cells. Cytoplasmic organelles are organised 
into domains representing nascent platelets, demarcated by a network of invaginated plasma 
membranes. Within the bone marrow, megakaryocytes are localised next to the sinusoidal 
walls, which facilitates the exit of large segments of cytoplasm into the circulation. The 
fragmentation of megakaryocytes cytoplasm due tq shear forces of circulating blood, perhaps 
largely in the pulmonary circulation, lead to the formation of number of platelets at one time. 
(Behnke and Forer, 1998). 
Normally, platelets are discoid, refractile and 2-3 mM in diameter. On activation they change 
their shape from normal discoid to spherical with long dendritic extensions facilitating 
adhesion. The cytoplasm is rich in actin and myosin, which brings about the change in shape 
and retraction of the clot. The discoid shape of the resting platelets is maintained by the ring of 
microtubule running around the edge of the disc immediately below the plasma membranes. 
The cytoplasm of platelets contains mitochondria with sparse cristae and granules. Generally, 
two types of secretory granules, also known as vesicles, viz. dense granules and glycogen 
granules are present in platelets. The dense granules store ADP, calcium and biogenic amines 
and reinforce platelet aggregation and platelet surface coagulation reactions. The glycogen 
granules secrete a vast array of proteins like von Willebrand factor and platelet factor 4. 
Fibrinogen is taken up from the plasma by receptor-mediated endocytosis and plasma proteins, 
albumin and IgG, are acquired by fluid-phase pinocytosis and stored in glycogen granules 
(George, 1990). Platelets also contain lysosomal granules, the contents of which are released 
only after stimulation of platelets with powerful aggregating agents such as thrombin or high 
concentration of collagen. Both secretion and endocytosis are facilitated by a network of deep 
invaginations of platelet surface membrane, the surface-connected canalicular systems. In 
addition to the contents from these granules, activated platelets may release pharmacologically 
active freshly synthesised substances such as prostaglandins, tliromboxane Aj, platelet 
activating factor (FAF). These substances are known to activate other platelets and affect 
vascular tone and permeability (Seiss, 1989). 
Platelet counts vary in the circulation and range from 200-500 x IOVL (Jamaluddin, 1993). The 
life span of platelets is 10-12 days on an average and the newly formed platelets have greater 
functional ability. Around one third of circulating platelets are sequestered into spleen. Passive 
congestion due to increased portal venous pressure increase the fraction of platelets retained in 
splenic sinusoids without decreasing overall platelet survival time and lead to splenomegaly. 
This retention causes the mild tlirombocytopenia associated with liver cirrhosis and portal 
hypertension (Aster, 1966). Most platelets are removed from the circulation after senescence, 
but a constant small fraction is continually removed by involvement in the maintenance of 
vascular integrity. 
Platelets and Haemostasis 
The process of haemostasis is quite complex and involves several steps. Various glycoproteins 
from I to IX are involved in this important physiological function. The largest glycoprotein is 
designated I and the smallest as IX. With the resolution in the separation of single protein in to 
two separate bands on electrophoresis these proteins have been termed as a and b. (e.g. 
glycoprotein I is termed as glycoprotein la and lb). Platelet adhesion to subendothelial matrix 
followed by activation of platelets, their conformation change, release of ingredients from the 
vesicles and subsequently aggregation are the principal steps (Santoro and Zutter, 1995; Shattil 
et al., 1998; Santoso et al., 1999) 
In normal haemostasis, platelets adhere to the severed margins of a vessel within seconds to few 
minutes. The most important stimulus to such adherence is the exposure of collagen fibrils 
(Mustard and Packham, 1975). Platelets once attached undergo a transformation to become 
relatively smooth spheres, broadening the area of adhesion. Contractile proteins, actin and 
myosin and their numerous microtubules are largely involved in the change of their shape. Soon 
after adherence, platelets are activated £ind release the contents of their granules. This release 
reaction is an energy requiring process analogous to secretion in other cell systems. It is 
triggered by collagen, thrombin, trypsin, plasmin, antigen-antibody complexes, endotoxin and 
fatty acids and a number of other compounds. Besides these agents, biogenic amine mostly 
serotonin is also released from the vesicles following activation of platelets and participate in 
haemostasis. It also induces vasoconstriction of small arteries, arterioles and veins. It is believed 
that these stimuli to platelet activation inliibit membrane bound adenylyl cyclase, since 
decreased levels of cAMP have been reported in aggregated platelets. There is a simultaneous 
increase in intraplatelet concentration of calcium. Increase in this divalent cation is a potent 
stimulus to platelet activation (contraction aggregation, release). A phospholipid, platelet factor-
3, becomes activated with platelet aggregation. Platelet factor-3 participates in the intrinsic 
pathway of clotting sequence, ultimately leading to the formation of thrombin which induces 
further platelet aggregation and release and polymerisation of fibrin. Alpha granule-derived 
fibrinogen and platelet factor 4 also favours coagulation. Released ADP during the is a potent 
mediator of platelet aggregation and release. Thus many influences act in concert to facilitate 
the build up of a platelet mass that serve as a temporary plug in small vessels. 
The initial platelet aggregation is an autocatalytic reaction, which, once initiated, enters a 
logarithmic phase with the release of more ADP, serotonin and ionized calcium. At this time, 
the clotting sequence leads to the formation of thrombin, which further augments platelet 
aggregation. But this initial platelet aggregation is temporary, and although the platelets are 
adherent, they have intact membranes. In addition to ADP and serotonin, prostaglandins and 
arachidonic acid also participate in platelets aggregation (Jamaluddin, 1993) 
Platelet aggregation can be influenced by a number of substances. Antigen-Antibody complex, 
fatty acids, and cigarette smoking renders platelets "hyperactive" to aggregating agents. Diets 
rich in saturated fats and cholesterol induce hypercholesterolemia and influence the 
phospholipid composition of platelet plasma membrane predisposing to aggregation (Halushka, 
1977). A number of drugs that inhibit PG synthesis, such as aspirin, phenylbutazone, and 
indomethacin also inhibit both collagen and thrombin induced platelet aggregation. These 
agents act on the enzyme cyclooxygenase to prevent the conversion of arachidonic acid to the 
next intermediate (Rossi, 1976). 
Glycoprotein Ib-V-lX is a constitutively active receptor for Von Willebrand factor, causing 
immediate platelet attachment to exposed perivascular von Wille brand factors (Lopez et al., 
1998). Glycoprotein la-lla, a constitutive receptor for collagen, is also involved in initial platelet 
adhesion to the subendothelial matrix (Santoro and Zutter 1995; Santoso et al., 1999). The 
most abundant surface protein, glycoprotein llb-llla, requires a conformational change during 
platelet activation to express receptor function mainly for fibrinogen (Shattil et al., 1998). 
Fibrinogen binding to glycoprotein llb-IIIa mediates platelet aggregation. 
These reactions define the clinical manifestations of bleeding disorders. Patients with 
thrombocytopenia have petechial and mucocutaneous bleeding, resulting from unseated small 
endothelial lesions. By contrast, patients with coagulation disorders, such as haemophilia, do 
not have petechial or excessive bleeding from small cuts because platelet adhesion and 
aggregation are sufficient to seal these lesions. Haemostasis for larger wounds require fibrin 
formation to reinforce the platelet aggregation. Therefore, in contrast to platelet disorders, 
coagulation disorders are characterized by the delayed occurrence of large haematomas. 
Platelets and Neurons: Major Similarities 
Platelets have been considered as a peripheral model for the central nervous system (CNS) for 
quite some time. Initially, platelets were proposed as a neuronal model on account of their 
ability to accumulate, store and release biogenic amines such as 5-HT, noradrenaline (NA) and 
dopamine (DA) (Stahl and Meltzer, 1978; Stahl, 1985; Dean and Copolov, 1989a,b). Some 
structural aspects of platelets are analogous to those of neurons (Seth et al., 1994). Interestingly 
both platelets and neurons possess a limiting membrane, mitochondria and dense-cored vesicles 
where neurotransmitters are stored. Mitochondria which provides energy for functioning of the 
cell and localises monoamine oxidase (MAO) for neurotransmitter catabolism is also present in 
platelet like neuron (Youdim, 1988). In spite of various similarities, platelets and neurons differ 
in some respects. While platelets contain a-granules and store ADP and glycogen, neurons do" 
not have. Neurons contain nucleus whereas platelets Eire anucleated. Platelets are not 
"innervated and do not innervate" and therefore they lack synapse. Neurons on the other hand 
form a well defined synapse. The structural similarities and differences between platelets and 
neurons are summarised in Table 1.1. 
Ever since with the demonstration of 5-HT in platelets in 1966 (Tranzer et al., 1966) extensive 
kudies have been carried out by several groups to investigate the pharmacological similarities 
and responsiveness between platelets and neurons. Platelets like neurons have the ability to 
accumulate, store and release neurotransmitters viz. 5HT, NE, DA and therefore they have been 
widely explored for their use as neuronal model (Stahl and Meltzer, 1978; Stahl, 1985, Dean 
and Copolov 1989a, b). Experimental studies on rats showed that reserpine depleted the 
serotonin contents in platelets in a similar manner as in brain (Shore et al., 1956; Paasonen and 
Pletscher 1959). Subsequently some neurotransmitter binding proteins such as, transport 
proteins, receptors were identified and found to have similarities with that of brain 
(Trukenmiller, 1983). This was further supported by the demonstration of structural identity 
between neuronal and platelet serotonin transporter (Lesch et al., 1993), 5-HT2a receptor (Cook 
et al., 1994) and monoamine oxidase-B proteins (Chen et al., 1993). In addition to this, few 
neuron specific proteins like neuron specific enolase (Marangos et al., 1980; Sternberg et al., 
1986) and neuron specific brain derived neurotrophic factor (Rivero et al., 1997) liave been 
shown in platelets. It is evident that platelets and neuroendocrine APUD (Amine precursor 
uptake and decarboxylation) cells are the only cell type other than neurons to contain the y-
enolase subunit, which led the speculation whether platelet could be embryologically derived 
from diffused neuroendocrine system (Marangos et al., 1980; Campbell et a l , 1981). A review 
of various biochemical parameters studied in platelets of neuropsychiatric patients is given in 
Table 1.2. 
Table 1.1 Comparison of properties of platelets and neurons 
Properties Platelets Neurons 
Morphology and Cytology 
Limiting membrane V V 
Mitochondria V V 
Storage granules V V 
Nucleus - V 
Glycogen granules V -
Biochemistry 
Neurotransmitter synthesis - V 
Monoamine oxidase A/B V V 
GABA transaminase V V 
Catechol-O-methyl transferase V V 
Phenol sulphotransferase V V 
Serotonin transporter V V 
Dopamine transporter V V 
5-HT2A receptor V V 
Dopamine D2 receptor V V 
Pharmacology 
5-HT transport inhibition by tricyclic antidepressants V V 
Monoamine oxidase inhibition by deprenyl and pargyline V V 
Depletion of 5-HT stores by reserpine V V 
Table 1.2 Status of some biochemical parameters in platelets of neuropsychiatric patients 
CNS DISEASE Receptor/Bio-chemical parameter Status References 
Alcohol dependence 5-HT concentration Decrease Bailly, 1990 
5-HT transporter affinity 
Increase 5-HT uptake (Bmax) 
Increase 
Increase 
Emoufer al.. 1993 
^H-imipramine binding 
'H-paroxetine binding 
Increase 
Increase 
Patkar, 1995 
Mellerup el al. 1993 
'H-paroxetine binding 
Kd 
Bmax 
Increase 
Increase 
Belen Arranze /a / . 1999 
Belen Armaz er a/. 1999 
5-HT2A receptor No change P a n d e y e / a / , 1992 
Adenylylcyclase (Gs stimulated) 
Membrane fluidity 
y-aminobutyrate amino transferase 
(GABA-T) 
Monoamine oxidase 
Agonist induced platelet aggregation 
Decrease 
Decrease 
Decrease 
Decrease 
Decrease 
Menninger er a/ 1998 
Thompson, 1999 
Sher i feJo/ 19992 
She r i f e / a / 1992 
Renaud and Ruf, 1996 
Unipolar depression 5-HT transporter (paroxetine binding) 
Inositol triphosphate level 
Decrease 
Increase 
A l v a r e z e s / 1999 
Alvarezes a/ 1999 
Depression 
Major depression 
Major depression 
IP3 receptors 
5-HT2A receptor 
Forskolin-stimulated platelet adenylyl 
cyclase activity 
Increase 
Increase 
Decrease 
Dwivedi et al 1998 
Pandey et al 1990; 
Hardin iera / 1995 
Menninger and Tabakoff 
1997 
Major depression 
Depression 
Platelet count 
5-HT concentration 
Increase 
Decrease 
M c b r i d e e / a / 1994 
Le-Quan-Bui e / a / 1984 
Major depression 
(fluoxetine/paroxetine treated) 
5-HT uptake Decrease Bakish etal 1997 
Depression Discoid platelets 
5-HT granule 
Increase 
Decrease 
Palmer e / a / 1997 
Palmer e / a / 1997 
Major depression (suicidal 
behavior) 
5-HT concentration Decrease Muck-Seler e( a/. 1996 
Depression (Unipolar and 
biolpolar) 
Major depression 
Major depression 
Intracellular calcium levels 
5-HT2A receptor (Bmax) 
5-HT2A receptor (Bmax) 
Increase 
Increase 
Increase 
Berk el al. 1995 
Biegone /o / 1987a 
Pandey e/£7/. 1990 
C N S D I S E A S E Receptor/Bio-chemical parameter Status References 
Schizophrenia Nitric oxide synthase activity (NOS) 
Intracellular calcium levels 
Increase 
Increase 
Dase/a/ 1995 
Dase/a/ 1995 
Schizophrenia (resperidone treated) 
Schizophrenia 
Schizophrenia 
Schizophrenia 
Schizophrenia 
5-HT2 receptor 
Intracellular calcium 
^H-spiroperidol (DA-D2) 
^H-PK i n 9 5 ( P B R ) 
^H-Yohimidine (a-adrenergic) 
'H-imipramine (5-HT uptake) 
Increase 
Increase 
Increase 
Increase 
Decrease 
Increase 
P a n d e y e M / 1993 
Ereshefsky e/f l / 1996 
Sethi e / f l / 1986 
G a v i s h e r a / 1986 
Ackenhesl e / a / 1986 
Desmedte^f l / 1987 
Schizopiirenia 5-HT2 receptor Increase Aroraela/ 1993 
Schizophrenia activity (abnormal 
HPA axis as reflected in DST non 
suppression) 
{DST-dexamethasone suppression 
test 
Post dexamethasone 5-HT 
concentrations 
5-HT 
Increase 
Increase 
Miick-Seier e/aJ 1999 
Jakovljevic e / « / 1997 
Schizoplirenia 
(+ Symptoms) 
5 -HT levels Increase Pivaceta/ 1997 
Schizophrenia 
(Seasonal effect) 
5 -HT content in schizophrenia bom in 
winter against schizophrenia bom in 
all other seasons 
Increase Miick-Seler 0/ 1999 
Schizophrenia 
(neuroleptic treated) 
Thrombin stimulated platelet inositol 
phosphates 
Increase Essali eta/ 1990; 
Yao etal 1992 
Schizophrenia 
(Drug free) 
Resting platelets 1,4,5,-1P3 content Increase R i p o v a e / a / 1997 
Eating disorder 
(anorexia nervosa/bulimia nervosa) 
5-HT2 receptor 
( 'H-LSD binding) 
Increase Sp igse te^a / 1999 
Seasonal affective disorder 
(under bright light therapy) 
5-HT2 receptor 
(^H-LSD binding) 
Decrease S m e d h e r o / 1999 
Panic disorder Thrombin induced intracellular 
calcium 
Increase Plein and Berk, 1998 
Generalized anxiety disorder Peripheral benzodiazepine receptor Decrease W e i z m a n e r a / 1987 
CNS DISEASE Receptor/Bio-chemical parameter Status References 
Obsessive compulsive disorder PBR binding Decrease Weizman et a! 1993 
Post traumatic stress disorder PBR binding Increase Gav i sheM/ 1996 
Obsessive compulsive disorder Phenol sulfotransferase activity Increase Marazziti ef al 1996 
Mania Phenol sulfotransferase activity Increase Marazziti e / a / 1996 
Epilepsy GABA-transaminase Increase Ar teagaeM/ 1993 
Migraine Membrane fluidity 
Cytosolic calcium 
Platelet aggregation (ADP/ Collagen 
induced) 
Decrease 
Decrease 
Decrease 
Tozzi-Ciancarelli et al 
mi 
do 
Migraine with aura 
5-HT2A receptor 
Platelet aggregation 
Superoxide dismutase activity 
Decrease 
Increase 
Decrease 
Govitrapong er a/ 1992 
Govitrapong er a/ 1992 
Shimomura et al 1994 
Sulfotransferase activity Decrease Alame/ f l / 1997 
Total nitrate/nitrite content 
Nitrite conc 
cGMP conc 
Increase 
Increase 
Increase 
Shimomura e/<7/ 1999 
Shimomura e? a/ 1999 
Shimomura e / a / 1999 
Transformed migraine 
5-HT2 receptor Increase Srikiat krachom e /a i 1994 
Chronic daily headache 
Platelet aggregation 
NO/cGMP 
Intracellular calcium 
Serotonin level 
Decrease 
Increase 
Increase 
Decrease 
Sarchielli a/ 1999 
Sarchielli et al 1999 
Sarchielli et al 1999 
Sarchielli et al 1999 
Idiopathic Parkinson's disease 
(stage III) 
Platelet serotonin levels Decrease Parkinson's a/ 1999 
Parkinson's disease Mitochondrial complex-1 activity Decrease Parker ero/ 1998 
5-HT uptake Decrease ]d\xnetal 1996 
Alzheimer's disease 
MAO-B 
^H-spiroperidol (DA-Dj) 
Membrane fluidity 
Increase 
Increase 
Increase 
Decrease 
Increase 
Increase 
Bongioanni e / a / 1996 i 1 
J a rmane /a / 1993 
Seth and Khanna, 1991 
Z u b e n k o e / a / 1996 
Zubenko et al 1999 
Platelet Neurotransmitters, Neurotransmitter Binding Sites and 
Neurological and Psychiatric Disorders 
Serotonin Receptors and Uptake sites 
Among the platelet neurotransmitters, serotonin receptors have been studied in detail. High 
affinity binding of ^H-5-HT has been demonstrated on the 5-HT uptake sites (Khanna and Seth, 
1987), as inhibitors of 5-HT uptake (amitryptiline, imipramine and nortryptamine) were potent 
inhibitors of binding rather than 5-HT receptor antagonists like methy-sergide and 
cyproheptadine. Parallel changes in the platelet and frontocortical ^H-5-HT binding have been 
observed in rats following exposure to neurotoxicants like endosulfan and acrylartiide (Seth and 
Khanna, 1991). Human platelets have been reported to posses 5-HT2A receptor which is distinct 
from the 5-HT uptake site and is stimulated and blocked by various 5-HT agonists and 
antagonists as well as drugs that inhibit platelet shape change (Pletscher et al., 1978). Binding 
of ^H-LSD was found to label 5-HT2A receptor in porcine platelets and both Kd and Bmax were 
correlated with those present in cortex (Ostrowitzki et.al., 1993) Studies by Roy (1986) have 
suggested that 5-HT2A receptors in platelets and brain are under genetic control. Human 
platelets 5-HT2A receptors have been cloned and the nucleotide sequence of 5-HT2A C D N A in 
platelets was found to be identical to that reported for the human frontal cortex 5-HT2A 
receptors except for nucleotide 102 (Cook et al., 1994). Several studies exhibited that brain 5-
HT2A receptors exist in two affinity states, which are regulated by G-protein (Teitler et al., 
1990; Waeber and Palacois 1994). Recently, ^H-ketanserin saturation experiments revealed that 
platelet 5-HT2A receptors display two agonist affinity states that exist as a fianction of their 
coupling to Gq protein upon agonist stimulation which is similar to brain (Gurguis et al. 1998). 
Lesch et al. (1993) reported that the human platelets 5-HT uptake site is identical with the 
human 5-HT transporter and both proteins are encoded by the same single copy gene. The 5-HT 
uptake mechanisms or 5-HT transporter is an important part of the 5-HT system which can be 
measured by the number of binding site for antidepressant drugs located on the 5-HT-
transporter in the membranes of serotonergic neurons or platelets. Although both ^H-paroxetine 
and ^H-imipramine are used to measure 5-HT presynaptic uptake sites, ^H-paroxetine is more 
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selective than other radioligand (Arranz and Marcusson, 1994); ^H-imipramine has been shown 
to be a more sensitive radioligand to detect variations in the platelet 5-HT-reuptake sites in 
some psychiatric patients (Rosel et al., 1997; 1999). 
Role of serotonin transporter in platelets serotonin uptake has been suggested (Jemej et al., 
1994). Difference in the 5-HT transporter mRNA levels in platelets of animals genetically 
selected for the extreme values of their serotonin uptake has been reported and ratio between 5-
HT transport velocities and mRNA levels was found practically identical in two independent 
experiments, suggesting interdependence of these two parameters (Jemej et al., 1999). 
Serotonin transporter protein has been linked with ethiopathogenesis of various 
neuropsychiatric disorders (Cook et al., 1997; Ogilvie et al., 1997). The platelet 5-HT2A 
receptors has been proposed as an effective model for 5-HT2A receptors in brain (Da Prada et 
al., 1988; Pletscher, 1988; Pandey et al., 1995) and could serve as the window to CNS disorders 
linked to 5-HT2A receptors such as anxiety, depression and schizophrenia. An increase in 
platelets 5-HT2A receptors has been reported in suicide attempters and their assay in platelets 
has been suggested as a peripheral marker to monitor the suicide episodes (Pandey et al., 1995). 
A significant decrease in platelet 5-HT2 receptors has been reported in Parkinson's cases, 
however, no correlation of clinical staging with 5-HT2 receptors alterations was observed 
(Atam, 1990). An increase in the ^H-5-HT binding has been observed in the cases of mental 
retardation and hyperkinesia as compared to controls and these alterations are well correlated 
with the clinical findings (Seth and Khanna, 1991). 
Dopamine Receptors and Uptake sites 
Presence of specific high affinity binding sites for DA-D| and DA-D2 receptors has been 
demonstrated on platelets using radioligands ^H-SCH-23390 and ^H-spiroperidol (Khanna et 
al., 1987a, De Keyser, 1988). More recently, DA-D3 receptors have been found to be present in 
human and rat platelets. Interestingly the binding affinities were fond to be close to that 
observed in striatum and cell lines (Pradeep et al., 1997; 1998). Exposure to neurotoxicants 
such as acrylamide, styrene, methylmethacrylate led to a significant increase in ^H-spiperone 
binding in platelet and striatal membranes (Seth, 1988) whereas methyl mercury chloride 
exposure resulted in significant decrease of binding in both the tissues (Seth, 1988). Earlier, 
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Boullin et al. (1978) reported that ^H-haloperidol labels intact blood platelets (platelet rich 
plasma) non specifically. Platelets DA-D2 receptors have been found to be altered in the 
neuropsychiatric and neurotoxicological conditions. In schizophrenia, an increase in the binding 
of ^H-spiperone to platelet membrane has been shown (Sethi et al., 1986). In another study on 
the clinically identified cases of idiopathic Parkinson's disease, two sub-groups were identified, 
one exhibiting an increase in the binding Eind responsive to L-dopa while the other a decrease 
binding and non-responsive to the drug. The changes in the binding were conelated with the 
clinical state and could to helpful in the monitoring of the disease and selecting the responders 
to L-dopa in Parkinson's cases. Interestingly, binding studies on the autopsied brain samples in 
Parkinson's cases have also been found to be both increased and decreased like the observations 
in platelets (Seeman, 1987). Individuals exposed to phosphomidon (an organophosphate) 
resulted in an increased binding of ^H-spiperone to platelet membranes. The increase in the 
binding persisted even 9 months after exposure (Seth et al., 1988). 
Earlier studies reported that blood platelets accumulate dopamine against a concentration 
gradient at physiological temperature (Solomon et al., 1970). Further, a highly selective, 
temperature dependent, uptake system for dopamine comprising of both high and low affinity 
components was reported in human platelets which is similar to brain dopamine uptake (Dodd 
1988; Dean and Copolov 1989a). Critical role of the synaptic transporter in the regulation of 
central neurotransmission has been demonstrated in the dopamine transporter knock-out mouse 
(Giros et al., 1996). Dean et al. (1996) reported that neuroleptic treatment increased platelet ^H-
dopamine uptake in subjects with schizophrenia and schizophreni-form disorder and in contrast 
to this neuroleptic treatment was shown to decrease platelet ^H-dopamine uptake in subjects 
with psychosis associated with other illness. In another study, rats treated with neuroleptics such 
as haloperidol and clozapine showed decreased platelet ^H-dopamine uptake in a dose and time 
dependent manner, and it was restored after termination of neuroleptic treatment (Sundram et 
al., 1996). This could be a possible reason that platelets of neuroleptic treated subjects reflect 
drug-induced changes in ^H-dopamine uptake. 
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Adrenoceptors 
Existence of multiple types of a-adrenergic receptors in different tissues and presence of some 
of them in platelets has been demonstrated (Motulsky and Insel, 1982). The initial observations 
that platelet aggregation induced by physiological catecholamine (Ardlie et al., 1966) could 
possibly be mediated by adrenoceptors led to the discovery of both a - and P-adrenoceptor 
(Alexander et al., 1978; Winther et al., 1985) in platelets. a2-Adrenoceptors on human platelets, 
like those on neurons in the rat brain, appear to become sub-sensitive after the long-term 
administration of tricyclic antidepressants (Maes et al., 1999). Further, chronic administration of 
tricyclics to endogenously depressed patients was found to reduce the number of ^H-clonidine 
binding sites on blood platelet. Validity of platelet a-adrenoceptors as model for brain versus 
vascular adrenoceptor has been suggested (Hamilton and Reid 1986). It has been suggested by 
several investigators that adrenoreceptors on human platelets are exclusively of the a j subtype 
(Shattil, 1981). Platelet a-adrenoceptors sites were significantly elevated in untreated depressed 
patients as compared to controls. However, electroconvulsive therapy in depressed patients led 
a significant reduction in platelet a-adrenoceptor numbers as compared to untreated patients 
which may be interpreted as a primary therapeutic "normalising" effect (Werstiuk et al., 1996). 
Platelet a2A-adrenoceptors are coupled to inliibitory G-protein (Gia) and stimulation of these 
receptors result in decrease in cAMP levels inside the platelets. Thus in platelets, unlike other 
types, occupation of the Gi-coupled aiA-adrenergic receptors does not result in the 
phospholipase C activation but rather in modulation of the Ca^^ response by relieving cAMP-
mediated suppression of inositide triphosphate dependent calcium induced calcium release 
(Keularts et al., 2000). 
Presence of P-adrenergic receptors, predominantly of P2 subtype have been shown on human 
platelets (Winther et al., 1985). Pi-selective antagonist (atenolol, metoprolol) had no influence 
on isoprenaline induced cAMP formation in human platelets. a-Adrenoceptors stimulation 
results in platelet aggregation, however, stimulation of P-adrenoceptors causes activation of the 
adenylyl cyclase system which increases the production of cAMP and inhibit platelet 
aggregation (Kerry and Scrutton, 1983; Winther et al., 1985). In a subsequent study, Winther 
and Naesh (1987) observed that platelet aggregability increases as age advances and suggested 
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that it might be partly due to a decrease in platelet P-adrenoceptor function. 
Glutamate and GABA Receptors 
Low affinity binding sites for ^H-glutamate have been demonstrated in human and rat platelets 
(Sah et al., 1991; Sah, 1992). Platelet glutamate receptors in schizophrenics have been found to 
be supersensitive as evident from increased intracellular calcium by glutamate (Berk et al., 
1999). Recently Berk et al. (2000) reported that glutamate receptors in platelets were 
supersensitive in schizophrenia and depression with psychotic features, however, no significant 
change in sensitivity of platelet glutamate receptors was observed in cases of mania with 
psychotic features. The possible role of GABAergic mechanisms in platelets have been 
reviewed (Oset Gasque et al., 1986). Platelet peripheral bezodiazepine receptors (PBRs) in 
generalized social phobia has been reported to be abnormally low like in other anxiety disorders 
such as panic disorder, post traumatic stress disorder and generalized anxiety disorder. The 
study suggests the role of PBRs in pathophysiology of some anxiety disorders (Johnson et al., 
1998b). A significant increase in platelet PBRs has been reported in patients suffering from 
migraine without aura (Pavese et al., 2000). 
Platelets and Other Binding Sites 
Purine and Pyrimidine Receptors 
Besides neurotransmitter receptors, extra cellular purines (adenosine, ADP and ATP) and 
pyrimidines (UDP and UTP) are important signalling molecules that mediate diverse biological 
effects via cell surface receptors, termed purine receptors. Two families of purine receptors, 
adenosine or PI receptors and P2 receptors, recognising primarily ATP, ADP, UTP and UDP 
have been identified (Relvic and Bumstock 1998) PI/adenosine receptors have been further 
subdivided according to convergent molecular and biochemical and pharmacological evidences 
into four subtypes, A), A2A, Aaa and A3 which are coupled to G-proteins. Various studies 
indicate that adenosine acts through the A2A receptors and elicits a number of physiological 
responses including, vasodilatation, inhibition of platelet aggregation and depression of central 
nervous activity (Cristalli et al., 1995; Varani et al., 1998). 
14 
Classical pharmacological studies have identified ADP receptors on platelets designated as P2T 
receptor. The P2T receptor is now resolved into tliree P2 receptor subtypes, the P2Y1, the P2X1 
and P2AC receptor. The P2Y and P2AC receptors are essential for ADP-induced fibrinogen 
receptor activation on platelets (Kunapuli, 1998). The P2Y1 receptor is coupled to the calcium 
mobilisation through the activation of phospholipase C and plays an important role in the ADP-
mediated platelet shape change (Jin et al., 1998). 
Imidazoline Binding Sites 
Compounds containing imidazoline or guanidinium moiety bind with high affinity to sites that 
are distinct from classical adrenergic receptors and termed as imidazoline/guanidinium 
receptive site (Michel and Insel, 1989; Parini et al., 1996; Regunathan and Reis, 1996). 
Initially, imidazoline subtypes II and I2 were defined by high affinity binding of ^H-clonidine 
and ^H-idazoxan respectively (Tesson and Parini, 1991; Miralles et al., 1993; Emsberger et al., 
1995). Subsequently, with the availability of selective ligands, ^H-BFI has been considered to 
be specifically to label h sites (Hudson et al., 1997). High affinity ^H-BFI binding sites on 
human platelets with similar characteristics to those in human and rat brain have been reported 
(Steinberg et al., 1999; Wiest and Steinberg, 1999). 
Imidazoline (I2) binding sites are directly associated with mitochondrial enzyme, monoamine 
oxidase (MAO) (Tesson et al., 1995; Raddatz and Lanier, 1997) but apparently distinct from the 
catalytic or cofactor binding site (Tesson et al., 1995). I2 receptors have been increasingly 
implicated in various clinical pathologies including Alzheimer's disease (Ruiz et al., 1993), 
Parkinson's disease (Gargalidis-Moudanos et al., 1997) and depression (Garcia-Sevilla, 1997). 
Platelets and Intracellular Calcium 
Calcium is vital for various platelet functions. Membrane bound Ca^^ is essential for platelet 
aggregation, as it controls the integrity of fibrinogen receptor. Intracellular-free calcium is 
involved in shape change and granular secretion. Several platelet proteins are regulated by Ca^^ 
either directly or via binding to calmodulin. These include the Ca^ "^ , Mg^^- ATPase, 
phospholipase Aj, calcium dependent neutral proteases (calpains), cytoskeletal proteins (Seiss, 
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1989). In the resting platelet, the cytoplasmic calcium level is maintained at approximately 100 
nM/L by limiting Ca^^ influx, promoting its efflux and also by actively sequestering Ca^ "^  
within the dense tubular system (DTS) (Ebbeling et al., 1992). The DTS associated Ca^^ pump 
has been characterised as a Ca^^ Mg^^ dependent ATPase with a Kd for free calcium 1 OOnM/L 
(Dean, 1984; Hack et al., 1986). 
On activation either by an agonist or external stimuli, calcium is rapidly discharged which 
causes an increase cytoplasmic levels (Ware et al., 1986). Many agonists can produce a rapid 
rise in Ca^^. These includes platelet activating factor (PAF), vasopressin, stable prostaglandin 
endoperoxides, ADP, serotonin, thromboxane Aj (TXA2), thrombin (Seiss et al., 1989). The 
diacylglycrol (DAG) can promote a modest Ca^^ independent secretion. In drug free cells, the 
arachidonate is converted to TXA2 which acts at surface receptors to mobilise Ca^^ and evoked 
a delayed use of Ca^^ (Shukla et al., 1987). 
Most agonists activate platelets through binding to transmembrane receptors coupled with G-
proteins. Second messengers such as (Ca^^ and IP3), protein kinase c (PKC) and protein 
tyrosine kinase increases platelet aggregation whereas cAMP inhibits it (Brass et al., 1993; 
Heemskerk and Sage, 1994). PAF and AA are directly or indirectly involved in the stimulation 
of TXA2 production. TXA2 interacts with its receptors on platelets in an autocrine fashion to 
activate Gq protein (Offermans et al., 1997). PAF is known to activate Gq-phospholipase C 
signalling pathway (Shukla et al., 1987). Stimulation of Gq protein leads to generation of 
second messengers IP3 and DAG which in turn induce the release of Ca^^ from the dense 
tubular system and activation of PKC respectively (Heemskerk and Sage 1994; James-Kracke 
et al., 1994; Clapham, 1995). Multiple isoforms of both IP3 receptor and PKC are present in 
platelets (Newton 1995; Quinton and Dean 1996). Any defect in signalling cascade may impair 
the platelet response to agonists. Recent studies have shown that transgenic mice deficient in 
Gq protein lack platelet aggregation capabilities (Offermanns et al., 1997). A rise in cytosolic 
Ca^^ levels causes platelet activation through stimulation of enzymes, which are not fully 
functional at the low Ca^^ concentration present in resting platelets (Heemskerk and Sage, 
1994). The stimulation of phospholipase C, activation of inliibitory G-protein (Gi), opening of 
receptor-operated calcium channels and mobilisation of intracellular calcium are other possible 
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mechanisms which may increase the cytoplasmic calcium (Seiss, 1989; Brass et al., 1993). The 
synergistic platelet aggregation response induced either by the ADP and adrenaline or ADP and 
5-HT is a specific receptor mediated process. It is inhibited by specific receptor antagonists viz. 
yohimidine and ketanserin and not entirely dependent on the effects of thromboxane (Vanags et 
al., 1992; 1998). 
Platelets and Oxidative Stress 
Although oxygen is essential for life it can give rise to variety of reactive oxygen species (ROS) 
as part of normal metabolism. The body is well equipped with variety of mechanisms, which 
serve to render ROS inactive. However, under certain conditions where ROS levels are raised 
beyond the capacity of these protective mechanisms (e.g. irradiation, environmental factors, 
iron loading etc.) or when these mechanisms are faulty (e.g. genetic issues), the ROS can cause 
a variety of disease and even death. Protein, lipid and DNA are substrates for ROS attack. 
Lipidperoxides are generated by the reaction of oxygen derived free radicals with 
polyunsaturated fatty acids (PUFA) of membrane phospholipids and can be formed both 
enzymatically and nonenzymatically (eicosaniods). Oxygen derived radical attack over-rumiing 
beyond the protective system leads to oxidative stress (Emerit et al., 1991). Blood platelets are 
enriched with PUFA and are the target of reactive oxygen radicals (Blache et al., 1999; Blandini 
1999). Superoxide radicals (O2") increases platelet response viz. platelet adhesion and 
aggregation, whereas hydroxyl radicals are not involved (Salvemini 1989). To combat with 
enhanced oxidative stress, platelets are equipped with both enzymatic and non enzymatic 
antioxidants. Among enzymatic antioxidants, platelets have superoxide dismutase (Marcus et 
al., 1979; Pandey et al., 1998), glutathione peroxidase (Menzel et al., 1983), glutathione 
reductase (Moroff and Kosow, 1978), glutathione transferase (De La Cruz et al., 1999) and 
catalase (Hill et al., 1989). Superoxide dismutase catalyzes the dismutation of superoxide 
radical O2" to yield hydrogen peroxide which is further decomposed by catalase or glutathione 
peroxidase to water and oxygen. These enzymes are preventive antioxidants as they remove the 
species involved in the initiation of free radicals chain reactions (Buettner et al., 1993). Non 
enzymatic antioxidants in platelets comprise of a-tocopherol (Polette et al., 1996) and reduced 
glutathione (Seung et al., 1978). P-carotene, vitamin A and ascorbate (vitamin C) are other 
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nonenzymatic antioxidants (Dikshit et al., 1987). 
Vitamin E is a lipid soluble antioxidants present in cellular membrane to maintain cellular 
integrity by inhibiting lipid peroxidation and prevents intracellular propagation of free radicals 
(Burton et al., 1983). In addition, ascorbate and a-tocopherol function together to protect 
membrane lipid damages (Buettner et al., 1993). 
Platelet oxidative stress and disease conditions 
Platelet oxidative stress has been implicated in various neurological disorders such as 
Parkinson's disease (Martignonini et al., 1999), migraine (Shimomura et al., 1994; Tozzi-
Ciancarelli et al., 1997) and Alzheimer's disease (Ghosh et al., 1999). Martignonini et al. (1999) 
found a higher amount of 2,3-dihydroxy benzoate, an index of hydroxyl radical generation, in 
the platelets of L-dopa treated Parkinson's patients in comparison to controls or untreated 
patients. Levels of 2,3-dihydroxy benzoate were positively coirelated with levels of L-dopa, 3-
o-methyl dopa in platelets and the score of disease severity in the early treated Parkinson's 
cases. Low concentrations of platelet SOD were found in patients with migraine with aura and 
migraine without aura, however the activity of platelet SOD decreased only in the cases of 
migraine with aura and not in patients with migraine without aura or tension type headache 
(Shimomura et al., 1994). In another study on migraine, an increase in oxidative stress as 
evident from increased platelet membrane rigidity and reduced platelet cytosolic Ca^^ in the 
resting condition and after thrombin stimulation was reported during headache free period. 
These cases also showed decrease in platelet aggregatory response to ADP and collagen (Tozzi-
Ciancarelli etal., 1997). 
Oxidative stress in platelets has also been implicated in the aetiology of several non 
neurological diseases including, diabetes (Ohtsuka et al., 1996; Leoncini et al., 1997), astlima 
(Hasselmark et al., 1990), Down's syndrome (Crosti et al., 1989), ageing (Di Massimo et al., 
1999; Lenazetal., 1999). 
Levels of H2O2, measured by intracellular levels of the fluorescent 2,7-dichloro-fluorescein 
(DCF), considered as an indicative parameter of free radical, was found higher in resting 
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platelets of diabetic patients (NIDDM). Moreover, platelets of diabetic subjects generated 
significantly higher amounts of hydrogen peroxide than controls after stimulation with 
thrombin, collagen, phorbol myristate acetate (PMA) and platelet activating factor (PAF). In 
diabetic patients, platelet free radical production and functional activity is reported to be 
enhanced, with increased risk of thrombosis (Leoncini et al 1997). Ohtsuka et al. (1996) found 
an increase in platelet GSH synthesis and reduction in platelet glutathione peroxidase activity in 
response to oxidative stress and suggested impairment in antioxidant defense mechanism in 
diabetic patients. 
In intrinsic astlmia, a lower platelet glutathione peroxidase activity has been reported and this 
was correlated with a tendency of lower selenium levels in plasma of asthmic patients 
(Hasselmark, 1990). 
In trisomy 21 or Down's syndrome patients, glutathione peroxidase activity was higher in blood 
cells including platelets, which could be an additive effect of overproduction of Cu-Zn-SOD 
due to gene dosage and the ordinarily higher content of oxygen radicals and peroxides (Crosti et 
al., 1989). 
Influence of ageing and exercise-induced stress on human platelet has been studied by Di 
Massimo et al.(1999). It was reported that oxidative stress might modulate platelet functions by 
influencing calcium homeostasis and platelet permeability. Lenaz et al. (1999) developed the 
Pasteur effect (enhancement of lactate production by mitochondrial inliibition) as a biomarker 
of mitochondrial bioenergetics in human platelets and found it to be decreased in aged 
individuals. Mitochondrial energetics declines under influence of reactive oxidative species 
produced by mitochondria (Lenaz et al., 1999). 
NEUROTOXICANTS 
Manganese 
Manganese (Mn) occurs in nature in varying degrees of purity and states of oxidation and is 
generally found in combination with other chemicals such as silicon, carbon and sulphur (NRC, 
1973). The oxidation state of inorganic Mn compound determines its action. Mn in the 2+-
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oxidation state (Mn^^) acts as a scavenger of free radicals and is necessary for normal brain 
function. Manganese dependent superoxide dismutase (Mn-SOD) makes use of the variable 
oxidation states of Mn in mitochondrial oxygen radical metabolism (Ali et al., 1995). Mn 
dependent protein plays an important role in the production of certain neurotransmitters. Eight 
percent of the Mn2+, in brain is associated with the manganoprotein glutamine synthetase, 
which synthesise glutamine (Wedler and Denman, 1984). Pyruvate carboxylase and 
phosphophenol pyruvate carboxykinase are other Mn dependent enzymes (Balyetal., 1985). It 
is an essential trace element, necessary for normal development; its deficiency is associated 
with skeletal deformities, sterility and neonatal death in animals (NRC, 1973; Hurley, 1981). 
Low levels of manganese have been detected in children with congenital disorders of bone 
development and growth (Hall et al., 1989) and with epilepsy, (Akram, 1989). Maternal 
manganese deficiency results in depletion of catecholamines in the brain of the foetus (Mena, 
1980). 
Exposure 
Exposure to manganese occurs both occupationally and non-occupationally. Occupational 
exposure to the metal in miners occurs while handling stock piles of the ore and crushers to 
prepare the ore for smelting (Huang and Quist, 1983). Besides, manganese is released during 
industrial processes such as metallurgical fabrication, welding, alloy manufacturing, chemical 
production, textile bleaching, leather tanning and electroplating (Saric, 1986; Sjorgren, 1996). It 
is an active ingredient in the production of potassium permaganate, manganese sulfate and 
certain fungicide, germicide and antiseptics and is used in the production of dry-cell batteries, 
glass, matches, fireworks, fertilisers, animal feed, paints and varnishes (Lucchini et al., 1999). 
Manganese is also used in organic compounds such as manganese ethylene-bis-dithio 
carbamate (Maneb), ah agricultural fungicide (Ferraz et al., 1988) and methyl-
cyclopentadienyl manganese tricarbonyl (MMT), a yellow liquid used as an antiknock gasoline 
additive and smoke inliibitor for oil (Mergler, 1996). Combustion of MMT generates 
manganese oxides (Ter Haar et al., 1975). 
Food is a major source of non-occupational manganese intake. Significant concentrations of 
manganese have been detected in wheat, rice, tea, nuts, meat and poultry (Sittig et al., 1985). 
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Ferraz et al. (1988) reported that the presence of manganese in food materials could be due to 
residues left behind from manganese containing insecticides. Dietary sources account for about 
4mg/day of manganese ingestion for the average adult (USEPA, 1984). Excess manganese 
may exist in drinking water as a result of contamination due to leaching from nearby mineral 
formation and improper toxic waste disposal (Vieregge et al., 1996). 
Exposure of general population to manganese in quantities above the permissible leads to 
adverse effects (Tanaka, 1988). Even normal dietary intake of manganese may result in 
manganese intoxication in individuals with decreased excretion due to chronic liver failure 
(Hauser et al., 1994). 
Exposure Limits and Safety Regulation 
A dose-response relationship between exposure and the emergence of clinical manifestations is 
not clearly established. Neurotoxic effects have been reported in individuals exposed to 
different levels of manganese (0.3 to 4.9 mg/m^, Saric et al., 1977). The Occupational Safety 
and Health Administration (OSHA), USA has established a short-term permissible exposure 
limit (STEL) ceiling for inhalation of manganese compounds to SmgW, for a 15-minute time-
weighted average (TWA) exposure limit (OSHA, 1995). Recommended exposure limit (REL) 
for manganese for 10 hours time weighted average has been reported to be 1 mg/m^ and 
3mg/m3 for 15 minute time weighted average as reported by National Institute for Occupational 
Safety and Health, USA (NIOSH, 1997). A level of 500 mg/m^ manganese has been reported to 
be immediately dangerous to life and health (NIOSH, 1997). 
Distribution and Excretion of IVIanganese 
Absorbed inorganic manganese is transported in systemic circulation and crosses the blood 
brain barrier (Aschner and Aschner, 1991). An average 70 Kg man carries a total body burden 
of about 12 to 20 mg of manganese (Tanaka, 1988). Manganese normally enters the brain 
across the cerebral capillaries, but entry can also occurs across the choroid plexus in cases of 
exposure to higher levels (Murphy et al., 1991). The highest tissue concentration of manganese 
is normally found in globus pallidus and striatum, the brain regions with higher levels of 
neuromelanin (Olanow et al., 1996). Manganese is excreted in faeces, urine, pancreatic fluids, 
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hair and breast milk (Saric, 1986). Excretion of inorganic Mn from the body is rapid and does 
not require active metabolism, and it does not pass through the glucouronidation pathway. 
Blood levels of manganese are increased in patients with impaired manganese clearance due to 
liver dysfunction (Hauser et al., 1994). 
Mechanism of Mn Toxicity 
The valence state of manganese is an important factor in determing its toxic effects on living 
tissues (Cotzias, 1958). Manganese neurotoxicity arises from the physiological dichotomy 
between the lower (Mn^^) and higher (Mn^^) oxidation states. Divalent manganese acts as a 
powerful antioxidant since it scavenges superoxide radicals. Trivalent manganese, on other 
hand produces reactive oxygen species and potentiates the autooxidation of dopamine with the 
concomitant production of neurotoxic by products (Archibald and Tyree, 1987; Parenti et al., 
1988; Ali et al., 1995; Shen and Dryhurst, 1998) and protein-bound cysteinyl dopamine and 
cysteinyl DOPAC (Hastings et al., 1996). Chiueh et al. (1993) proposed that striatal damage 
associated with exposure to Mn might be the outcome of lifetime accumulation of OH-induced 
oxidant stress elicited by dopamine, oxygen and iron. OH, in addition to attacking membrane 
lipid bilayers, induces Ca^^, leading to intracellular Ca^^ overload and the activation of 
proteases, which in turn, cause K^ over flow and release of excitatory amino acids such as 
glutamate. Involvement of dopamine receptors has also been demonstrated in manganese 
neurotoxicity (Seth, 1981; Sun et al., 1993). 
Factors Affecting Manganese Toxicity 
Experimental and clinical studies show that a variety of factors influence manganese toxicity. 
Development of manganese poisoning is alleviated under chronic infection such as syphilis, 
malaria, and tuberculosis and also under alcoholism (Chandra et al., 1983). Miners under iron 
deficiency (anaemia) were found to be more susceptible to toxic effects of manganese exposure 
(Mena et al., 1969). Higher concentrations of manganese were found in liver and kidney of rats 
fed on iron deficient diets, than those maintained on nonnal iron diets (Chandra and Tandon, 
1973). Protein or calorie malnutrition is another factor, which modulates manganese toxicity. 
Ali et al. (1983) showed that the animals maintained on a low protein diets during early 
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development were reported to exhibit grater decrease in brain GABA content and seizure 
tlireshold and an increase in seizure duration in comparison to controls on exposure to 
manganese. 
Toxicity in Humans 
Occupational workers exposed to manganese have been reported to be at a greater risk of 
developing Parkinson's disease (Gorell et al., 1999). Although the exact relationship between 
manganese exposure and Parkinson's disease has not been clearly explained, since only some 
individuals suffer from the disease. Based on this an environmental etilogy has been suggested 
in the pathophysiology of Parkinson's disease (Blake 1997; Cramner 1998). 
Human exposed to high levels of manganese through inhalation usually Mn02 lead to a 
disabling syndrome of neurological effects, which resemble parkinsonism, and is referred to as 
Manganism or manganese induced parkinsonism. The first signs of disorder are usually 
subjective and involve the feeling of weakness, heaviness or stiffness of the legs, anorexia, 
muscle pain, nervousness, irritability and headache (Seth and Chandra, 1988). As the disease 
progresses, the patients exhibit problems of articulating words, a fixed facial expression, 
spasmodic weeking, euphoria, clumsiness, hyper motionalism and exaggerated lower limb are 
the other clinical symptoms. Eventually the patient's condition may worsen and symptoms may 
include muscular hystonia, emotional disturbance, tremors, excessive salivation or sweating and 
increased frequency of spasmodic laughter (Rodier, 1955). Early preclinical effects of Mn in 
exposed workers have been studied using a battery of neurobehavioural tests (simple reaction 
time, digit span, finger lapping, verbal ability, hand dexterity and finger dexterity). Although 
the subjects did not exhibit the signs of clinical manganism described above, more subtle effects 
were present. Performance in tests was inferior in exposed workers. They also exhibited 
significantly lower levels of cognitive flexibility and difficulty in set shifting (Iregren, 1990; 
Mergler, 1994). 
Neurobehavioral Toxicity in Animals 
Extensive studies have been carried out to investigate the mechanism involved in the 
neurological manifestations of manganese. Clinical signs such as weakness, ataxia, or altered 
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gait following or at dosing with manganese have been reported in monkeys, rats and mice 
(Gupta et al., 1980; Singh and Junnarker 1991). Weakness and muscular rigidity has been 
reported in monkeys exposed to manganese (25 mg/kg) for 18 months (Gupta et al., 1980). In 
another study rats were found to develop a rigid and unsteady gait following exposure to 
manganese (150mg/kg) for 2-3 weeks. The changes were found to be transient and were not 
apparent by 7 weeks (Kristensson et al., 1986). A decrease in spontaneous activity, alertness, 
muscle tone and respiration has been reported following manganese exposure in mice (Singh 
and Junnarkar, 1991). Ishizuka (1991) in an another study on mice reported staggered gait and 
histochemical changes in two third generation following exposure to manganese (10.6 mg/kg) 
in drinking water. 
The turnover of catecholamine has reported to be affected following manganese exposure. 
Mustafa and Chandra (1971) reported a decrease in dopamine and norepinephrine and no 
change in serotonin in whole brain of adult rabbits 24 months after a single intractracheal 
injection of manganese dioxide. Decrease in dopamine levels in caudate nucleus and globus 
pallidus brain regions of Rhesus monkey were found after inhalation of manganese dioxide dust 
for a period of 2 years (Bird et al., 1984). Administration of triated L-tyrosine in mangeinese 
exposed animals causes an increase in ^H-dopamine and ^H-epinephrine levels as compared to 
those of controls suggests an increased synthesis of these amines from their precursors (Chandra 
and Shukla, 1981). Seth et al. (1981) studied the effect manganese on turnover of dopamine, 
norepinephrine, and serotonin by estimating the metabolites of these amines in striatal region of 
the brain of rats exposed to the metal for 15 days. Except for an increase in the level of 5-
hydroxyindole acetic acid (5-HIAA), no significant changes were observed in any other 
metabolites of these amines. Activities of enzymes responsible for synthesis and breakdown of 
neurotransmitter amines have been investigated to understand possible mechanism of alteration 
of biogenic amines levels. A decrease in tyrosine hydroxylase activity associated with a 
decrease in dopamine levels in hypothalamic areas of neonatal manganese-exposed rats have 
been reported (Deskin et al., 1980). Monoamine oxidase activity was found to increase in the 
brain of developing and adult rats exposed to manganese (Deskin et al., 1980; Seth et al., 
1984). Neurotransmitter receptors also have been shown as the target manganese neurotoxicity. 
Seth et al., (1981) have studied the effect of i.p. administration of manganese (10 or 15 mg/kg) 
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for 15 days on high affinity binding sites of certain key neurotransmitters in rats using 
appropriate hgands and brain regions. They observed that manganese at both doses caused a 
significant increase in striatal binding of ^H-spiperone while at lower dose it had no effect on 
binding of ^H-serotonin, ^H-diazepam or ^H-strychnine to frontal cortex membranes or binding 
of ^H-QNB to striatal membranes. The higher dose of metal was found to decrease the binding 
of ^H-serotonin ^H-mucimol, and ^H-QNB and to have no effect on binding of ^H-diazepam 
and ^H-strychnine. Levels of neurotransmitter substances were altered in age dependent manner 
in rats exposed to manganese (Seth and Chandra, 1984). Seth and Chandra (1988) have 
observed that administration of manganese (10 mg/kg. i.p.) to rat pups for 15 days from day 7 
after birth causes a decrease in the binding ^H-spiperone to striatal membranes. However, 
no such effect of manganese was seen from day 1 of birth. It is interesting to note that under the 
same treatment schedule, the neonatal rats exposed to manganese from the day of birth showed 
a decrease in ^H-serotonin binding but no such change when the exposure started day 7 after 
birth. Such a selective effect of manganese may perhaps be due to difference in the maturation 
of the receptor sites. 
Studies on animals have only been able to detect alterations in motor activity (hypo- or 
hyperactivity) or change in brain neurotransmitter levels and receptors (Subhas and 
Padamshree, 1991; Seth et al., 1981; 1984; Bonillaand Prasad, 1984). 
Cypermethrin 
Synthetic pyrethroids the second generation pesticides are largely used insecticide in agriculture 
and public health programme because of their low mammalian toxicity and high bio-efficacy 
and less persistence in soil. Chemically, pyrethroids are esters, which contain acid 
(chrysanthemic acid, halo-substituted chrysanthemic acid, 2-[4-chlorophenyl]-3-methyl butyric 
acid) and alcohol. The commercial products usually consist of both optical (IR/IS and D/L) and 
geometric (cis/trans) isomers. On the basis of the symptoms of poisoning, pyretliroids have 
been classified into two types, viz. Type I and 11. The Type 1 class of pyretliroids are non 
cyanogen molecules and are known to cause T-syndrome. The clinical symptoms of which are 
tremors, hyperexcitation, ataxia, convulsions and paralysis. The Type II pyrethroids contain a 
cyano group at the a-carbon position and cause hypersalivation, hypersensitivity to external 
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stimuli, choreo-athetosis, and paralysis and lead to CS-syndrome (Kamrin, 1997). 
Cypermethrin, a type II pyrethroid, initially synthesized in 1974 is a preferred pesticide in the 
cotton field (Battelle, 1982) while other agricultural uses of cypermethrin include the treatment 
of hop, vegetables and maize. Cypermethrin is also used for the control of insects, such as flies, 
lice and mites. Residues of cypermethrin have been detected in food material including stored 
grains and environment (WHO, 1998; Friedrich et al., 1998; Pang et al., 1997). Exposure to 
cypermethrin has been found to affect liver and kidney (USEPA, 1989). It has also been 
reported to cause neurobehavioral impairments both in humans and experimental animals 
(McDaniel and Moser 1993; USEPA, 1989). In view of this, studies on cypermethrin have been 
carried out both in humans and experimental animals to understand the mechanism of toxicity. 
Studies pertaining to the neurobehavioral toxicity of cypermetlirin are briefly reviewed here. 
Physical and Chemical properties 
Cypermethrin is the a-cyano-3-phenoxy-benzyl ester of the dichloro analogue of chrysanthemic 
acid, 2,2-dimethyl-3- (2,2-dichlorovinyl) cyclopropane carboxylic acid. The molecule contains 
three chiral centres, two in the cyclopropane ring and one on the alpha cyano carbon (WHO, 
1989). 
H ^ CH = CCl2 
Cypermethrin 
Eight isomers of cypermethrin, four cis and four trans have been identified. The cis group has 
more powerful insecticide activity as compared to trans group. The ratio of cis to trans isomers 
varies from 50:50 to 40:60. Pure isomers of cypermetlirin fomi colourless crystals, while, 
mixed isomers are present generally as viscous semi-solid or a viscous, yellow liquid (Ray, 
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1991; Kidd and Janies, 1991). The molecular weight of cypemietlirin is 416.3 and melting point 
of pure isomer is 60-80°C. The vapour pressure at 70°C is 5.1X10'^ nPa. It is soluble in organic 
solvents like methanol, acetone and xylene and insoluble in water. Cypermethiin is highly 
stable to light and at temperature below 220°C. It is more resistant to acidic than in alkaline 
medium with an optimum solubility at pH 4 (Kidd and James, 1991) 
Exposure 
Occupational exposure to cypermethrin occur among workers handling, these pesticides in 
manufacturing units. Farmers and spray workers are also getting exposed to this pesticide 
(WHO 1989; Maroni et al., 2000). The general population is exposed to cypermethrin both 
through the environment and due to consumption of food grains contaminated with 
cypermethrin. Residues of cypermethrin have been detected in food materials of animal origin 
like milk and milk products, egg and meat. Although total diet of market basket studies are not 
available yet it was inferred that daily intake of cypermethrin in human will be below the 
acceptable daily intake (WHO, 1989). 
Metabolism 
Extensive work on cypermethrin on metabolism in rat (Crawford et al., 1981), mice (Hutson et 
al., 1981), dog, cow, sheep, chicken and fish has been undertaken (WHO, 1989). Elimination of 
radioactivity in experimental animals dosed with cis- or trans- cypermethrin, ('''C-labelled in 
either the benzyl or cyclopropyl moiety) has shown that a greater part of the administered dose 
was excreted in the urine and faeces. Quantitative differences were found between the amounts 
eliminated via urine and faecal routes in various species. The variation in the amounts 
according to the route of elimination probably reflects the inter-group difference in ratio of 
absorption of labelled materials (WHO, 1989). 
In Wistar rats following given single oral administration (2.5 mg/kg) of either cis- or trans-
cypermethrin; (both ''^ C labelled in benzyl ring), a major part of both isomers were found to be 
rapidly eliminated tlirough urine and smaller part of both isomers tlirough faecal route 
(Crawford et al., 1981). However, in mice the radioactivity from trans isomer was mainly 
eliminated in the urine and that from the cis-isomer in the faeces (Hutson et al., 1981). Three 
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days after dosing, residues of radioactivity from both labels were found to be low in various 
organs except for fat. The order of magnitude of residues in various organs was 
fat>liver=kidney>blood=muscle>brain. Residues fell rapidly during the '"'C-benzyl study, with 
the exception of the residues derived from the cis-cypermethrin in fat, which did not decrease 
during the study period (Hutson et al., 1981). Skin was another tissue where retention of 
radioactivity was similar to fat. No major differences in the metabolism of cypermethrin were 
found in various species investigated. Only difference that occurred were related to rate of 
metabolite formation rather than to the nature of the metabolite formed. 
Cypermethrin metabolism has also been studied in human volunteers. Following a single dose 
of 0.25, 0.5, 1, 1.5 mg cypermethrin in com oil in capsule, male human volunteers, excreted an 
average 78% of the dose of trans-isomer and 49% of cis-isomer within 24 hours. These figures 
were quite similar to those found in rat. Metabolism of trans-isomer was faster than cis-isomer 
of cypermethrin as reported in other animal species (Eadsforth and Baldwin, 1983). The percent 
excretion of the cis and trans isomers of cypermetlirin in 24 hours period after administration of 
0.25, 0.75 or 1.5 mg/man, daily for 5 consecutive days was similar to that observed after a 
single oral administration of the respective dose. Therefore, no accumulation in the body was 
found (Van Sittert 1985a). Metabolites of cypermethiin were also detected in urine samples of 
human volunteers given a single dermal application of a ULV formulation, 25 mg cypemietlirin 
in hexylene glycol/Shellosol A (Van Sittert et al., 1985b) In humans, urinary excretion of 
cypermethrin metabolites was complete within 48 hours after the last of five doses of 1.5 
mg/kg/day (Woollen et al., 1992). 
Toxicity in Humans 
Studies on field operators and laboratory workers handling natural and synthetic pyrethroids, 
including cypermethrin, have been undertaken by several investigators. A transient sensation 
(tingling or buming) of the skin in the peri-orbital area of the face and other sites after direct 
skin exposure have been reported. The sensations have been interpreted as being caused by 
spontaneous repetitive firing of local sensory nerve fibres or nerve ending and were found to 
lasts on\y for few hours (Le Quesne et al., 1980). 
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Studies on 23 laboratory workers who had been exposed to synthetic pyrethroids revealed only 
facial sensations, no neurological and electro-physiological abnormalities were reported in these 
workers (Le Quesne et al., 1980). Suthers and Marlow (1981) in an field study carried out in 
India, on sprayman, mixers and loaders exposed to cypermethrin for 5 consecutive days, found 
no adverse clinical effects of peripheral neuropathy in any workers. Another field study on 
Indiein workers performed prior to, during, and after spraying cotton with cypermethrin also 
revealed adverse clinical effects (Hart et al., 1982). Biological monitoring and health 
surveillance carried out in 11 spray workers during the whole year in comparison with 10 
control persons, showed no significant changes in biological parameters or health injuries in 
exposed individuals as compared to control (Desi et al., 1986). 
Exposure to high doses of pyrethroids can be fatal as evident from a reported death after eating 
a meal cooked in 10% cypermetlirin concentrate mistakenly used for cooking oil. He had 
symptoms of nausea that progressed to stomach pains, to diarrhoea, to convulsions, to 
unconsciousness and then to coma. Death then occurred due respiratory failure (Ray, 1991). 
Neurobehaviourai Toxicity in Animals 
The oral LDjo for cypermethrin in rats is 250 mg/kg (in com oil). The EPA reports an oral 
LDso of 187 to 326 mg/kg in male rats and 150 to 500 mg/kg in female rats (USEPA, 1989). 
This wide variation in toxicity may reflect different mixtures of isomers in the material tested. 
CYP administered orally to rats and hamsters in high, acute and subacute doses produces 
reversible and clinical signs of ataxia, behavioural changes i.e. in-co-ordination, muscle 
trembling, tonic clonic convulsions and histological changes consistent with wallerian 
degeneration (WHO, 1989). The sequence of signs of CNS toxicity observed were salivation, 
pawing to rolling convulsions, tonic seizures, low blood pressure and finally death. 
Cypermethrin was not found to exert any tertogenic and mutagenic effects, it has been classified 
as a possible carcinogen by US EPA based on the development of benign lung tumours in 
female mice at the highest dose tested (229 mg/kg/day). However, no tumours occurred in rats 
given high doses of up to 75mg/kg/day (USEPA, 1989). 
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The primary target site cypermethrin (and of pyrethroid insecticide in general) in tlie vertebrate 
nervous system is the sodium channel in the nerve membrane. Cypermethrin like other a-cyano 
pyrethroids, cause a long lasting prolongation of the normally transient increase in sodium 
permeability of the nerve membrane during excitation, resulting in long-lasting train of 
repetitive impulses in sense organs and a frequency dependent depression of the nerve impulse 
in nerve fibres (Eells et al., 1993). 
Calcium-independent chloride channels have been found as the alternative second site of action 
of type II pyrethroids including cypermethrin. Inhibition of these charmels by pyretlnoids 
would therefore greatly enhance the excitable state induced by actions on the sodium currents 
(Ray et al., 1997). Pyrethroids of both groups act by keeping the sodium channel of the nerve 
membrane open, causing a depolarisation of neurons (He, 1994). Neonatal treatment with 
cypermethrin induces long-lasting impairment of renal dopamine Di and D2 like receptors 
(Cantalamessa et al., 1998). 
Effect of cypermetluin on functional impairment of blood brain barrier has been studied in 
developing and adult rats. A significant increase in blood brain barrier permeability was 
obsereved in developing rats exposed to cypermetlirin at low doses (l/50"^ and l/lOO"' of 
LD50). Since the changes were found to be persistent for a longer period of time, a high 
vulnerability of developing rats to cypermethrin, as compared to adults was suggested (Gupta et 
al., 1995; 1999). In another study by these investigators, a significant increase in brain uptake 
index of HRP and a decrease in membrane fluidity was observed in neonatal rats exposed to 
cypermethrin at l/50"' dose of LD50 from postnatal day 10 to 17 suggesting a significant 
impairment in the maturation of the BBB (Gupta et al., 2000). 
Region specific changes in rat brain polyamine levels following in utero exposure to 
cypermethrin has been reported by Husain et al (1992). The study suggested that alterations in 
polyamine levels in localised brain areas might affect the ontogeny of neurotransmitter system 
and impair behavioural functions and cause a delay in cerebral maturation (Husain et al 1992). 
A delay in the development of morphological events and reflexes was also observed in these 
studies. 
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A differential sensitivity of striatal dopamine and muscaranic receptors in rats was noted 
following exposure to cypermetlirin during gestation and lactation periods (Malaviya et al 
1993). Rats exposed to cypermethrin during gestation period exhibited a decrease in striatal 
dopamine and muscaranic receptors which, an increase both in dopamine and muscaranic 
receptors following lactational exposure (Malaviya et al 1993). Exposure to cypermethrin 
during lactation period also caused a significant decrease in the activity of brain 
acetylcholinesterase and Na^, K'^-ATPase however, no such change was observed in rats 
exposed during gestation period (Malaviya et al., 1993). 
Oral exposure to cypermetlirin at high doses has been reported to cause an abnormal gait in rats 
(WHO, 1989). Neuropathological changes have been reported in rats following single oral 
exposure to cypermethrin (100, 200 or 400 mg/kg body weight). The animals treated with high 
dose (400 mg/kg) exhibited a damage in the axons of the sciatic nerve and swelling in myelin 
sheath with in two days of dosing (Carter and Butterworth, 1976). Signs of intoxication and 
neuropathy observed in these rats were found to be dose dependent. Ultrastructural changes in 
sciatic nerves were observed following exposure of rats to cypermethrin at high doses (2500 
and 5000 mg/kg diet) through diet for 14 days Mortality, clinical signs of neurotoxicity viz. 
hind limb paralysis, ataxia and hypersensitivity were recorded in these rats (WHO, 1989). In 
other studies, no significant abnormality in nerve fibres was observed in rats exposed to 
cypermethrin for 2 years at different doses (1, 10, 100 or 1000 mg/kg diet) as compared to 
controls (Trigg et al., 1977; McAusland et al., 1978). Exposure to cypermethrin in hamsters 
caused nerve lesions and axonal swelling (Butterworth and Clark, 1977) while no signs of 
intoxication or delayed neurotoxicity were observed in chickens (Owen and Butterworth, 1977). 
6-Hydroxydopamine 
The observations that 6-hydroxydopamine (6-OHDA), a neurotoxic agent selectively damages 
the dopaminergic neurons of the nigro-striatal pathways in rats resulting in severe depletion of 
dopamine in the striatum like Parkinson's disease, have led to development of animal model of 
Parkinson's disease (Uretsky and Iverson, 1970; Onn, 1986). The treated animals also exhibited 
behavioural deficits (Zigmond, 1987; Carder et al., 1989). Interestingly, such an effect is 
produced only after intra cerebero-ventricular injection and not tlirough peripheral 
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administration of 6-OHDA, since it does not crosses the blood brain barrier (Kostrzewa and 
Jacobowitz, 1974). 
Stability of 6-OHDA in aqueous solution is very poor at neutral pH and in presence of oxygen. 
Reaction of 6-OHDA and molecular oxygen yields hydrogen peroxide (H2O2) and red quinone 
[Eq. (1)]. The rapid formation red quinoidal products over 10-20 seconds at pH 7.4 is readily 
apparent visually. This observation led many early workers to add ascorbic acid as a reducing 
agent to "protect" the 6-OHDA from oxidation. However, ascorbate plays a more prominent 
role as an agent that exacerbates the neurotoxic effect of 6-OHDA. Entry into 
catecholaniinergic neurons requires 6-OHDA be present in its reduced form, which is 
recognised by catecholamine transporter. Hence, ascorbate helps to maintain 6-OHDA in 
transportable form. However the same role is served by endogenous ascorbate (e.g. in blood 
plasma). Tissue ascorbate also promotes toxicity by recycling the quinones [Eq. (2)] 
6-OHDA+ O2 •O-and p-quinones + H2O2 (1) 
ascorbate + quinone • dehydroascorbate + 6-OHDA (2) 
Fe^^ + H2O2 • Fe^^ + "OH + OH" (3) 
The H2O2 generated as described in [Eq. (1)] can damage dopaminergic neurons (Heikkila 
and Cohen, 1971). Formation of hydroxyl radicals [Eq. (3)] as neurotoxic intermediate during 
the reaction has also been'suggested (Cohen et al., 1976). The quinones may cause toxicity via 
formation of adducts with protein - SH leading to inactivation of enzymatic or structural 
properties of key proteins (Graham, 1978). 
The generation of superoxide radical by 6-OHDA was detected in experiments with superoxide 
dismutase (Heikkila and Cohen, 1973). By scavenging superoxide radicals, superoxide 
dismutase suppressed both the formation of quinones and accumulation of H2O2. Based on 
these observations it was suggested that superoxide dismutase catalyses a reaction that 
generates H2O2, its net effect is to suppress the over all formation of H2O2 and subsequently, the 
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hydroxyl radicals. However, the paradoxical situation was also suggested in the reaction 
mechanisms for auto oxidation of 6-OHDA. 
6-OHDA + O2 • SQ + O2" + H^ (4) 
(Slow) 
6-OHDA + O2" + H^ • SQ + H2O2 (5) 
(Fast) 
SQ + O2 • Q + O2" (6) 
(Fast) 
Where Q stands for 6-OHDA-quinone, SQ is the corresponding semiquinone, and O2" is the 
superoxide radical anion. 
The direct reaction of oxygen with 6-OHDA is relatively slow [Eq. (4)] whereas the oxidation 
of 6-OHDA by superoxide is much faster [Eq. (4)]. After initiation of the reaction sequence 
[Eq. (4) and (5)], SQ reacts rapidly with molecular oxygen to regenerate superoxide [Eq. (6)]. 
Equation (5) and (6) establish a radical chain reaction in which superoxide is consumed as it 
oxidizes 6-OHDA and then it is regenerated. The reaction chain bypasses the slow step [Eq. (4)] 
and promotes formation of H2O2 [Eq. (5)] and quinones [Eq. (6)]. The chain reaction can be 
intercepted by superoxide dismutase or by catecholamines (such as DA or NE) which are also 
oxidized by superoxide (Sachs et al., 1975; Cohen and Heikkila, 1977). Therefore, the 
catecholamines act as scavengers for superoxide, suppressing the overall rate of production of 
H2O2 and quinones by replacing the extraordinarily rapid autooxidation sequence for 6-OHDA. 
6-OHDA is a hydroxylated analogue of dopamine and is easily recognised by the catecholamine 
transporters present in the axonal membranes of catecholaminergic neurons and enters the 
neurons via this pathway. The major target is catecholaminergic neurons tlirough axonal 
transport leads to neurotoxicity (Kostrzewa and Jacobowitz, 1974). 
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CHAPTER - 2 
MATERIALS AND METHODS 
Chemicals 
Radioligands ^H-spiperone (24 Ci/mniol) and ^H-ketanserin (63.3 Ci/mmol) used during the 
study were purchased from New England Nuclear Corporation, USA. The fluorescent dye 
quin-2 acetoxymethyl ester (Quin-2AM), probe-1,6-diphenyl 1,3,5-hexatriene (DPH) and 
other chemicals like kynuramine, 5-5'-dithiobis-2-nitrobenzoic acid (DTNB), 4-
hydroxyquinoline, serotonin, dopamine, 6-hydroxydopamine (6-OHDA), reduced glutathione 
(GSH), pargyline, bovine serum albumin (BSA) were procured from Sigma Chemicals Co., 
St. Louis, USA. Pharmacological agents such as haloperidol, reserpine, clomipramine, 
mazindol, fenfluramine, cinanserin were purchased from Research Biochemical Inc. (RBI), 
USA. 4,6-dihydroxy-2-mercaptopyrimidine (TBA) was purchased from Acros Organics, 
New Jersey, and USA. Nitroblue tetrazolium (NBT), b-nicotinamide adenine dinucleotide 
(NADH), ethylenediamine tetraacetic acid (EDTA), ethylene glycol-bis(b-aminoethyl ether)-
N, N, N', N'-tetraacetic acid (EGTA), naphthalene, 2, 5-diphenyloxazole (PFO), 1, 4-bis (5-
phenyloxazol-2-yl) benzene (POPOP) were purchased from SISCO Research Laboratory, 
Mumbai, India. Manganous chloride (MnCli) was procured from BDH, Qualigens, Mumbai, 
India. Cypermethrin-25% EC (w/w) was purchased from Zeneca ICI Agrochem Limited, 
Chennai, India. All other chemicals used in the study were of AR or GR grade, available in 
India. 
Instruments 
Sorvall RC-5B high speed centrifuge (Dupont, USA), Sigma 3K30 centrifuge (Sigma, 
USA), Cell Harvester (Brandel, USA), LKB-Wallac Rack P-Scintillation counter (LKB, 
Sweden), spectrophotometer (GBC Cintra 20), spectrofluorometer (Shimadzu, RF-5000, 
Japan) and stereotaxic apparatus (TWCO, Ambala, India) were the major instruments used 
during the course of this study. 
Animals 
Albino rats {Rattus norvegicus) of the Wistar strain obtained from the animal breeding 
colony of Industrial Toxicological Research Centre were used throughout the study. The 
animals were housed in stainless steel cages in groups and in plastic polypropylene cages 
individually under standard animal house conditions with a 12 hour light/dark cycle and a 
temperature of 25±2°C. The animals had free access to food in the form of pellet obtained 
from Lipton India Ltd., Mumbai. 
Treatment of Animals 
Adult male or female albino rats of Wistar strain weighing 180-200 gm of Industrial 
Toxicology Research Centre animal breeding colony were acclimatized in the animal room 
with controlled temperature. 
(a) Manganese 
Male rats were divided into three groups of 25 each. Animals of two groups were treated 
with manganese as manganous chloride (MnCh, dissolved in normal saline) either at 10 or 
15 mg/kg body weight/day intraperitoneally for 15 or 45 days. The third group was injected 
with normal saline in an identical manner to serve as control. A set of 10 animals from each 
group were sacrificed 24 hours after 15 days of treatment while rest of the animals continued 
to receive MnCb upto 45 days and were sacrificed 24 hours after the last injection. 
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(b) Cypermethrin 
Female rats were randomly divided into three groups of 30 each. Animals in two groups were 
treated with cypermethrin (mixed in corn oil) either at 15 or 30 mg/kg body weight 
dose/day, p.o. for 10 or 21 days. The third group received corn oil identically to serve as 
control. Effect of cypermethrin on behavioural and biochemical parameters was studied 10 or 
21 days after treatment while a set of 10 animals from each group were left as such 21 days 
after treatment for 10 days to investigate persistence/reversal of the biochemical changes. 
(c) Reserpine 
Male rats were divided into four groups of eight animals each and treated with reserpine as 
per the following schedule. 
Group I - Reserpine, 1 mg/kg/day, i.p. for 5 consecutive days. 
Group II - Vehicle identically as in Group I. 
Group III - Reserpine, 5 mg/kg, i.p., single exposure. 
Group IV - Vehicle identically as in Group III. 
Blood and brain from the rats of groups I & II were collected 12 hours and in groups III & 
IV at 18 hours after the last reserpine treatment.. 
(d) 6-Hydroxydopamine lesioning 
Twenty male rats were injected bilaterally with 6-hydroxydopamine hydrochloride (6-
OHDA, Sigma; 8 ^g/^l, dissolved in saline with 0.1 % ascorbic acid) into the striatum under 
sodium pentobarbital anesthesia. The fresh solution was delivered from a microsyringe at a 
rate of 1 ^l/min. Stereotaxic coordinates were 0.7 mm anterior to the bregma, 2.8 mm lateral 
from the midline, and 4.6 mm below the dura with the incisor bar located 3.3 mm below the 
interaural line (Paxinos and Watson, 1986). After 72 hours of lesioning, rats were 
anaesthetized with anesthetic ether and blood was drawn by cardiac puncture and brains were 
removed and kept frozen. 
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Clinical Cases and Controls 
(a) Idiopathic Parkinson's Cases and Controls 
Cases of idiopathic Parkinson's disease (IPD) included in the present study were those 
attending the outdoor/indoor clinics of the Department of Neurology, King George's Medical 
College, Lucknow, India. The clinical diagnosis and classification of the patients were done 
by the attending neurologists. The degree of severity was evaluated according to the Hoehne 
and Yahr Scale (Hoehne and Yahr 1967; Calne et al. 1992). The patients were already taking 
L-DOPA and all cases showed a clear response following the L-DOPA treatment. This was a 
blind study and clinicians were not aware of the laboratory findings and the laboratory 
examiners were also blinded about the clinical profiles of the patients. It was ascertained that 
none of participants was taking drugs like aspirin, phenothrazine and antidepressant etc. 
before collection of blood samples. Cases suspected of progressive supranuclear palsy (PSP), 
oligopontocerebellar atrophy (OPCA), multisystem atrophy (MSA), multi-infarct dementia, 
essential tremors, manganese toxicity were excluded from the study. 
Informed consent was taken in all cases for participation in the study. After a thorough 
screening and detailed clinical examination cases which matched the diagnostic criteria for 
IPD and control subjects were selected for assay of DA-D2 receptor and monoamine oxidase 
activity in blood platelets. 
Platelet DA-D2 receptor was assayed in 25 IPD cases and 13 control subjects. Severity of the 
disease was graded on Hoehne and Yahr Scale (Hoehne et al. 1967, Calne et al. 1992) and 
based on that cases were graded on stage I (n=10), stage II (n=3) and stage III (n=12). 
Similarly for the assay of platelet monoamine oxidase activity, 26 IPD cases which were 
graded into stage I (n=IO), stage II (n=6) and stage III (n=10) and 26 control subjects were 
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Table 2.1 
Subject characteristics for assay of platelet dopamine D2 receptor 
Parkinson's disease Control 
Number 25 13 
Age 56 ±2.47 35.15±3.61 
Age range 3 0 - 7 6 2 0 - 5 5 
Male: Female (ratio) 21:4 12:1 
Duration of disease (DOD) 2.39 ±0.52 -
DOD range 0 .16-12 -
Age, age range, duration of disease and range of DOD are expressed in terms of 
years. Age and duration of disease is expressed as mean ± SE. 
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Table 2.2 
Subject characteristics for assay of platelet monoamine oxidase activity 
Parkinson's disease Control 
Number 26 26 
Age 56.65 ± 1.82 40.65 ±2.52 
Age range 4 0 - 7 6 2 0 - 6 5 
Male: Female (ratio) 22 : 4 22 : 4 
Duration of disease (DOD) 3.07 ±0.48 -
DOD range 0 .16-11 -
Age, age range, duration of disease and range of DOD are expressed in terms of 
years. Age and duration of disease is expressed as the mean ± SE. 
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selected. The mean age, age range, sex ratio, duration of disease and range of duration of 
disease in IPD cases for both DA-D2 receptor and monoamine oxidase activity are given in 
Table 2.1 and 2.2. The mean age, age range, sex ratio for control subjects used against IPD 
cases also given in the Table 2.1 and 2.2. 
(b) Migraine Cases and Controls 
Thirty-three patients of migraine attending the Headache Clinic in the Neurology outpatients 
department of the King George's Medical College, Lucknow, India were included. The 
diagnosis of migraine was based on the criteria given by the International Headache Society 
(HCCISC, 1988). A detailed history was taken according to a pre-designed proforma and 
complete physical examination was done. The severity of headache was measured by 
calculating the Headache Index (Number of attacks per month x Severity of pain x Duration 
of pain in hours). The severity of pain in the attacks was graded on a three point scale: 1 = 
Mild headache, does not interfere with the patients daily routine; 2 = Moderate headache, 
interfere with the daily routine but patient can continue his work; 3 = Severe headache, 
patient has take bed rest. Thirty healthy controls comprising of paramedical staff and 
relatives of the patients were also included. The patient characteristics of the subjects 
included in the study are given in Table 2.3. 
None of the subjects included in the study were suffering from hypertension, diabetes 
mellitus, ischaemic heart disease or any psychiatric illness, which may affect 5-HT 
metabolism. Food items (banana, chocolates, nuts) containing 5-HT were forbidden for at 
least 14 days and drugs like aspirin, psychotropics, antidepressants were not allowed for at 
least 7 days prior to collection of blood samples. 
Migraine with aura and without aura was diagnosed as per the following criteria. 
Criteria for Diagnosing Migraine Without Aura 
(a) At least 5 attacks fulfilling b to d. 
(b) Headache attacks lasting 4 to 72 hours ( untreated or unsuccessfully treated) 
(c) Headache has at least two of the following characteristics : 
i) Unilateral location 
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ii) Pulsatile quality 
iii) Moderate or severe intensity 
iv) Aggravation by walking stairs or similar routine physical activity, 
(d) During headache one or the following: 
i) Nausea and/or vomiting 
ii) Photophobia and phonophobia 
Criteria for diagnosing migraine witli aura (typical) 
Headache attack fulfilling both a and b. 
(a) Headache attacks including all of the following four characteristics: 
i) One or more fully reversible aura symptoms indicating focal cerebral cortical -
and for brain-stem dysfunction 
ii) Atleast one aura symptom develops gradually over more than four minutes or, 
two or more symptoms occur in succession 
iii) No aura symptom lasts for more than 60 minutes. If more than one aura symptom 
is present, accepted duration is proportionally increased. 
iv) Headache following aura with a free interval of less than 60 minutes ( i t may also 
begin before or simultaneously with the aura) 
(b) One or more aura symptom of the following types: 
i) Homonymous visual disturbance. 
ii) Unilateral paresthesia and/or numbness. 
iii) Unilateral weakness. 
iv) Aphasia or unclassifiable speech difficulty. 
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Table 2.3 
Subject characteristics for assay of platelet 5-HT2a receptor 
Migraine Control 
Number 33 30 
Age (years) 30.45 ± 1.70 36.23 ± 1.85 
Age range (years) 12-50 20-48 
Male: Female (ratio) 8 :25 17: 13 
Type 
With aura 6 -
Without aura 27 -
Duration of disease ( years) 7.41 ±0.91 -
Time since last attack 
(days) 
7.12 ±0.86 -
Headache index 284 ± 38 -
Positive family history 12 -
Age, age range and duration of disease are expressed in terms of years. Age, duration of 
disease and time since last attack are expressed as mean ± SE. 
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Collection of Blood from Patient and Control Subjects 
After obtaining the informed consent from the subjects of the study group, 9mi of venous 
blood was drawn from the antecubital vein using disposable plastic syringe fitted with a 20 
gauge needle and immediately transferred into plastic tube containing 1 ml of 3.89% 
trisodium citrate and mixed gently. 
Collection of Blood for in vitro Studies on Human Platelets 
Human blood from healthy volunteers was procured through the authorised blood bank 
(Kohli Pathology, Aliganj, and Lucknow). The blood from the donors was collected by the 
pathologist between 9-10 AM in a plastic bag containing 3.89% trisodium citrate in the ratio 
of 9 ml of blood and 1 ml of trisodium citrate. 
Collection of Rat Blood and Brain 
The blood from the anaesthesised rats was drawn by cardiac puncture using a disposable 
plastic syringe fitted with 20 gauge needle and transferred immediately into plastic tubes 
containing 3.89% trisodium citrate (in the ratio of 9:1) for preparation of platelets. 
Immediately after withdrawal of the blood, animals were sacrificed and brains removed and 
kept on ice. The corpus striatum was dissected out for biochemical studies (Glowinski and 
Iverson 1966). 
Platelet counts 
Platelet counts were measured using Neubauer haemocytometer. Briefly, 0.1 ml PRP and 1.9 
ml formal citrate were mixed for 2 minutes in a plastic tube and transferred to the counting 
chamber. The counting chamber was placed in moist and left untouched for about 20 
minutes for the platelets to settle. The number of platelets in 1 mm^ were counted. 
Preparation of Platelet Membranes 
PRP was centrifuged at 12,000 x g for 10 min at 4''C and the platelet pellet obtained was 
washed twice with Tris-HCl buffer (5 niM, pH 7.4), to wash off endogenous amines and 
suspended in Tris-HCl buffer (5 mM, pH 7.4). The platelet suspension was homogenised 
and centrifuged at 50,000 x g for 10 min at 4°C for preparation of platelet membrane. The 
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pellet membranes were finally suspended in incubation buffer Tris-HCl buffer (15.4 niM. pH 
7.4) and used for membrane fluidity and receptor binding assay. 
Processing of Rat Brain for Biochemical Studies 
Freshly dissected wet corpus striatum was homogenised in chilled 0.1 M phosphate buffered 
saline (10 % W/V) using a glass homogenizer with a teflon pestle under cold conditions for 
assay of reduced glutathione and lipid-peroxidation. The homogenate was centrifuged at 
15,000 X g for 10 min at 4 ^ . The pellet was suspended in phosphate buffered saline (0.1 M) 
and used for determination of superoxide dismutase and monoamine oxidase activity while 
supernatant was used for assay of catalase activity as described elsewhere. 
Intracellular calcium levels were measured in crude synaptosomal preparation, for which 
corpus striatum was homogenised in 0.32 M sucrose, centrifuged at 1,500 x g for 10 minutes 
at 4''C, to remove nuclear fractions, supernatant was centrifuged at 17, 800x g, for 30 minutes 
at 4°C, resulting pellet suspended in Hepes buffer (Komulainen and Bondy, 1987). 
Dopamine receptors were assayed in crude synaptic membranes following the method of 
Khanna et al (1994). Briefly the corpus striatum was homogenised in 19 volumes of sucrose 
(0.32 M) followed by centrifugation at 50,000 x g for 10 min at 4°C. Subsequently the pellet 
was washed with deionized water and centrifuged at the same speed for 10 min to remove 
endogenous amines. Finally, the pellet was suspended in Tris-HCl buffer (40 mM, pH 7.4). 
In vitro Studies 
(a) Preparation of Platelet Rich Plasma and Platelets 
The citrated blood was centrifuged at 200 x g for 10 min at room temperature and the 
supernatant, platelet rich plasma (PRP), transferred into another plastic tube. Platelets were 
isolated by centrifuging the PRP at 4,000 x g for 10 min at 4°C. The platelet pellet was 
suspended in 0.1 M phosphate buffered saline, and used for the determination of lipid 
peroxidation, reduced glutathione, membrane fluidity and activities of catalase and 
superoxide dismutase. Intracellular calcium (i [Ca^^]) was measured using PRP. For the assay 
of monoamine oxidase activity, PRP was centrifuged at 15,000 x g for 10 min at 4°C. The 
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resulting pellet was suspended in double distilled water, re-centrifuged at 15,000 x g for 10 
min and finally suspended in distilled water and frozen at -20"C till assay. 
(b) In vitro Effect of Reserpine on Dopamine Receptors (DA-D2) in Rat 
Platelets 
Rat PRP was incubated with reserpine at concentrations - 1 |ag/ml or 2 |ig/ml for 60 minutes 
at 37°C. Separate tubes of PRP were pre-incubated at 37°C for 5 minutes with pargyline 
(2mM) followed by incubation with reserpine (1 |ig/ml or 2 |ag/ml) for 60 minutes under 
similar conditions. The control tubes without reserpine or pargyline were run in parallel. 
After the incubation, PRP was processed for platelet membrane preparations followed by ^H-
spiperone binding assay as described above. 
(c) In vitro Effect of Dopamine and Mazindol on Dopamine Receptors (DA-
D2) in Human Platelets 
Human PRP was pre-incubated with pargyline (2|iM) at 37° C for 5 minutes followed by 
incubation with mazindol (DA uptake inhibitor) and dopamine at varying concentrations i.e. 
0.5, 1, 5'and 10 nM for 15 minutes at 37°C. A set of tubes which without these agents were 
run in parallel to serve as control. Reaction was terminated by placing the tubes in an ice bath 
and the PRP was processed for platelet membrane preparations followed by ^H-spiperone 
binding assay. 
(d) In vitro Effect of Serotonin, Clomipramine & Fenfluramine on 
Serotonin Receptors (5-HT2a) in Human Platelets 
Human PRP was pre-incubated with pargyline (2|aM) at 37°C for 5 minutes followed by 
incubation with clomipramine, fenfluramine and 5-HT at varying concentrations i.e. 0.5, 1, 5 
and 10 nM for 15 minutes at 37°C. A set of tubes without these agents was run in parallel to 
serve as control. Reaction was terminated by placing the tubes in an ice bath and the PRP 
was processed for platelet membrane preparations followed by ^H-ketanserin binding assay. 
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Protein estimation 
Protein concentration in samples was determined following the method of Lowery et al 
(1951) using bovine serum albumin (BSA) as a reference standard. 
Assay of Reduced Glutathione 
Glutathione levels were assayed following the method of Hasan and Haider (1989), in 
platelets and corpus striatum. Briefly, platelet suspension or brain homogenate (Iml) was 
deproteinised with an equal volume of 10 % trichloroacetic acid and allowed to stand at 4°C 
for 2 hours. This mixture was centrifuged at 2,000 x g for 15 minutes and a suitable aliquot 
of the supernatant (375 for platelet and 1 ml for brain) was added to 2 ml of Tris-HCl 
buffer (0.4 M, pH 8.9) containing EDTA (0.02 M). Finally 0.1 ml of DTNB (0.01 M) was 
added. The mixture was diluted with 0.5 ml of distilled water, stirred and the absorbance was 
recorded at 412 run. A standard containing 10 l^g of GSH was also run in parallel. 
Assay of Lipid Peroxidation 
As a measure of lipid peroxidation, malonaldialdehyde (MDA) formation was estimated 
using the level of thiobarbituric acid reactive substances (TBARS) according to method of 
Bohme et al. (1977). Equal volumes 120 i^l of EDTA (10 niM), ascorbate (10 mM) and 
mixture of EDTA (16.7 mM) and FeS04 (16.7 mM) were mixed and to this platelet 
suspension (840 ml) was added. The starting mixture was incubated at 37''C for 0 and 90 
min. The reaction was stopped by adding 1 ml of ice cold 10 % trichloroacetic acid (TCA). 
The mixture was centrifuged at 2,000 x g for 10 min and supernatant was aspirated out. Brain 
homogenates were incubated at 37°C for 0 and 60 min and the reaction was stopped by 
adding 10 % ice cold TCA using the same incubation medium. Deproteinised homogenates 
were centrifuged at 2000x g for 10 min and supernatant was aspirated out. Supernatants (2 
ml) was mixed with equal amount of 0.67 % TBA and kept in boiling water bath for 15 to 20 
min. The intensity of pink colour developed was read at 532 nm on a spectrophotometer. 
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Assay of intracellular calcium 
Intracellular calcium was determined by the fluorenieteric determination of the hydrolysed 
acetyl methyl ester of Quin-2AM in platelets and crude synaptosomal preparations. In 
platelets the intracellular calcium levels were assayed by the method of Srivastava et al 
(1994). Fluorescence dye Quin-2AM was loaded into the platelets at a final concentration of 
25 laM by incubating the dye with PRP for 60 min at 37°C in dark. After the incubation, 
platelets were sedimented by centrifugation of the Quin-2AM loaded PRP at 1,900 x g for 10 
min at 4°C. The Quin-2AM-loaded platelets were washed twice with platelet wash buffer 
(Na2HP04, 4.26 mM; NaH2P04, 7.26 mM; sodium citrate, 4.77 mM; citric acid, 2.35 mM; 
bovine serum albumin, 0.35g%; glucose, 5.5 mM; and NaCl, 128 mM, pH 6.5) to remove 
unbound Quin-2AM and resuspended in modified Hepes buffer (NaCl, 125 mM; KCl, 5 niM; 
K H 2 P O 4 , 6 mM; MgS04, 1.2 mM; Hepes, 25 mM; glucose, 6 mM; and CaCb, 1 mM, pH 
7.4). The emitted fluorescence of the samples was recorded over a Shimadzu RF-5000 
spectrofluorometer at the excitation and emission wavelengths of 339 and 492 nm 
respectively. 
Intracellular calcium levels in crude synaptosomal preparations were assayed following the 
method of Olsen et al. (1991). Briefly, synaptosomes containing 150-250 mg protein were 
incubated in 3 ml Hepes buffer (12 mM NaCl, 5 mM KCl, 1.2 MgS04, 6 mM glucose, 6 mM 
CaCb, 5 mM NaHCOs, 25 mM Hepes, pH 7.4) with fluoremeteric dye Quin-2AM at a final 
concentration of 25 |aM for 45 min in dark at 37''C. After incubation the assay mixture was 
centrifuged at 34,000 x g for 15 min. To remove unbound Quin-2AM the pellet was carefully 
washed twice with assay buffer and centrifuged a.t the same speed and time. Finally, pellet 
was suspended in 2 ml assay buffer. The emitted fluorescence of the sample was recorded 
over a Shimadzu RF-5000 spectrofluorometer at excitation and emission wavelengths of 339 
and 492 nm respectively. 
In both the above methods, extracellular calcium was quenched by adding MnCh (40 |iM) 
and the fluorescence R was measured. Fluorescence R minimum (Rmi,,) was recorded after 
addition of sodium dodecyl sulphate (0.1 %) and alkaline EGTA (5 mM) while Rn,ax was 
determined by addition of CaCb (7 mM) and intracellular calcium levels were calculated 
using the formula: 
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Intracellular calcium ([Ca^^Ji) = Kd (R-RmirARnm-R) 
Kd = 115nM, is the dissociation constant of Quin-2-Ca complex. 
Assay of Membrane Fluidity 
Membrane fluidity was determined by fluorescence polarization of the lipid probe - 1,6-
diphenyl-l,3,5-hexatriene (DPH) in platelets and synaptosomal membrane by the method of 
Shattil and Cooper (19.76) and Shinitzky et al. (1978) respectively. Platelets/synaptic 
membranes were incubated with DPH for 60 or 40 min respectively at 37°C at a final 
concentration of 4 |aM in dark. Fluorescence polarization was measured with a Shimadzu 
RF-5000 spectrofluorometer equipped with rotating polarizer. Relative fluorescence intensity 
was measured into different directions viz. Ivv, IVH, IHH, Iiiv (where V is vertical and H is 
horizontal) and fluorescence polarization (P) was calculated: 
P = Ivv -IvH -G / Ivv +IvH .G 
Where G = IHV / IHH IS the correction factor. 
Assay of Catalase Activity 
The activity of catalase in platelets and corpus striatum was assayed following the procedure 
of Sinha (1972) using H2O2 as substrate. Appropriate volumes of platelet suspension and 
brain homogenates were mixed with 1 ml of phosphate buffer (0.01 M, pH 7.0). The enzyme 
mixture was incubated with H2O2 (0.2 M) at 37°C for 1 min and reaction was stopped with 
addition of 2 ml of dichromate-acetic acid reagent and immediately keeping the tubes to a 
boiling water bath for 15 min. The green colour developed during the reaction was read at 
570 nm over spectrophotometer. Control tubes, which were devoid of enzyme preparations, 
were processed in parallel. Enzyme activity was calculated using extinction coefficient of 
H2O2 and expressed in terms of |imoles/min/lxlO^ platelets or ^moles/min/mg protein for 
brain. 
Assay of Superoxide Dismutase Activity 
The activity of superoxide dismutase (SOD) was assayed following the method of Kakkar et 
al (1984) with minor modifications. The assay mixture in a final volume of 3 ml contained 
sodium pyrophosphate buffer (0.082 M, pH 8.3), phenazine methosulphate (186 (iM), 
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nitrobluetetrazolium (300 |iM), NADH (780 ^M), diluted enzyme preparation and distilled 
water. The reaction was initiated by addition of NADH, followed by incubation at 3TC for 
90 seconds. The reaction was stopped by 1ml glacial acetic acid and the reaction mixture was 
vigorously shaken with 4 ml of n-butanol. The mixture was allowed to stand for 10 min, 
centrifuged and butanol layer was separated. The colour intensity of the chromogen in 
butanol was measured at 560 nm against butanol over a spectrophotometer. A mixture 
without enzyme preparations was run in parallel to serve as control. The SOD activity was 
expressed in units/1 x 10^ platelets or mg protein. One unit of the enzyme was the amount 
required to inhibit the rate of chromogen formation by 50%. 
Assay of monoamine oxidase activity 
Activity of monoamine oxidase were measured fluorometrically using kynuramine as 
substrate by the method of Suzuki et al (1988) both in platelets and corpus striatum. The 
reaction mixture in final volume of 1 ml containing K 2 H P O 4 (0.5M), enzyme preparation 
(0.314 -0.966 mg protein) and distilled water was pre-incubated for 10 min at 37''C. After 
pre-incubation, kynuramine (10 |aM) was added to the reaction mixture and tubes incubated 
at 37°C for 30 min. The pH of incubation mixture was 7.0. The enzyme reaction was stopped 
by adding 2 ml NaOH (1 N) solution. The samples were centrifuged at 2,000 x g for 10 min 
to obtain clear supernatants. Finally, the fluorescence intensity was measured with a 
Shimadzu RF-5000 spectrofluorometer at excitation 318 nm and emission 380 nm. The assay 
mixture without substrate served as the control. Substrate to the control was added after 
inactivation with NaOH. As an internal standard, 0.1 ml 4-hydroxyquinoline solution (1-10 
rmioles) was added to the mixture, which then under went the same procedure as that for the 
blank test. 
Assay of ^H-Spiperone Binding to Platelet and Striatal Membranes 
Binding of ^H-spiperone both in platelets and striatal membranes known to label dopamine 
receptors was carried out following the standard methods (Khanna et al., 1987b, 1994). 
Briefly, binding tubes containing 1 nM / 3 nM ^H -spiperone, 0.1 ml platelet/striatal 
membrane suspension and 15.4 / 40 niM Tris-HCl buffer (pH 7.4) in a final volume of 1 ml 
in triplicate were incubated for 15 min at 37°C for platelet and striatal membranes assays 
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respectively. The reaction was terminated by placing the tubes in an ice bath and the samples 
were rapidly filtered on glass fibre discs (GF/B for platelets and GF/C for corpus striatum). 
The filters were washed twice with 5 ml cold Tris-HCl buffer (40 mM, pH 7.4), dried and 
counted in vials containing 10 ml scintillation fluid using LKB-Wallac Rack beta-II 
Scintillation Counter at an efficiency of 50% for tritium. The scintillation fluid was the 
mixture PPO, POPOP, naphthalene, methanol, toluene and dioxan. Control incubations 
containing haloperidol (IxlO'^M) were carried out simultaneously to determine the extent of 
non-specific binding. The result was expressed as pmoles ^H-spiperone bound/gm protein. 
Saturation experiments were also-performed using a concentration range of 0.1-10 nM of ^H-
spiperone and data was analyzed by linear regression analysis to determine the affinity (Kd) 
and number of receptor sites (Bmax)-
Assay of ^H-Ketanserin Binding in l-iuman Platelet Membranes 
Binding assays of ^H-ketanserin to platelet membranes were carried out as described by 
Oshuka et al. (1995). Briefly, binding tubes containing assay buffer (50 mM Tris-HCl, pH 
7.5), platelet membrane protein (150-300 ijg/tube) and ^H-ketanserin (3 nM) in final volume 
of 1ml, in triplicates were incubated for 60 min at 4°C. Following incubation, the contents in 
the tubes were rapidly filtered over GF/B glass fibre filter sheets (Whatman, USA) over the 
cell harvester. The filter discs were washed twice with cold Tris-HCl buffer (40 mM, pH 7.4) 
to remove unbound radioligand and dried and placed in scintillation vials and counted with 
10 ml of scintillation fluid on the LKB-Wallac Rack beta-II Scintillation Counter at an 
efficiency of 50% for tritium. Non specific binding was determined using cinanserin (1x10' 
^M). Specific binding was obtained by subtracting nonspecific binding from the total binding. 
Saturation experiments were performed using a varying concentration of ^H-ketanserin (0.25 
nM to 9 nM) and the data was analyzed by linear regression analysis to determine the Kd and 
Btnax-
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CHAPTER - 3 
STUDIES ON THE MECHANISM OF MODULATION OF 
DOPAMINE-D2 AND 5-HT2A RECEPTORS IN PLATELETS 
INTRODUCTION 
Blood platelets, due to certain similarities with neurons with respect to morphology and 
pharmacology, have attracted the attention of several neuroscientists for their use as 
peripheral model for neurons (Pletscher, 1978; Stahl, 1985; Rehavi et al., 1988). Presence of 
dopaminergic, serotonergic and adrenergic receptors and their sub-types have been 
demonstrated in blood platelets (Garcia-Sevilla et al., 1981; Leysen et al., 1983; Winther et 
al., 1985 Khanna et al., 1987a; Khanna and Seth, 1987; Dekeyser et al., 1988; Da Prada et al., 
1988) and found to be altered in certain neuropsychiatric disorders (Geaney et al., 1984; 
Sethi et al., 1986; Hamilton and Reid, 1986; Pandey et al., 1990; Seth and Khanna, 1991). 
Further, similarity in pharmacological responsiveness between platelet and brain dopamine 
receptors following exposure to selected dopaminergic agents/drugs in experimental studies 
on rats have been reported (Seth and Khanna 1991). A parallel response between platelet and 
brain 5-HT receptors of rats has also been reported following exposure to drugs like tricyclic 
antidepressants and neurotoxicants acting on the serotonergic system (Klianna et al., 1987b). 
These studies have strengthened the usefulness of platelets as a peripheral model (Seth and 
Khanna, 1991). 
Serotonergic and dopaminergic systems have been shown to be predominantly involved in 
certain neuropsychiatric disorders like depression (Mann et al., 1986), schizophrenia (Mita et 
al., 1986), dementia (Piggott et al., 1999), Parkinson's disease (Rinne, 1982; Paraskevas et 
al., 1999), and alcoholism (Engel et al., 1992). 
The platelet 5-HT2A receptor have been reported to exhibit similar characteristics to those 
reported for the S-HTIA receptor in human brain (Elliot and Kent, 1989; Andres et al., 1992) 
and moreover, nucleotide sequence of human platelet 5-HT2A C D N A was found identical to 
that reported for the human frontal cortex 5-HT2A receptors except for nucleotide 102 (T-C) 
(Cook et al., 1994). A significant correlation between the inhibition of ^H-LSD binding in 
human platelets membrane and frontal cortex has also been observed (Peters and Grahame-
Smith, 1980; Geaney, 1984; Grahame-Smith et al., 1988). In clinical cases of schizophrenia 
and depression an increase in platelet 5-HT2A receptors (Biegon et al., 1987; Arora and 
Meltzer, 1989; Pandey et al., 1990; Pandey et al., 1993b; Medelson et al., 2000) which 
parallels with other studies on post-mortem brain samples of such disorders (Mann et al., 
1986; Mita et al., 1986) have been reported. Human and rat blood platelets have been shown 
to possess both DA-Di and DA-D2 receptor binding sites (Khaima et al., 1987a; DeKeyser et 
al., 1988) and platelet DA-D2 sites have been proposed as possible peripheral marker for 
CNS dopaminergic alterations in neurotoxic and neuropsychiatric conditions like 
schizophrenia and Parkinson's disease (Sethi et al., 1986; Seth and Khanna, 1991). 
While the platelet appears to be a promising peripheral model for CNS neurotransmitter 
system, the mechanism by which dopamine and serotonin receptors are modulated in 
platelets is not clear. It is yet to be ascertained whether availability of dopamine and 5-HT 
levels has any influence in modulating the sensitivity of dopamine and serotonin receptors 
respectively in platelets like neurons. The present study is therefore aimed to investigate 
whether alteration in DA and 5-HT levels, using selective pharmacological agents acting on 
them under in vivo and in vitro conditions, has any influence on the sensitivity of DA-D2 and 
5-HT2A receptors in platelets. In vivo and in vitro studies with reserpine and in vitro studies 
with dopamine and mazindol were undertaken on human and rat platelets to study the effect 
on DA-D2 receptors. In vitro studies with 5-HT, fenfluramine and clomipramine were 
undertaken to study the effect of altered 5-HT levels on human platelets 5-HT2A receptors. 
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MATERIALS AND METHODS 
The details of treatment of rats with reserpine and in vitro studies on human and rat platelets 
with pharmacological agents acting on dopaminergic system viz. reserpine, dopamine and 
mazindol and those acting on the serotonergic system like serotonin, fenfluramine and 
clomipramine have been described in Materials and Methods Section (Chapter -2). 
RESULTS 
In vivo Effect of Reserpine on Dopamine Receptors (DA-D2) in Platelets and 
Striatum of Rats 
Rats treated with reserpine at a dose of 1 mg/kg /day for 5 days showed a significant increase 
in the binding of ^H-spiperone to platelet (36%) and striatal (47%) membranes in comparison 
to controls. Reserpine at a dose of 5 mg/kg (single exposure) caused a decrease in the 
binding of ^H-spiperone to platelet (33 %) and striatal (44 %) membranes at 18 hours after 
the treatment (Table 3.1). Scatchard analysis revealed that the increase in the binding of ^H-
spiperone to platelet and striatal membranes following daily reserpine treatment for 5 days 
and the decrease in binding following a single exposure was due to change in the affinity 
(Kd) with no significant change in the receptor number (Bmax) in comparison to controls 
(Table 3.2). 
In vitro Effect of Reserpine on Dopamine Receptors (DA-D2) in Rat Platelets 
Incubation of PRP with reserpine at both the concentrations, i.e. at 1 |ag/ml and 2 ^ig/ml 
caused a decrease in the binding of ^H-spiperone to platelet membranes by 37% and 42% 
respectively. It was, however, interesting to note that PRP preparations pre-incubated with 
pargyline followed by incubation with reserpine showed a higher degree of decrease in the 
binding of ^H-spiperone to platelet membranes in comparison to those incubated with 
reserpine alone (Figure 3.1). 
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Table 3.1 
In vivo effect of reserpine on rat platelet and striatal DA-Dz receptors 
^H-spiperone (pmoles) bound/gm protein 
Control 
Reserpine 
1 nig/kg 
5 mg/kg 
Platelet membranes 
210± 17 
287± 10* 
142±15* 
Striatal membranes 
354 ± 18 
521 ±25* 
197±11* 
Values are mean ± SE of five animals in each group. 
* Statistically significant from controls (p <0.05). 
Table 3.2 
Scatchard analysis of dopamine receptor binding in platelet and striatal membranes in 
reserpine treated rats 
Platelet membranes Striatal membranes 
Kd (nM) Bmax (pmoles 
bound/g protein) 
Kd (nM) Bmax (pmoles 
bound/g protein) 
Control 2.18 504 2.85 612 
Reserpine 
1 mg/kg 1.42 490 1.72 594 
5 mg/kg 3.68 512 4.54 620 
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Figure 3.1: In vitro effect of reserpine on rat platelet DA-Dj 
receptors. Values are mean of two separate set of 
experiments and represent % change in comparison to 
control values. 
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Figure 3.2: In vitro effect of varying concentration of 
dopamine on human platelet DA-Dj receptors. Values are 
mean of three separate set of experiments and represent % 
change in comparison to control values. 
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Figure 3.3: In vitro effect of varying concentration mazindoi 
on liuman platelet DA-Dj receptors. Values are mean of three 
separate set of experiments and represent % change in 
comparison to control values. 
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Figure 3.4: In vitro effect of varying concentration of 
clomipramine on human platelet S-HTJA receptors. Values are 
mean of three separate set of experiments and represent % 
change in comparison to control values. 
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Figure 3.5: In vitro effect of varying concentration of 
fenfluramine on human platelet 5-HT2A receptors. Values are 
mean of three separate set of experiments and represent % 
change in comparison to control values. 
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Figure 3.6: In vitro effect of varying concentration of serotonin 
on human platelet S-HTJA receptors. Values are the mean of 
three separate set of experiments and represent % change in 
comparison to control values. 
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In vitro Effect of Dopamine and Mazindol on Dopamine Receptors (DA-D2) in 
Human Platelets 
Incubation of PRP with DA caused a decrease in platelet ^H-spiperone binding following 
incubation of PRP with DA (5.14, 15.11, 36.97 and 64.63%) and mazindol (2.22, 16.07, 
30.54 and 44.69%) at concentrations- 0.5, 1, 5 and lO.nM respectively (Figure 3.2, 3.3). 
In vitro Effect of Clomipramine, Fenfluramine and Serotonin on Serotonin 
Receptors (5-HT2a) in Human Platelets 
A significant decrease in the binding of ^H-ketanserin to platelet membrane was observed 
following incubation of PRP with clomipramine (4.22, 19.7, 43 and 55.8%), fenfluramine 
(1.89, 41.77, 60.69, and 68.70%) and serotonin (45.7, 64, 68 and 83.4%) at concentrations -
0.5, 1, 5 and 10 nM respectively (Figure 3.4, 3.5, 3.6). 
DISCUSSION 
The increase in the binding of ^H-spiperone to platelet and striatal membranes following 
daily reserpine treatment for 5 days and a decrease at 18 hours after single exposure to 
reserpine in both preparations provides the evidence, perhaps for the first time, that platelet 
DA-D2 receptors exhibit similar pharmacological responsiveness to DA concentration like 
brain. Earlier parallel changes in platelets and brain DA and 5-HT receptors following 
exposure to selected drugs acting on the dopaminergic and serotonergic systems respectively 
in rats were observed (Klianna and Seth, 1987; Seth and Khanna, 1991). In a study 
conducted on neurosurgical patients it was observed 'that the 5-HT2 receptors on platelets are 
identical with those found in cortex and are regulated by the endogenous 5-HT (Andres et al., 
1992) and correlation with the decrease in 5-HT2 receptors in platelets with high 5-HT 
concentrations was speculated. 
Experimental studies have shown that prolonged neuroleptic or reserpine treatment or 
denervation leads to the supersensitivity of the dopaminergic system (Ungersteddt and 
Arbuthnott, 1970; Creese et al., 1977; Nowycky and Roth, 1977; Schultz, 1982; Hu et al., 
1990). The increase in the ^H-spiperone binding to striatal membranes observed in the 
present study is consistent with earlier studies in mice following consecutive reserpine 
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treatment (Rubinstein et al., 1989). Reserpine is known to deplete the levels of dopamine in 
platelets, brain and other tissues (Nickerson and Collier, 1975). In a study conducted on 
rabbits by Da Prada and Picotti (1979), a pronounced depletion in 5-HT and catecholamines 
(including dopamine) in platelets following reserpine treatment was observed. The observed 
increase in the binding is presumably related to depletion of dopamine levels following 
reserpine treatment. It has been shown earlier that reserpine depletes catecholamines in brain 
by causing an excessive release and simultaneous decrease in the uptake of the amines. The 
decrease in the binding of ^H-spiperone following exposure to reserpine at a higher dose as 
observed in the present study may possibly be due to excessive release of dopamine from the 
stores and its increased availability at the binding site. 
Monoamines including dopamine which are stored in the platelets are suggested to be of 
plasma origin since the enzymes involved in their synthesis are not present in the platelets 
(Lahovaara et al., 1968; Solomon et al., 1970; Boullin and Green, 1972). Therefore, 
possibility that fluctuations in the plasma concentration of dopamine may influence the 
sensitivity of dopamine receptors is quite immense. Incubation of reserpine with PRP in an 
atmosphere of nitrogen was found to induce the release of 5-HT from the platelets (Carlsson 
et al., 1957). Further studies conducted by Paasonen and Pletscher (Paasonen and Pletscher, 
1 9 5 9 ) have shown that incubation of PRP from rats pretreated with MAO inhibitor, with 
reserpine (1 jig/ml) and benzoquinone derivative caused a pronounced increase in 5-HT 
concentration in plasma after 180 minutes. They also showed that the 5-HT increase in the 
plasma corresponded to the 5-HT decrease in platelets. The decrease in the binding of 
platelet ^H-spiperone following incubation of PRP with reserpine in vitro as observed in the 
present study may possibly be due to the availability of higher concentration of dopamine 
following release from storage sites and subsequently its diffusion into plasma. A greater 
decrease in the binding observed in PRP preparations preincubated with pargyline may 
possibly be due to increased availability of dopamine in the circulation as a result of MAO 
inhibition both in the platelets and plasma. 
Studies on human platelets also exhibited a decrease in platelet DA-D. and 5-HT. . receptors 
X incuba t i l with dopamine and serotonin respectively. The availability of . o r e 
l a m i n e and serotonin due to increased e o — o n s of the agomst .self could 
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possible reason for such a response. An inliibition in the dopamine and serotonin uptake 
following incubation with mazindol and clomipramine respectively may cause an increase in 
the availability of dopamine and serotonin levels. This may lead to a decrease in the 
dopamine and serotonin receptors in platelets, as observed in the present study. Incubation of 
human PRP with fenfluramine, a potent 5-HT releaser also caused a decrease in 5-HT2A 
receptors. Excessive release of 5-HT from the stores leading to more availability of 5-HT at 
the site could be a possible reason for such an effect. 
The data indicates that like in brain, the modulation of circulating levels of dopamine and 
serotonin can influence the sensitivity of DA-D2 and 5-HT2A receptors respectively in 
platelets. The study also suggests that there could be a common mechanism of modulation 
for platelet DA-D2 and 5-HT2A receptors and strengthen the usefulness of platelets for 
understanding the dopaminergic and serotonergic mechanisms of brain although a further 
validation is required. 
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CHAPTER - 4 
EFFECT OF MANGANESE, 6-HYDROXYDOPAlVIINE AND 
CYPERMETHRIN ON SELECTED BIOCHEMICAL 
PARAMETERS IN BRAIN AND PLATELETS 
INTRODUCTION 
A variety of new chemicals are being introduced in our environment to which man gets 
exposed directly and indirectly. Several of them affect the central nervous system (CNS) and 
lead to neurobehavioral alterations and neurodegenerative disorders resembling 
Parkinsonism, Alzheimer's disease and cognitive dysfunction. The exposure to these 
chemicals occurs over the entire period of life and the outcome is often dependent upon the 
time and duration of exposure. Factors like nutritional status, exposure to other chemicals 
and genetic make up also influences the outcomes. 
Manganese (Mn) is an abundant metal widely used in the manufacture of steel, dry cell 
batteries, methyl-cyclopentadinyl manganese tricarbonyl (MMT) and permanganate products 
(Wenberg et al., 1991; Pal et al., 1999; Zayed et al., 1999). In biological system, it serves as 
an essential constituent of some metalloproteins including the mitochondrial (Mn-SOD, 
pyruvate carboxylase) and glial (glutamine synthetase) specific enzymes (Prohaska, 1987; 
Wedler, 1993). Excessive exposure among workers to manganese during mining and 
processing operations and production of ferro-alloys has been reported to lead to crippling 
diseases resembling parkinsonism (Chia et al., 1993; Calne et al., 1994). Non-occupational 
exposure to manganese tlirough drinking water and air has also been reported and poses a 
serious health hazard to general population (Hudnell, 1999). Exposure to manganese even at 
low levels has been reported to produce adverse effects on the CNS (Smargiassi and Mutti, 
1999). Experimental and clinical studies have established that striatum is the target and 
alteration of dopaminergic functions and multiple mechanisms including oxidative stress 
have been proposed in the manganese neurotoxicity (Seth et al., 1981; Aschner, 1997). 
6-Hydroxydopamine (6-OHDA), a hydroxylated analogue of dopamine (DA), is widely used 
as a tool to develop symptoms resembling Parkinson's disease in rat. Selective damage of 
dopaminergic neurons leading to deficiency of dopamine in the striatum has been reported 
following lesioning with 6-OHDA in rat (Sakai and Gash, 1994; Ben et al., 1999b). Besides 
dopaminergic deficiency, free radical mediated mechanisms are also involved in the 
neurotoxicity of 6-OHDA (Hiramatsu et al., 1994; Kumar et al., 1995). 
Among insecticides, the synthetic pyrethroids constitute an unique group having pyrethrin 
like structure with better performance characteristics and account for over 30% of insecticide 
used globally (Vijverberg and Van den Bercken, 1982; Soderlund and Bloomquist, 1989). 
They are potent neurotoxicants in both vertebrates and invertebrates, but acute toxicity in 
mammals is low (Elliot and Janes, 1978). Their selective toxicity seems to be based mainly 
on the response of neuronal sodium channels since pyrethroids act potently and stereo-
specifically on sodium channels by slowing kinetics of both opening and closing sodium 
channels. Inhibition of G A B A A receptor is an additional mechanism proposed for type II 
pyrethroids (Narahashi, 1992). Two distinct classes of pyrethroids viz. Type I and Type II 
have been identified. Type I pyrethroids leads to hyperexcitation and fine tremors while type 
II possess a a-cyano group and produce a more complex syndrome including clonic seizure 
(Vershoyle and Aldridge, 1980). 
Cypermethrin, a class-II pyrethroid is extensively used in protection of a wide range of crops 
(WHO, 1989). Earlier studies from this laboratory and by others have reported 
neurobehavioral alterations affecting catecholaminergic system and motor behaviour at sub-
lethal doses both in the developing and adult rats (Husain et al., 1992; Malaviya et al., 1993; 
McDaniel and Moser 1993). Workers handling these pesticides have also been reported to 
develop clinical symptoms of numbness, tingling, itching, burning sensation, loss of bladder 
control, incordination after high dermal exposure. In addition, nausea, prolonged vomiting, 
stomach pains and diarrhoea that progresses to convulsions, unconsciousness and coma are 
observed after high dose-ingestion (USEPA, 1989; Ray, 1991). Because of extensive and 
injudicious use, the pesticide has been reported to be present in the enviroiunent and their 
residues detected in grains and food materials (Friedrich et al. 1998, Maroni et al 2000). 
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Therefore, continuous exposure to these pesticides to general population and farm workers 
poses a serious health risk, and needs a continuous monitoring. 
Due to structural and functional similarities between neurons and blood platelets and 
interaction between platelets and neurotransmitters, Seth and his associate and others have 
proposed the use of platelets as peripheral model of neuronal activity (Stahl, 1985; Rehavi et 
al., 1988; Seth and Khanna, 1991; Seth et al., 1994). Further experimental studies by them 
have shown parallel changes in platelet dopamine and serotonin receptors following exposure 
to selected drugs and neurotoxicants acting on these receptors (Khanna et al., 1987b). 
Platelets have also been found to be useful in study of the involvement of free radicals and 
oxidative stress mediated pathological conditions (Srivastava et al., 1994). Keeping in view 
of this, the present study has been carried out to investigate whether changes in selected 
parameters like dopamine receptors, monoamine oxidase activity, membrane fluidity, 
intracellular calcium levels and other parameters related with oxidative stress in brain are 
reflected in platelets. Study was also aimed to further evaluate the use of peripheral markers 
for neurotoxic disorders and validate the usefulness of platelets as a peripheral model. 
MATERIALS AND METHODS 
The details regarding the animals and treatment with manganese, cypermethrin and 6-
OHDA and methods for the collection of blood, isolation of brain, preparation of platelets, 
platelet and synaptic membranes and procedures for the assay of biochemical parameters in 
platelets and brain has been described in Chapter-2. 
RESULTS 
Effect of Manganese on Reduced Glutathione Levels, Activity of Superoxide 
Dismutase and Catalase in Rat Platelets and Striatum 
A decrease in reduced glutathione level was observed following manganese exposure in 
corpus striatum (13 and 24%) and platelets (12 and 20%) at both the doses. The change was 
statistically significant only at the higher dose i.e. 15 mg/kg both in platelets and striatum 
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Table 4.1 
Effect of manganese (45 days exposure) on reduced glutathione levels in corpus 
striatum and platelets. 
Group Corpus striatum 
(nmoles/ gm tissue) 
Platelets 
(^moles/lxlO' platelets) 
Control 2.54 + 0.15 0.40 ± 0.02 
MnCh 10 mg/kg 2.20 ±0.16 0.35 ±0.02 
MnCh 15 mg/kg 1.91 ±0.16* 0.32 ±0.02* 
Values are mean + SE of five animals in each group. 
* Statistically significant from controls (p<0.05) 
Table 4.2 
Effect of manganese (15 days exposure) on dopamine receptor binding in corpus 
striatum and platelets. 
Group Corpus striatum 
(pmoles bound/ gm protein) 
Platelets 
(pmoles bound/ gm 
protein) 
Control 251 ± 17.62 162 ±7.08 
MnCb 10 mg/kg 347 ± 32.69* 252 ± 13.78* 
MnCh 15 mg/kg 330 ±26.90 227 ± 22.4* 
Values are mean + SE of five animals in each group. 
* Statistically significant from controls (p<0.05) 
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Figure 4.1: Effect of manganese exposure for 45 days on 
superoxide dismutase activity in corpus striatum and platelet. 
Values are meaniSE of five rats in each group. "Statistically 
significant from controls (p<0.05). 
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Figure 4.2: Effect of manganese exposure for 45 days on 
catalase activity in corpus striatum and platelets. Values are 
meaniSE of five rats in each group. "Statistically significant from 
controls (p<0.05). 
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(Table 4.1). A significant increase in the activity of superoxide disniutase was observed both 
in platelets (24 and 37%) and striatum (31 and 42%) following exposure to manganese at 
both the doses i.e. 10 and 15 mg/kg respectively (Figure 4.1). Catalase activity was decreased 
both in platelets (16 and 35%) and striatum (18 and 44%) following manganese exposure 
(Figure 4.2). 
Effect of Manganese on Membrane Fluidity and Intracellular Calcium Levels in 
Rat Platelets and Striatum 
Exposure to manganese 10 or 15 mg/kg doses for 45 days caused a significant increase in 
membrane fluidity as evidenced by decreased fluorescence polarisation both in platelets (11 
and 14%) and striatum (9 and 13%) respectively as compared to controls (Figure 4.3). The 
rats treated with manganese also exhibited an increase in intracellular calcium levels in 
striatum (27 and 40%) and platelets (26 and 38%) respectively at both dose levels (Figure 
4.4). 
Effect of Manganese on Rat Platelet and Striatal Dopamine Receptors 
Exposure to manganese (10 or 15 mg/kg, 15 days) caused a significant increase in the 
binding of ^H-spiperone to striatal (38 and 31%) and platelet (55 and 40%) membranes. 
Change in the binding was more prominent at lower dose (10 mg/kg) both in the striatum and 
the platelets (Table 4.2). Scatchard analysis revealed that treatment with MnCh caused an 
increase in the maximum number of binding sites ( B m a x ) without any significant change in 
the affinity (Kd) of dopamine receptors, both in striatal and platelet membranes (Figure 4.5, 
4.6). 
Effect of 6-OHDA on Lipid peroxidation, Reduced Glutathione Levels, 
Membrane Fluidity and Intracellular Calcium Levels in Striatum and Platelets 
Intrastriatal lesioning with 6-OHDA in rats caused an increase in degree of lipidperoxidation 
(38%) and intracellular calcium levels (83%) in striatum as compared to sham group. These 
rats also exhibited a decrease in reduced glutathione levels (19%) and membrane fluidity as 
evidenced by an increase in fluorescence polarisation (20%) in striatum. However, no 
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Table 4.3 
Effect of striatal 6-OHDA lesions on reduced glutathione levels in corpus striatum and 
platelets. 
Group Corpus striatum (fxmoles/ 
gm tissue) 
Platelets (^imoles/lxlO" 
platelets) 
SHAM 2.62 ±0.12 0.39 ±0.03 
6-OHDA 2 . i2±0 .15* 0.38 ±0.03 
Values are mean + SE of five animals in each group. 
*Statistically significant fi-om controls (p<0.05). 
Table 4.4 
Effect of striatal 6-OHDA lesions on dopamine receptor binding in corpus striatum and 
platelets. 
Group Corpus striatum (pmoles 
bound/ gm protein) 
Platelets (pmoles bound/gm 
protein) 
Control 254 ±45.23 116 ± 14.02 
6-OHDA 410±41.56* 167± 16.51* 
Values are mean + SE of five animals in each group. 
*Statistically significant from controls (p<0.05). 
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Figure 4.7: Effect of striatal 6-OHDA lesions on 
lipidperoxidation in corpus striatum and platelets. Values 
are mean±SE of five animals in each gruop. * Statistically 
significant from controls (p<0.05). 
• SHAM S 6-OHDA 
s c 
600 T 
500 --
400 •• 
300 
200 
100 - -
Corpus striatum Platelets 
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Figure 4.9: Effect of striatal 6-OHDA lesions on fluorescence 
polarisation in corpus striatum and platelets. Values are 
meaniSE of five animals in each gruop. * Statistically 
significant from controls {p<0.05). 
• SHAM S 6-OHDA 
400 T 
0) a> 
•D 
C 3 O 
m 
300 
200 + 
100 + 
200 400 
Bound 
600 800 
GRUOP Kd(nm) Btnax (pmoles bound/g protein) 
SHAM 2.71 565 
6-OHDA 2.82 711 
Figure 4.10: Scatchard analysis of dopmine Dj receptor 
binding in striatal membrane of 6-OHDA lesioned rats. 
• SHAM 6-OHDA 
I 
c 
3 
O 
m 
300 T 
2 0 0 - • 
100 
100 200 300 
Bound 
400 500 600 
GRUOP Kd(nm) Bmax (pmoles bound/g protein) 
SHAM 2.22 486 
6-OHDA 2.16 496 
Figure 4.11: Scatchard analysis of dopmine Dj receptor 
binding in platelet membrane of 6-OHDA lesioned rats. 
• SHAM 6-OHDA 
significant change in these parameters was observed in platelets of the 6-OHDA lesioned rats 
(Figure 4.7, 4.8, 4.9 and Table 4.3). 
Effect of 6-OHDA on Platelet and Striatal Dopamine Receptors 
Rats lesioned with 6-OHDA in striatum exhibited a significant increase in striatal dopamine 
receptors (61%) as compared to sham. Interestingly, increase in dopamine receptors (43%) 
was also observed in platelets in lesioned rats (Table 4.4). Saturation experiments, using 
varying concentrations of ^H-spiperone, revealed that increased binding in striatum in the 
lesioned rats was due to an increase in the maximum number of binding sites (Bmax) without 
any change in affinity (Kj) (Figure 4.10). However, no change in Bmax and Kj of ^H-
spiperone was observed in platelets in 6-OHDA lesioned rats (Figure 4.11). 
Effect of Cypermethrin on Membrane Fluidity and Intracellular Calcium Levels 
in Rat Platelets and Striatum 
Exposure to cypermethrin (15 or 30 mg/kg) for 10 days did not cause significant changes in 
fluorescence polarisation and intracellular calcium levels in both platelets and corpus 
striatum. However, a decrease in fluorescence polarisation was observed in platelets (7.6 and 
12%) and corpus striatum (7 and 13%) 21 days after the exposure to cypermethrin at both the 
doses suggesting an increase in membrane fluidity. Treatment of rats with cypermethrin also 
caused an increase in intracellular calcium levels in platelets (24 and 44 %) and striatum (29 
and 55 %) as compared to respective controls. Interestingly, changes in fluorescence 
polarization and intracellular calcium levels were restored to control values at the lower dose 
(15 mg/kg) and persisted at the higher dose (30 mg/kg) of cypermethrin both in platelets and 
corpus striatum following cessation of treatment for 10 days in the 21 days cypermethrin 
exposed group (Figure 4.12,4.13, 4.14, 4.15). 
Effect of Cypermethrin on Monoamine Oxidase Activity in Rat Platelets and 
Striatum 
No significant change in the activity of monoamine oxidase was observed in platelets and 
corpus striatum following exposure to cypermethrin (15 or 30 mg/kg) for 10 days. However, 
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Table 4.5 
Effect of cypermethrin on dopamine receptors (DA-Di) 
Group 10 days after treatment 21 days after treatment 10 days after cessation of 
treatment in 21 days 
exposed rats 
Corpus 
striatum 
Platelet Corpus 
striatum 
Platelet Corpus 
striatum 
Platelet 
Control 234±20 33 174±15 63 330±I8 83 206±i0 66 248±14 55 177±12 77 
C y p ( 1 5 m g / k g ) 225±24 53 165±16 48 211±14 22* 131±7 92* 236±18 26 I64±16 58 
Cyp (30 mg/kg) 2I6±22 69 162±15 53 177±10 78* 105±7,22* 180±1I 30* 15I±12 36* 
Values are mean ± SE of five animals in each group. Units expressed as pmoles bound / mg 
protein. *Significantly differs from control (p<0.05). 
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Figure 4.13: Effect of cypermetlirin exposure on membrane fluidity in 
corpus striatum. Results are meaniSE of five rats per group. 
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Figure 4.14: Effect of cypermethrin exposure on intracellular 
calcium in rat platelets. Results are meaniSE of five rats per 
group. "Statistically significant from control (p<0.05) 
• Control m CYP 15 mg/Kg B CYP 30 mg/Kg 
21 £ o 
E c 
500 T 
400 --
300 --
2 0 0 • • 
1 0 0 • • 
10 Days 
* T 
X 
+ 
1 
H 
21 Days 10 Days cessation of 
treatment 
Figure 4.15: Effect of cypermetlirin exposure on intracellular 
calcium in corpus striatum. Results are meaniSE of five rats per 
group. * Statistically significant from control (p<0.05) 
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Figure 4.16: Effect of cypermethrin exposure on monoamine 
oxidase activity platelets of rat. Results are mean±SE of five 
animals per group. * Statistically significant from control 
(p<0.05) 
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Figure 4.17: Effect of cypermethrin exposure on monoamine 
oxidase activity corpus striatum of rat. Results are mean±SE of 
five animals per group. * Statistically significant from control 
(p<0.05) 
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exposure to cypermethrin for 21 days caused a dose-dependent decrease in monoamine 
oxidase activity both in platelets (34 and 62%) and corpus striatum (29 and 49%). 
Interestingly, the decrease in monoamine oxidase activity was found to persist both in 
platelets (29%) and corpus striatum (25%) of rats exposed to cypermethrin at higher dose 
following cessation of treatment for 10 days. The changes in monoamine oxidase activity 
recovered in both platelets and corpus striatum at the lower dose (15 mg/kg) of cypermethrin 
(Figure 4.16, 4.17). 
Effect of Cypermethrin on Dopamine Receptors in Rat Platelets and Striatum 
Rats exposed to cypermethrin (15 or 30 mg/kg) for 21 days exhibited a significant decrease 
in the binding of ^H-spiperone to platelet (36 and 49%) and striatal membranes (36 and 46%) 
as compared to controls (Table 4.5). The decrease in the binding was found to persist even 
after cessation of treatment for 10 days in the rat exposed to cypermethrin (30 mg/kg) for 21 
days in corpus striatum (27%) and platelets (15%) as compared to controls (Figure 4.5). 
Scatchard analysis revealed that decrease in the binding was due to decreased Bmax without 
any change in the Kd, both in platelets and corpus striatum (Figure 4.18, 4.19). 
DISCUSSION 
Formation of free radicals following manganese exposure and 6-OHDA lesioning leading to 
neurotoxicity has been reported by several investigators (Shukla and Chandra, 1981; 
Donaldson et al., 1982; Ali et al., 1995; Kumar et al., 1995; Soto-Otero et al., 2000). Since 
GSH protects body tissues from adverse effects of reactive oxygen species, any imbalance in 
its level may enhance the toxic response of the chemical. Earlier, a decrease in GSH levels 
both in the whole brain and striatum in manganese exposed rats has been reported (Liccione 
and Maines 1988; Desole et al., 1995). It was also suggested that the decrease in GSH was 
associated with the decreased GSH-peroxidase activity. In agreement with these workers, a 
decrease in the levels of reduced glutathione (GSH) in corpus striatum and platelets 
following exposure of rats to manganese has been observed in the present study. Consistent 
with the earlier reports from this laboratory a decrease in GSH and an increase in lipid-
peroxidation was also observed in striatum following 6-OHDA lesioning (Hiramatsu et al., 
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1994; Kumar et al., 1995). However, no significant change was observed in platelets in these 
studies. 
For the maintenance of normal cellular functions and intracellular defense, antioxidant 
enzymes viz. superoxide dismutase (SOD) and catalase play an important role. Manganese, 
being the constituent of anti-oxidant enzyme Mn-SOD which catalyses the dismutation of O2 
and also maintains a balance between oxidants and anti-oxidants, has an important function 
in the cell (Keen et al., 1984). An increase in Mn-SOD activity in brain has been reported in 
rats following exposure to manganese at low doses i.e. 2.5 or 5 mg/kg body weight (Hussain 
et al., 1997). In another study on humans, a significant increase in human lymphocyte Mn-
SOD has been reported following Mn supplementation (Davis and Greger, 1992). Moreover, 
rats fed Mn deficient diet showed a significant decrease in Mn-SOD activity in kidney and 
heart (Thompson et al., 1992). At present it is difficult to explain the exact mechanism for an 
increase in the Mn-SOD activity although several possibilities have been suggested. 
Accumulation of Mn in the cell accelerate the free radical formation, enhanced expression of 
Mn-SOD may decrease the oxygen mediated injury. Further, because of accumulation of 
manganese as a result of treatment, it is likely that Mn-SOD activity increased (Thongphasuk 
et al., 1999). The observed increase in the activity of Mn-SOD both in platelets and brain 
suggests that antioxidant capacity may possibly be enhanced to combat the oxidative stress 
following manganese exposure. Catalase is an important enzyme, involved in the removal of 
hydrogen peroxide formed during the redox reaction in the biological system. Decrease in 
the catalase activity in rat striatum has been reported earlier following exposure to 
manganese and based on this it was suggested that process of removal of peroxides may be 
affected (Liccione and Maines, 1988). In an interesting study on isolated hepatocytes, Jones 
et al. (1987) demonstrated the predominant role of catalase in the catalysis of H2O2 under 
conditions of GSH depletion. A decrease in the catalase activity in striatum and parallel 
change in platelets, as observed in the present study, may enhance oxidative stress. 
Integrity of the membrane is important for the normal physiological and pharmacological 
functions including ion permeability, enzyme activity and receptor related events. A 
significant decrease in fluorescence polarization observed in striatum following manganese 
exposure indicates an increase in the membrane fluidity and is consistent with earlier studies 
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from this laboratory (Kumar et al., 1996). It was also shown that manganese increases the 
composition of selected membrane phospholipids and alters the membrane fluidity (Kumar et 
al., 1996). A parallel increase in the membrane fluidity in platelets, like striatum, in the 
manganese exposed rats is interesting. Under the conditions of 6-OHDA lesioning, 
peroxidative stress in striatum membranes promotes a decrease in membrane fluidity (Kumar 
et al., 1995). Alterations in the chemical structure of membranes due to the formation of 
covalent cross-linking between adjacent lipids and a reduction in the unsaturation/saturation 
ratio of fatty acids are possible factors associated with the decrease in membrane fluidity 
(Eichenberger 1982; Bruch and Thayer, 1983). 
Synthetic pyrethroids of both type I (allethrin, permethrin) and type II (cypermethrin and 
fenvalerate) have been shown to alter membrane fluidity of liposomal and native membranes 
under in vitro conditions (Stelzer et al., 1985; Sarkar et al., 1993; Moya-Quiles et al., 1994; 
1995; 1996). It has been suggested that pyrethroids partition into membrane bilayer and 
produce a change in the lipid order and membrane environment (Shinitzky and Barenholz, 
1978). In the present study in vivo exposure to cypermethrin caused a decrease in 
fluorescence polarisation in synaptosomal and platelet membrane, suggesting increase in 
membrane fluidity. The alterations in membrane fluidity following cypermethrin exposure is 
similar to earlier in vitro studies on cypermethrin and fenvalerate (Stelzer et al., 1985; Sarkar 
et al., 1993). Although it is difficult at present to explain the mechanism for alteration in 
membrane fluidity in platelets following cypermethrin exposure, the decrease in fluorescence 
polarization in platelets like brain, in these animals is interesting and suggests a common 
mechanism for such an effect. 
Intracellular calcium plays an important role in the cell function and has been reported to 
mediate the neurotoxic effects of various toxicants (Carafoli, 1987; Komulainen and Bondy, 
1988). Pyrethrins and pyrethroids have been shown to inhibit various adenosine 
triphosphatases including neural Ca ATPases and Ca-Mg ATPase (Clark, 1981). 
Deltamethrin, a type II pyrethroid, has been shown to increase intracellular calcium levels in 
synaptosomal preparations by activating phosphoinositide/protein kinase C pathway (Enan 
and Matsmura 1993). Earlier studies from this laboratory by Husain et al. (1992) have shown 
that exposure to synthetic pyrethroids increases polyamine levels in various brain regions and 
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increased polyamines enhance intracellular calcium levels (Koenig et al., 1988). Kaul et al. 
(1996) showed that fenvalerate, another class II pyrethroid, causes a significant increase in 
total calcium levels in whole brain and in hypothalamus alone. In the present study exposure 
to cypermethrin, a type II pyrethroid also caused an increase in intracellular calcium in brain. 
Interestingly a parallel increase in intracellular calcium was also observed in platelets. 
Exposure to manganese has been reported to cause striatal damage due to accumulation of 
OH-induced oxidant stress and may affect the whole cascade (Chiueh et al., 1993). This rxiay 
affect the lipid bilayer and induce calcium conductance leading to increase in the intracellular 
calcium (Chiueh et al., 1993). Consistent with this, an increase in intracellular calcium levels 
was observed both in platelets and striatum in the present study. 
Oxidative stress has been shown to enhance intracellular calcium level beyond the normal 
level. Receptor mediated Ca^ "^  mobilisation is influenced by oxidative stress at various levels 
(Vliet and Bast, 1992). Oxidative stress decreased the number of Ca^^ mobilising receptors 
(Pruijn et al., 1989) and increased Ca^^ releasing second messenger such as IP3 (Bellomo et 
al., 1987). In the present study, 6-OHDA induced oxidative stress in corpus striatum may be 
responsible for increased intracellular calcium. 
Studies of Seth and his associates has shown that dopamine receptors are one of the targets of 
certain neurotoxicants and alteration in their sensitivity may lead to neurochemical and 
behavioural dysfunction (Agrawal et al., 1981; Zaidi et al., 1985; Khanna et al., 1991; 1994). 
The striatal dopamine receptors have often been found to be more sensitive to neurotoxicants 
as compared to other neurotransmitter receptors. 
Studies carried out with manganese suggest the vulnerability of striatal dopamine receptors in 
its neurotoxicity and consistent with this an increase in the binding of ^H-spiperone to striatal 
and platelet membrane has been observed (Seth et al., 1981). Developing rats exposed to 
cypermethrin during gestation showed a significant decrease in striatal dopamine receptors 
(Husain et al., 1992). In the present study also, a decrease in the binding of dopamine 
receptors was observed both in platelets and brain, 21 days after exposure to cypermethrin. 
Significantly, the change in the binding was dose-dependent and was due to decreased Bmax 
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both in the platelet and the brain. The change in the binding persisted even after cessation of 
treatment for 10 days in rats exposed to cypermethrin at high dose for 21 days. The decreased 
binding following cypermethrin exposure could be due to excessive release of dopamine 
since synthetic pyretliroids including cypermethrin have been reported to increase the 
catecholamine release (Clark and Matsumura, 1982). A decrease in monoamine oxidase 
activity both in platelets and brain, in the present study, is consistent with earlier report on 
developing rats exposed to cypermethrin during gestation (Husain et al., 1992). Parallel 
changes in monoamine oxidase activity in brain and platelets have been reported following 
exposure to environmental pollutants like methyl mercury and styrene (Chakrabarti et al., 
1998; Coccini et al., 1999). Based on this, it was suggested that change in platelet 
monoamine oxidase activity could be a reflection of alterations in brain. It is quite possible 
that the decrease in monoamine oxidase activity may increase the dopamine concentration, 
which could affect the sensitivity of dopamine receptors in platelets and brain following 
cypermethrin exposure. 
Lesioning with 6-OHDA in rat striatum has been reported to cause destruction of 
dopaminergic neurons and severe depletion of dopamine levels (Sakai and Gash, 1994; 
Amalric et al., 1995; Gerlach and Riederer, 1996; Ben et al., 1999b). The reduced dopamine 
levels have been associated with the super-sensitivity of striatal dopamine receptors in the 
lesioned rats (Neve et al., 1984; Joyce, 1991). Consistent with this, an increase in striatal 
dopamine receptors in the 6-OHDA lesioned rats and an increase in the binding was observed 
in platelets in the present study. Recently, Xiao et al. (1999) reported that 
intracerebroventricular injection of interleukin-1 stimulates the release of high levels of 
interleukin-6 and interleukin-1-receptor antagonist into peripheral blood in the primate. In 
another study on rats, interleukin-1 b which acts within the brain has been reported to release 
large amount of interleukin-6 into peripheral blood (De Simoni et al., 1990; 1993; Romero et 
al., 1996). Based on this they proposed a mechanism by which inflammation within the brain 
could induce a number of systemic responses which may range from acute phase response to 
a variety of peripheral endocrine and immune response (Xiao et al., 1999). It is difficult to 
explain the exact mechanism for increased platelet dopamine receptors like brain following 
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6-OHDA lesioning in rats at present, however, these observations suggests a parallel 
mechanism for such a response. 
In the present study exposure to manganese caused an increase in superoxide dismutase 
activity, membrane fluidity, intracellular calcium levels, dopamine receptors and a decrease 
in catalase activity and reduced glutathione content both in platelets and corpus striatum. 
Exposure to cypermethrin caused an increase in membrane fluidity, intracellular calcium and 
decrease in dopamine receptors and monoamine oxidase activity both in platelets and corpus 
striatum. 6-OHDA lesioning in rats increased the dopamine receptors in platelets and corpus 
striatum. Parallel changes in platelets and striatum suggest the usefulness of platelets as a 
neuronal model for monitoring the changes induced by exposure to these chemicals. 
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CHAPTER - 5 
STATUS OF SOME BIOCHEMICAL PARAMETERS IN 
PLATELETS OF IDIOPATHIC PARKINSON'S DISEASE 
AND MIGRAINE PATIENTS 
INTRODUCTION 
Both Parkinson's disease and migraine are common disorders, wliich significantly affect a 
number of persons throughout the world. Parkinson's disease (PD), a progressive 
extrapyramidal movement disorder is prevalent in all ethnic groups in more than 3% 
individuals over the age of 65 years (Moghal et al., 1994). Although several hypothesis 
including excitotoxicity, impaired energy metabolism, oxidative stress and ageing have been 
proposed in the aetiology of Parkinson's disease, selective vulnerability of dopaminergic 
neurons in the substantia nigra leading to deficiency of dopamine in the striatum is believed 
to be the primary cause (Lang and Lozano, 1998; Kim et al., 1998; Cohen, 1999). L-dopa has 
been a drug of choice for therapy but several studies have shown that a number of 
Parkinson's patients do not exhibit the expected response to the drug. It is not clear whether 
this is due to (a) deficiency of dopa decarboxylase in the brain of non-responsive Parkinson's 
patients or (b) that the patients are not IPD cases at all or exhibit Parkinson's plus syndromes 
such as progressive supranuclear palsy (PSP), oligopontocerebellar atrophy (OPCA), multi-
infarct dementia or multisystem atrophy (MSA). Detailed studies are therefore warranted in 
humans to understand the mechanism involved in pathogenesis of the disease. 
Post-mortem brain samples of Parkinson's patients have been used for studying the 
neurotransmitters levels and receptors (Reisine et al., 1977; Rinne, 1982; Scatton et al., 1983; 
Agid et al., 1987), but the data obtained from such studies are often not reliable due to 
deterioration of tissues in post-mortem samples. Moreover there is no choice over the age 
group, sex and getting controls where confounding factors liice genetics and nutrition could 
be avoided. In recent years, study of dopaminergic functions in the living human brain using 
positron emission tomography (PET) has become possible. The calculation and interpretation 
of PET images has some problems since the caudate nucleus radioactivity varies with age 
(Seeman, 1987). 
Migraine is a complex neurological disorder that affects about 15% of the population and can 
be disabling. During the last decade much progress has been made in understanding the 
molecular basis of migraine (Senior, 2000). The possibility that serotonin (5-
hydroxytryptamine, 5-HT) might be an important endogenous factor responsible for the pain 
of migraine was first proposed by Wolff and colleagues in the late 1950's (Wolf, 1955). 
Supporting evidence for a role 5-HT in the migraine was provided by changes in circulating 
levels of 5-HT and its metabolites during the phases of a migraine attack and the ability of 
serotonin releasing agents to induce migraine like symptoms (Kimball et al., 1960; Sicuteri et 
al., 1961; Curran et al., 1965; Fozard, 1982). The development of serotonin receptor agonists 
which are effective in the alleviation of migraine pain further implicated serotonin as the key 
molecule in migraine (Peroutka, 1990). Role of 5-HT receptor subtypes such as 5HTIA, 
5HTIB, 5HTID, 5HT2B, 5HT2c, 5HT2A has been speculated in the aetiology of migraine 
(Goadsby, 1998; Goadsby and Hoskin, 1998) in recent years. 
The development of a suitable peripheral model which may reflect the state of central 
dopamine (DA) and serotonin (5-HT) receptors will be of inestimable value for 
understanding the mechanism and factors responsible for IPD and migraine. The value of 
such a marker in monitoring and treatment of such a disease in their early stages would be 
very useful. Lymphocytes from human volunteers have been used in the past to understand 
Parkinson's disease (Le Fur et al., 1980). Unfortunately, the variable results have excluded 
its application as a peripheral model (Arnold et al., 1993; Maloteaux et al., 1983). 
The circulating platelets in the peripheral blood constitute an important dynamic reservoir of 
5-HT and are able to rapidly accumulate and secrete serotonin and thus they have aroused 
considerable interest on their possible involvement in migraine (Andrea et al., 1989; Joseph 
et al., 1989). The biogenic amine functions of the platelets closely resemble with those of 
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serotonergic neurones (Cambell et al., 1981; Malingren and Hasselniark, 1988). As the 
platelets can be easily obtained by a simple venipuncture so they could serve as a readily 
available tool to study various serotonergic mechanisms. The circulating 5-HT stored within 
the blood platelets can under certain circumstances interact with the different compartments 
of the vascular wall via serotonergic receptors. The currently accepted classification of 5-HT 
receptors includes seven classes known as 5-HT| through 5-HT7 and the class most 
implicated in migraine is 5-HTi (which consist of the A, B, D, E and F subtypes) and 5-HT2A 
. Although decrease in ^H-imipramine binding to platelet membrane of patients with classical 
migraine has been reported (Geaney et al., 1984), the role of 5-HT2A is still not clearly 
understood. 
Several studies have shown that human blood platelets possess binding sites for serotonin, 
dopamine and norepinephrine which are altered in disease conditions (Garcia Sevilla et al., 
1983; Carstens et al., 1986; Sethi et al., 1986; Wolfe et al., 1987; Desmedt et al., 1987). 
Presence of DA-D] (De Keyser et al., 1988) and DA-D2 (Khanna et al., 1987a) receptor sites 
as detected by using specific ligands in platelet membrane preparation has been 
demonstrated. Further studies conducted on experimental animals from this laboratory have 
established that changes in striatal DA receptors correspond to those in platelets following 
exposure to drugs acting on the dopaminergic system and neurotoxicants (Seth and Khanna, 
1991). Specific DA-D2 receptors in human blood platelets and their involvement in 
schizophrenia have been demonstrated (Sethi et al., 1986). 
Role of monoamine oxidase (MAO) in the aetiology of Parkinson's disease has been 
suggested by several investigators. It is a membrane bound enzyme, localized in 
mitochondria which catalyses the oxidative deamination of monoamines including dopamine 
(Weyler et al., 1990). Two distinct isoforms viz. MAO-A and MAO-B of the enzyme have 
been identified. Both isoforms are encoded by separate genes on the x chromosomes and 
differ with each other with respect to substrate specificity, tissue localization and sensitivity 
to inhibitors (Kochersperger et al., 1986). Although the brain is equipped with both forms of 
the enzyme, human platelets predominantly contain MAO-B. A recent study on a large group 
of Australian population has suggested that variations in the MAO-B genes are associated 
with increased risk of Parkinson's disease (Mellick et al., 1999). The enzyme also plays an 
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important role in the expression of toxicity of 1-methyl 4-phenyl 1,2,3,6 teterahydro pyridine 
(MPTP) activating it to the toxic metabolite, 1-methyl-4-phenyl 1,2,3,6-teterahydro 
pyridinium ion (MPP^) (Kinemuchi et al., 1993). 
Data with respect to the status of platelet MAO-B activity in the Parkinson's cases is not 
consistent. Both an increase and a decrease in the enzyme activity has been reported 
(Danielczyk et al., 1988; Bonucceli et al., 1990; Steventon et al., 1990; Bongioanni et al., 
1996) and variation has been suggested due to substrate variations and relative activity defect 
in platelet and MAO-B from Parkinson's disease patients (Humfrey et al., 1990). Moreover, 
polymorphism of this enzyme has been reported by various groups and found to be 
associated with increased risk of Parkinson's disease (Checkoway et al., 1998; Mellick et al., 
1999). 
The present study has therefore been aimed to investigate (i) the status of platelet DA-D2 
receptors and monoamine oxidase-B activity in Parkinson's cases responsive to L-dopa and 
(ii) involvement of platelet 5HT2a receptors in migraine patients. 
MATERIALS AND METHODS 
The details regarding the selection of cases of idiopathic Parkinson's disease, migraine and 
controls and methods for the collection of blood, preparation of platelet membrane and assay 
procedures of platelet DA-D2, 5-HT2a receptors and monoamine oxidase activity have been 
described in Chapter-2. 
RESULTS 
Status of Platelet DA-D2 Receptors and Monoamine Oxidase-B Activity in 
Idiopathic Parkinson's cases 
Binding of ^H-spiperone to platelet membrane, known to label DA-D2 receptors was carried 
out in Parkinson's cases (n=25) and age matched healthy controls (n=13). The duration of 
disease ranged from 0.16-12 years and the mean was 2.39 years (Table 2.1). The severity of 
the disease, assessed on Hoehne and Yahr scale showed that 10 cases are of Stage - 1 , 3 cases 
of Stage - II and 12 cases of Stage - III. 
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Table 5.1 
Univariate analysis of platelet ^H-spiperone binding in relation to various demographic 
features of Parkinson's disease cases. 
Demographic 
features 
Number 
of cases 
Binding Characteristics 
Kd (nM) Bmax (pmoles bound/g protein) 
Age 
<50 Years 6 2.70 ±0.41 1387 ± 4 9 .71 
>50 Years 19 1.87±0.13 1185 ±58.39 
Sex 
Male 21 2.11 ±0.52 1250± 150 
Female 4 1.88 ±0.28 1142± 161 
Values are mean ± SE; *The p values for Kd and Bmax in various subgroups are statistically 
not significant. 
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Table 5.2 
Univariate analysis of platelet ^H-spiperone binding in relation to various clinical 
features of Parkinson's disease cases. 
Demographic 
features 
Number of cases Binding Characteristics 
Kd (nM)* Bmax (pmoles bound/g 
protein)* 
Duration of disease 
<2 years 16 2.22 ±0.22 1251 ±68.79 
>2 years 9 1.81 ±0.14 1201 ±61.92 
Stage 
I 10 2.39 ±0.29 1241 ±72.81 
II 5 2.26 ±0.17 1303 ±145 
III 10 1.66±0.18 1190 ±73.49 
Values are mean ± SE; *The p values for Kj and Bmax in various subgroups are statistically 
not significant. 
Table 5.3 
Correlation between ^H-spiperone binding characteristics with age and duration of 
disease of Parkinson's patient. 
Age Duration of disease 
Kd r = -0.42* significant r = -0.21 (NS) 
Bmax r = -0.33 trend r - - 0 . 1 6 (NS) 
r ( correlation coefficient). NS= Non significant 
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Table 5.4 
Univariate analysis of platelet monoamine oxidase activity in relation to various 
demographic features of Parkinson's disease cases. 
Demographic features Number of cases Monoamine oxidase activity (n 
moles 4 OH-quinoline 
formed/min/mg) 
Sex 
Male 22 1.32 ±0.09 
Female 4 1.24 ±0.25 
Age 
<50 years 7 1.28±0.17 
>50 years 19 1.36 ±0.11 
Values are mean ± SE. n represents number of subjects in each group. 
Table 5.5 
Univariate analysis of platelet monoamine oxidase activity in relation to various clinical 
features of Parkinson's disease cases. 
Demographic features Number of cases Monoamine oxidase activity 
(n moles 4 OH-quinoline 
formed/min/mg) 
Duration of disease 
<2 years 11 1.44 ±0.16 
>2 years 15 1.21 ±0.08 
Stage 
1 10 1.54±0.19 
II 3 1.38±0.16 
III 13 1.26 ±0.09 
Values are mean ± SE. n represents number of subjects in each group. 
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Figure 5.1: [^H]-spiperone binding cliaracteristics(Kd) in platelet 
membrane of control and Parkinson's disease subjects, n 
represents number of subjects in each group, 
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Figure 5.2: [ H]-spiperone binding characteristics(Bn,ax) 
platelet membrane of control and migraine subjects, n 
represents number of subjects in each group. "Significantly 
differs from controls(p<0.05). 
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Figure 5.3: Platelet monoanine oxidase activity in control 
and Parkinson's disease subjects, n represents number of 
subjects in each group. "Significantly differs from 
controls(p<0.05). 
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Table 5.6 
Univariate analysis of platelet ^H-ketanserin binding in relation to various demographic 
features of migraine. 
Demographic 
features 
Number 
of cases 
Binding Characteristics 
Kd (nM) Bmax (pmoles bound/g protein) 
Age 
<30 Years 14 2.83 ±0.44 367 ±32.58 
>30 Years 19 3.19 ±0.46 339 ±25.61 
Sex 
Male 84 2.65 ± 0.44 374 ±39.48 
Female 25 3.16 ±0.40 343 ±23.51 
Values are mean ± SE; *The p values for Kd and Bmax in various subgroups are statistically 
not significant. 
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Table 5.7 
Univariate analysis of platelet ^H-ketanserin binding in relation to various clinical 
features of migraine. 
Clinical features Number of 
cases 
Binding Characteristics 
Kd (nM)* Bmax (pmoles 
bound/g protein)* 
Type 
With aura 6 3.97 ±0.65 330 ±36.25 
Without aura 27 2.82 ± 0.40 354 ±23.33 
Duration of disease 
<5 years 12 2.94 ± 0.46 358 ±22.71 
>5 years 21 3.09 ±0.43 345 ±29.07 
Time since last attack 
<7 years 19 2.67 ±0.35 346 ±31.25 
>7 years 14 3.53 ±0.57 354 ±22.31 
Headache index 
<240 18 2.67±0.30 372±22.29 
>240 15 3.47±0.60 327±34.65 
Family history 
Positive 12 3.46 ±0.46 357±31.51 
Negative 21 2.79 ±0.42 346 ±36.39 
Values are mean ± SE; *The p values for K j and B^ax in various subgroups are statistically 
not significant. 
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Table 5.8 
Correlation coefficient of platelet ^H-ketanserin binding with various clinical and 
demographic features of migraine. 
Clinical features Binding Characteristics 
Kd* R * Dpiax 
Age -0.05 0.16 
Duration of disease 0.31 -0.10 
Time since last attack 0.20 -0.09 
Headache index 0.06 -0.29 
*The correlation between Ka and Bmax with various clinical and demographic features was 
statistically not significant. 
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Figure 5.4: [3H]-Ketanserin binding characteristics(Kd) in 
platelet membrane of control and migraine subjects, n 
represents number of subjects in each group. "Significantly 
differs from controls(p<0.05). 
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Figure 5.5: [^H]-Ketanserin binding characteristics(Bmax) 
platelet membrane of control and migraine subjects, n represents 
number of subjects in each group. 
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Based on the binding of ^H-spiperone to platelet membrane, a significant increase in the in 
the maximum number of binding sites (B,nax) was observed in the Parkinson's cases 
compared to controls (Figure 5.1). Affinity (Kd) of ^H-spiperone binding was not altered 
significantly in platelets of idiopathic Parkinson's cases as compared to controls (Figure 5.2). 
Univariate analysis of the binding characteristics with respect to demographic and clinical 
features did not reveal any significant difference (Table 5.1, 5.2). No correlation between the 
^H-spiperone binding with respect to the stage or duration of disease was observed (Table 
5.3). 
Assay of monoamine oxidase activity in platelets was carried out in 26 IPD cases of IPD and 
equal number of healthy controls. A significant increase (55%) in the activity of platelet 
MAO-B was observed in .Parkinson's cases as compared to controls (Figure 5.3). However, 
no significant difference in platelet MAO-B activity was observed in Parkinson's cases when 
the data were analysed with respect to age, sex or duration of disease (Table 5.4, 5.5). 
Interestingly, a trend of decrease in the activity of platelet MAO-B was observed in 
Parkinson's cases with respect to stage although the change was not significant (Table 5.5). 
No significant correlation was found between MAO-B activity and the age (r = 0.21) or 
duration of disease (r = -0.25). In the control subjects also, no correlation in platelet MAO-B 
activity was observed with respect to age or sex. 
Status of Platelet 5-HT2a Receptors In Migraine cases 
Assay of ^H-ketanserin binding to platelet membranes, known to label 5-HT2a receptors was 
carried out in cases of migraine and healthy controls. Among the cases, there were 25 
females and 8 males. In 12 patients family history of migraine was found to be positive. The 
mean duration of disease was 7.41 and the time since last attack was about 7.12 days. 
Migraine cases with aura were 6 and without aura 27. 
No significant difference in platelet counts in PRP was observed in migraine as compared to 
controls. The Ka of ^H-ketanserin binding in migraine cases was significantly higher as 
compared to controls. However, no significant change in Bmax was observed in migraine 
cases (Figure 5.4, 5.5). Univariate analysis of the binding characteristics with the 
demographic variables like age and sex did not reveal any significant difference (Table 5.6). 
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Similarly, no significant difference in binding characteristics with clinical features viz. type 
of migraine, duration of disease, time since last attack, headache index and family history 
was observed on univariate analysis (Table 5.7). The correlation coefficient (r) between the 
binding characteristics with age, duration of disease, time since last attack and headache 
index was statistically not significant (Table 5.8). 
DISCUSSION 
In the present study, an increase in the binding of ^H-spiperone to platelet membranes 
observed in Parkinson's cases responsive to L-dopa suggests increased platelet DA-D2 
receptors. However, the platelet binding studies did not demonstrate any correlation of ^H-
spiperone binding alterations with the duration or stage of the disease. 
Based on the clinical and .autopsied brain studies, it has been reported that density of striatal 
DA-D2 receptors is selectively increased only in the IPD cases and not in those exhibiting 
other parkinsonian like syndrome. Patients of progressive supranuclear palsy have been 
found to exhibit a decrease in DA-D2 receptor in the caudate nucleus and putamen (Bokobza 
et al., 1984; Baron et al., 1985). However, Ruberg et al. (1985) suggested that the decreased 
receptor density be due to the degeneration of dopaminoceptive-cholinergic neurons and 
result in a loss of response to L-dopa treatment. Strikingly, based on studies on autopsied 
samples, a selective response to L-dopa in the Parkinson's cases exhibiting increased ^H-
spiperone binding and not in those exhibiting a decreased a ^H-spiperone binding was 
observed (Rinne, 1982). It was proposed that non-responsiveness to L-dopa in IPD cases 
might be related to the loss of postsynaptic DA receptors while the increase in the binding 
indicated denervation supersensitivity and could be clinically associated with dyskinesias, 
psychotic episodes and fluctuations in the daily performance. 
At present, it is difficult to explain the possible biochemical mechanism(s) responsible for 
such alterations in the platelet ^H-spiperone binding among IPD cases. Though DA uptake in 
platelets is reported to be decreased in the Parkinson's cases, but it does not appear to affect 
the sensitivity of DA-D2 receptors in this disease as Dean and Copolov have reported that the 
DA uptake mechanism in platelets is independent and not mediated through the DA-D2 
receptors (Dean and Copolov, 1989a; Dean et al., 1991). The study suggests that alterations 
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in the DA levels appear to be responsible for modulating the receptor sensitivity since 
accumulation of dopamine in platelets have been reported to be decreased in IPD cases 
(Boullin and O'Brien, 1970). 
Because of the involvement of MAO-B in the metabolism of dopamine and other biogenic 
amines, studies on the platelet MAO-B activity have been carried out extensively in 
neuropsychiatric conditions (Murphy and Wyatt, 1972; Glover et al., 1981; Littlewood et al., 
1984; Caramona et al., 1990; Diaz-Marsa et al., 2000). Interestingly, changes in the activity 
of the enzyme were found to be specific. Decreased activity of platelet MAO-B has been 
reported in schizophrenia, anorexia nervosa and migraine (Murphy and Wyatt, 1972; 
Caramona et al., 1990; Diaz-Marsa 2000) and assay of enzyme activity in platelets has been 
proposed as a marker for the disease. Involvement of MAO-B in the pathophysiology of 
Parkinson's disease has been speculated by several investigators (Kinemuchi et al., 1993; 
Bongioanni et al., 1996; Andreu et al., 1997; Mellick et al., 1999). Both an increase and a 
decrease in platelet MAO-B activity has been reported in Parkinson's cases and it was 
suggested that such a differential effect could be due to substrate specificity of the enzyme 
(Humfrey et al. 1990). In a study on 6 drug free parkinsonians, Jarman et al (1993) reported 
an increase in platelet MAO-B activity using both phenylethylamine (PEA) and dopamine as 
substrates. One of the important facts in this context is that the use of MAO-B inhibitors like 
selegiline alone or in combination with L-dopa is a common therapeutic strategy for 
Parkinson's disease. Dose-dependent studies on selegiline alone and their effect on platelet 
MAO-B activity in Parkinson's cases have suggested the clinical efficacy of the drug (Andreu 
et al., 1997). Chronic exposure of rats to deprenyl and clorgyline increased striatal DA 
microdialysate levels at doses selective for inhibition of MAO-B and MAO-A respectively. It 
was suggested that chronic MAO-B inhibition leads to the build up of endogenous beta-
phenylethylamine (PEA) which inhibits DA-uptake and also causes the release of dopamine 
from the storage granules (Peterson et al., 1991; Berry et al., 1994). Age related increase in 
the activity of platelet MAO has been reported in a study on human subjects (Veral et al., 
1997). The activity of the enzyme was found to be higher in females as compared to males. 
In the present study, a decrease in the activity of platelet MAO-B was observed with respect 
to stage in Parkinson's cases. Though at present it is difficult to comment for such an effect 
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due to small sample size, it is possible that at early stage of the disease the activity of enzyme 
increases with the time and decreases due to high intake of the drug and comes down. The 
enzyme involved in the catabolism of dopamine and other biogenic amines, plays a pivotal 
role in modulating the disease state. The enzyme activity in the brain was found to be 
decreased in cigarette smokers and based on that an inverse risk of Parkinson's disease in 
smokers was suggested (Fowler et al., 1996; Franklin et al., 1997). 
Polymorphism of MAO is well documented and several studies to identify genetic 
polymorphism and susceptibility to Parkinson's disease have been carried out (Kurth et al., 
1993; Checkoway et al., 998; Mellick et al., 1999). Recently, Mellick et al (1999) in a study 
on Australian population reported that the 186 and >188 bp repeat alleles in intron 2 of the 
MAO-B genes are strongly associated with increased risk of Parkinson's disease and that the 
G-A polymorphism in intron 13 of the MAO-B gene is not associated with the risk of 
Parkinson's disease as reported earlier (Kurth et al., 1993). 
An increase in platelet MAO-B activity in Parkinson's cases, observed in the present study is 
consistent with earlier reports (Danielczyk et al., 1988; Bonucceli et al., 1990; Bongioanni et 
al., 1996). The duration of the disease does not seem to have an effect on MAO-B activity 
since in the present study no significant effect on platelet MAO-B activity was observed. In 
Parkinson's cases, however, a trend of decrease in the enzyme activity was observed in 
Parkinson's cases with respect to stage that was not significant. 
Recent advances in receptor biochemistry of serotonin have given important insight in to the 
mechanisms of migraine pain and treatment. Neurogenic inflammation resulting from 
antidromic stimulation of trigeminal fibres has been proposed as a possible pathogenic 
mechanism for migraine. The neurogenic anti-inflammatory activity is mediated by 
activation of 5-HT auto-receptors present in sensory fibres innervating blood vessels in 
duramater (Buzzi and Moskowitz, 1992). Experimental observations have shown that 5-HT 
inhibits evoked trigeminal nucleus firing via the 5-HT|B/ID receptor (Goadsby and Hoskin, 
1998). 
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The present findings of a significant increase in the equilibrium constant (Kj) in the migraine 
cases without any change in the maximum number of binding sites (Bmax) is in contrast to the 
two previous reports of decreased Bmax in migraine (Ribeiro et al., 1990; Govitrapong et al., 
1992). The decrease in Kd did not have any significant correlation with the clinical features 
of migraine like age, duration of disease, time since last attack and severity of disease as 
determined by headache index. The reported decrease of platelet serotonin receptors in 
patients with migraine could be due to an autoimmune reaction. However, no statistically 
significant difference was found in the frequency of platelets antibodies of known or 
unknown specificity in patients with migraine with/without aura as compared to controls 
(Schabetet al., 1998). 
A reduced 5-HT uptake has been reported in platelets obtained from migraine subjects during 
and within 5 days of migraine attack (Malmgren et al., 1980). This reduced uptake could be 
due to either a decrease in number of receptors or the affinity of the 5-HT receptors. The 
findings of the present study provide supportive evidence for the decrease in the affinity of 
the receptor. An earlier study has reported that the Michaelis Menten constant (Km) was 
significantly increased, as compared with control subjects, in attack free patients of migraine 
without aura and tension headache but not in those suffering from migraine with aura 
(Hannah et al., 1991). This finding was independent of age, sex, and presence of anxiety or 
depression and drug intake during the previous week. The difference however, appeared 
greater in the morning than in the afternoon. It was concluded that the 5-HT uptake sites of 
platelets of patients having migraine without aura or with tension headache have reduced 
affinity for 5-HT. 
A progressive increase in 5-HT expression on monocytes has been demonstrated during 
headache induced by isosorbide dinitrate in patients of migraine without aura before and after 
administration of sumatriptan. This increase may be due to the activation of 5-HT turnover 
and to the increased availability of 5-HT displaced by sumatriptan from cerebrovascular 
receptors during head pain (Martelletli et al., 1994). 5-HT2 binding sites are highly 
concentrated in middle layers of frontal cortex and are bound avidly to methylsergide, 
pizotifen and cyproheptadine (Peroutka, 1988). However, measurement of the brain 
radioactivity, positron emission tomography, after intravenous injection of '^F-
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fluorosetoperone (a 5-HT2 specific radioligand) has demonstrated no change in the age 
adjusted specific distribution volumes of ligand in migraineurs as compared to controls 
(Chabriat et al., 1995). Alteration of serotonin receptor function is one of the possible 
mechanisms of analgesic induced headache (AIH). A greater density of receptor number has 
been reported in patients with AIH and control as compared to migraine patients while the Kd 
was unchanged. Thus up-regulation of 5-HT2 serotonin receptors may be a possible 
mechanism of headache transformation in patients with AIH (Srikiatkhachorn and Anthony, 
1996). The up-regulation of serotonin receptors observed in patients of chronic daily 
headache (so called transformed migraine) provides support to the "serotonergic 
hypofunction theory" of migraine pathogenesis and may explain the unusual loss of 
episodicity seen in the transformed migraine patients. Further suppression of an already 
abnormal antinociceptive system with up-regulation of post synaptic receptors is one of the 
explanations of transformation of episodic migraine to chronic daily headache 
(Srikiatkhachorn et al., 1994). The decrease in 5-HT2 receptors that occurs with ageing may 
account for the tendency of migraine to improve or disappear with increasing age (Raskin, 
1988). 
In terms of migraine pathogenesis, the evidence regarding involvement of serotonin receptors 
remains ambiguous. On the one hand there a long standing implied role for serotonin 
mobilisation and deletion during migraine attack, suggesting that a tonic activation of 
serotonin receptors is in some way crucial to a normal modulation of cranial nociception. On 
the other hand, drugs that activate specific serotonin receptor subtypes are clearly effective in 
the symptomatic treatment of an attack of migraine. Many of the most prophylactic drugs, 
including propranolol, block 5-HT2B receptors with a potency that matches the drug dose. 
Furthermore, the functional affinity of serotonin for this receptor subtypes is high, so that 
activation can be a dissipated serotonin concentration as low as 1 nmol per litre (Martin, 
1997). Perhaps such a dichotomy is not unreasonable given that as many as 14 distinct 5-HT 
receptors have now been identified. Although understandably circumstantial, this body of 
accumulated information continues to encourage the view that serotonin and serotonin 
receptors are somehow implicated in migraine pathogenesis (Johnson et al., 1998). One 
theoretical model envisages 5-HT a link between the neural and vascular systems, but the 
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gastrointestinal tract as well, with incidental reverberations on platelet functions. Such 
altered serotonergic transmission might originate from altered 5-HT dynamics, a molecular 
change in turn produced by genetic mechanisms. 
The results clearly exhibit (i) that platelet DA-D2 receptors and MAO-B activity is high in 
Indian Parkinson's cases treated with L-dopa and that assay of platelet DA-D2 receptors and 
MAO-B activity could be used in monitoring the disease, (ii) the increase in the activity of 
platelet MAO-B in Parkinson's cases strengthen the notion of use of MAO-B inhibitors in the 
treatment of this disease and therefore could possibly be used as a tool to titrate the dose 
following treatment with the drug (iii) the involvement of platelet S-HTIA receptors in 
migraine strengthen the usefulness of platelets as a peripheral model. 
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SUMMARY & CONCLUSIONS 
It is well accepted that disturbances in the central synaptic transmission lead to a variety of 
neurological disorders. Numerous investigators have shown alterations in the levels of 
neurotransmitters due to change in activity of the enzymes involved in their synthesis, uptake, 
release and degradation. Neurotransmitter receptors depending upon the availability of their 
specific neurotransmitters at the site, exhibit alterations in their numbers and affinity. Such 
modulations in the receptor sensitivity have been observed in neurological disorders like 
Parkinson's disease, post traumatic seizure, Huntington's chorea, Alzheimer's disease and 
psychiatric disturbances such as schizophrenia and depressive disorders. Altered receptor 
sensitivity has also been reported on exposure to xenobiotics including drugs or after surgical 
destruction of specific neurons. 
Most of the direct information about the role of neurotransmitters in diseased conditions has 
been obtained using postmortem brain samples which are not reliable since conditions of 
collection and preservation of such samples are not uniform and there is hardly any choice of 
age, sex, or stage of the disease. Several techniques have been employed to quantitate the 
neurotransmitter receptors. Although the recent advances have lead to development in non-
invasive imaging techniques such as PET, SPECT and NMR for the assay neurotransmitters 
and neurotransmitter receptors in live brain. There are some limitations including the high 
cost of operation as well as expertise for their operation and interpretation of the data. The 
neuroscientists have therefore been interested in developing and validating a peripheral 
neuronal model, which can be used for the study of the neurotransmitter parameters in 
neuropsychiatric and neurotoxicological conditions. 
Circulating blood components such as lymphocytes and blood platelets have been used to 
study the uptake and release of certain neurotransmitters and neurotransmitter receptors. 
Alterations in the binding of ^H-spiperone to lymphocytes in Parkinsonism and Wilson 
disease and that ^H-dihydroalprenolol in depressed patients have reported. Several 
similarities between platelets and neuron with respect to morphology, biochemistry and 
pharmacology have further strengthened their usefulness as peripheral model. As the changes 
are specific and parallel with those observed in the brain, the assay of platelet receptors 
appears to be a useful tool for these studies. Such studies have not only helped in 
understanding the disease process but also in monitoring the disease condition during the 
course of treatment and follow up. With demonstration of several neurotransmitters and their 
receptor sites and related enzymes, platelets can be considered as multi-neurotransmitter sites 
similar to neurons. The use of blood platelets as a model system for the synaptic apparatus 
can however, be justified only for those parameters where it can be shown that blood platelets 
and nervous tissue share almost identical characteristics. Although platelets appear to be 
fascinating model to study the functions of brain, the mechanism by which dopamine and 
serotonin receptors are modulated is not clearly understood. The response of neurotoxicant 
and specificity to platelets is also not clear. Changes in the biochemical parameters in platelet 
such as neurotransmitter receptors and enzymes have been reported in disease condition or on 
exposure to toxicants but their validation is required to establish the use of platelets as 
peripheral model. 
In view of the above, present study was aimed investigate the mechanism of modulation of 
platelet DA-D2 and 5-HT2A, study the effect of selected neurotoxicants (Manganese, 6-
Hydroxydopamine and cypermethrin) on platelet and brain neurotransmitter receptors and 
membrane function parameters. Study was also aimed to investigate the status of platelet DA-
D2 and monoamine oxidase activity in idiopathic Parkinson's disease cases and status of 
platelet 5-HT2A receptor in clinical cases of migraine. 
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Studies on the Mechanism of IVIodulation of Dopamine-D2 and Serotonin-5-
HT2A Receptors in Platelets 
Both in vivo and vilro studies on human and rat platelets were undertaken to investigate the 
possible mechanism of modulation of DA-D2 and 5-HT2A receptors using selective 
pharmacological agent acting on dopaminergic and serotonergic systems respectively. 
Rats treated with reserpine at a dose of 1 mg/kg /day for 5 days showed a significant increase 
in the binding of ^H-spiperone to platelet (36%) and striatal (47%) membranes, known to 
label DA-D2 receptors as compared to controls. Reserpine at a dose of 5 mg/kg (single 
exposure) caused a decrease in the binding of ^H-spiperone to platelet (33 %) and striatal (44 
%) membranes at 18 hours after the treatment. Scatchard analysis revealed that the increase 
in the binding of ^H-spiperone to platelet and striatal membranes following daily reserpine 
treatment for 5 days and the decrease in binding following a single exposure was due to 
change in the affinity (Kd) with no significant change in the receptor number (B,„ax)-
Incubation of platelet rich plasma (PRP) with reserpine at both the concentrations, (1 |ig/ml 
and 2 ^ig/ml) caused a decrease in the binding of ^H-spiperone to platelet membranes by 37% 
and 42% respectively. It was, however, interesting to note that PRP preparations pre-
incubated with pargyline followed by incubation with reserpine showed a higher degree of 
decrease in the binding of ^H-spiperone to platelet membranes in comparison to those 
incubated with reserpine alone. A decrease in platelet ^H-spiperone binding was observed 
following incubation of PRP with dopamine (5, 15, 37 and 65%) and mazindol (2, 16, 30 and 
45%) at concentrations- 0.5, 1, 5 and lOnM respectively. 
Binding of ^H-ketanserin to platelet membrane known to label 5-HT2A receptors was found to 
be decreased following incubation of PRP with clomipramine (4, 20, 43 and 56%), 
fenfluramine (2, 42, 61, and 69%) and serotonin (46, 64, 68 and 83%) at concentrations - 0.5, 
1, 5 and 10 nM respectively. The results suggest that the availability of dopamine and 
serotonin at the site influence the sensitivity of DA-D2 and 5-HT2A receptors respectively in 
platelets as in the brain. 
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Effect of Manganese, 6-Hydroxydopamine and Cypermethrin on Selected 
Biochemical Parameters in Brain and Platelets 
With the understanding that the environmental chemicals like manganese (Mn) may cause 
extrapyramidal symptoms like Parkinsonism, there has been considerable interest to 
understand the possible mechanism of Mn induced neurotoxicity. Although there are 
convincing evidences concerning the role of dopamine in Mn neurotoxicity, several 
investigators have shown involvement of oxygen free radicals in the neurotoxic effects of this 
metal. As the occupational workers in the metal industries and mining are at a greater risk to 
Mn induced neurotoxicity, there is an urgent need of a validated peripheral test system which 
could be utilised to monitor such neurotoxicological disorders. Since blood platelets have 
been shown to reflect changes of the CNS and are proposed as a peripheral model, the present 
study was undertaken to investigate whether neurotoxic effect of Mn are reflected in platelets. 
Exposure of Mn (10 or 15 mg/kg bw, i.p) in adult rats for 45 days caused a significant 
increase in membrane fluidity as evidenced by decreased fluorescence polarisation (platelets 
11 and 14%, striatum 9 and 13%), intracellular calcium (platelets - 25 and 38%, striatum - 28 
and 40%) and superoxide dismutase (platelets - 23 and 37%, striatum - 31 and 42%) activity 
both in platelets and striatum in comparison to controls. A significant decrease was observed 
in the reduced glutathione content (platelets - 22%, striatum - 25%) and catalase activity 
(platelets - 35%, striatum - 44%) following exposure to Mn at a dose of 15 mg/kg body 
weight. Exposure of Mn at both the doses for 15 days also caused an increase in the binding 
of ^H-spiperone to striatal and platelet membranes in comparison to controls. The results 
suggest that exposure to Mn may alter the membrane functions and also impair the 
antioxidant defense mechanism both in the platelets and brain. 
Selective lesioning with 6-OHDA into brain causes destruction of nigrostriatal dopamine 
containing neurons and lead to behavioural and biochemical deficits. Earlier studies have 
shown the involvement of free radical mediated neurotoxicity in 6-OHDA lesioned rats and 
their effect on membrane related functions. In order to investigate whether neurotoxic effects 
of 6-OHDA are reflected in platelets, the present study was undertaken on rats and effect on 
selected biochemical parameters studied both in corpus striatum and platelets. Rats lesioned 
with 6-OHDA exhibited a significant increase in striatal dopamine receptors (61%), lipid 
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peroxidation (38%) and intracellular calcium (83%) and a decrease in reduced glutathione 
levels and membrane fluidity as evidenced by an increase in fluorescence polarization (20%) 
in comparison to sham. Interestingly, a significant increase in the binding of ^H-spiperone to 
platelet membranes (43%) was observed in the 6-OHDA lesioned rats however, marginal 
changes were observed in all other parameters in platelets in these rats. The results suggest 
that alterations in striatal dopamine receptors following bilateral lesioning be reflected in 
platelets. 
Cypermethrin, a type II synthetic and photostable pyrethroid of high bio-efficacy is widely 
used in agriculture for pest management. Several reports exhibit its adverse effects on the 
CNS and cardiovascular functions. As the pesticide has been shown to be persistent in the 
environment and detected in mammalian tissues, it can pose risk to human health. Keeping 
this in view, studies were carried out to understand the mechanism of neurotoxicity and 
investigate whether such changes are reflected in platelets on selected biochemical 
parameters to validate usefulness of platelets as a peripheral model. Effect of cypermethrin 
(15 or 30 mg/kg) was studied on membrane fluidity, intracellular calcium, monoamine 
oxidase activity and DA-D2 receptors both in the platelets and brain of rats after 10 and 21 
days of exposure. A decrease in fluorescence polarization (7 and 12%) and monoamine 
oxidase activity (34 and 62%) in platelets was observed like corpus striatum (fluorescence 
polarization 8 and 13%, monoamine oxidase activity 29 and 49%) following exposure to 
cypermethrin for 21 days at both the doses i.e. 15 and 30 mg/kg respectively in comparison to 
controls. These rats also exhibited an increase in intracellular calcium levels (platelets - 24 
and 40%; corpus striatum -29 and 54%) 21 days after exposure at both the doses. 
Cypermethrin treatment in rats for 21 days also caused a decrease in the binding of ^H-
spiperone to platelet (36 and 49%) and striatal membranes (36 and 46%). No significant 
change on these parameters was observed in rats 10 days after exposure to cypermethrin at 
both the doses. Saturation studies revealed that the decrease in binding both in platelets and 
corpus striatal membranes was due to decreased maximum number of binding sites (B,nax) 
without any significant change in the affinity (Kd). Interestingly, changes in these 
biochemical parameters were restored to control values at the lower dose (15 mg/kg) and 
persisted at the higher dose (30 mg/kg) of cypermethrin both in platelets and corpus striatum 
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following cessation of treatment for 10 days in the 21 days cypermethrin exposed group. The 
results suggest that exposure to cypermethrin may alter the membrane functions and 
dopaminergic functions, which are evident both in platelets and brain. 
Status of Some Biochemical Parameters in Platelets of Idiopathic Parkinson's 
Disease and Migraine Patients 
Parkinson's disease (PD) is a crippling neurodegenerative disease, which results from 
degeneration of dopaminergic neurons responsible for dopamine loss in the striatum. Various 
studies have shown the alteration in the dopamine receptors and monoamine oxidase activity 
in the brain of PD patients. Platelets have been used as peripheral neuronal model to study the 
reflections of brain biochemistry in PD. In the present study of dopamine (DA-D2) receptors 
and monoamine oxidase activity were measured in platelets of PD patients. Binding of ^H-
spiperone to platelet membranes known to label DA-D2 receptors was assayed in clinical 
cases of PD (n=25) and control subjects (n=13). The binding characteristics: equilibrium 
dissociation constant (Kd) and maximum number binding sites (Bmax) determined by 
scatchard analysis revealed a significant increase in the Bmax and no change in the affinity in 
the cases of Parkinson's disease in comparison to controls. A significant increase in the 
activity of monoamine oxidase was observed in Parkinson's cases in comparison to controls. 
No significant change in these parameters was observed while the data were analysed with 
respect to age, sex and clinical variables viz. duration and stage of disease. Results suggest 
alterations in the DA-D2 receptors and monoamine oxidase activity in platelets in Parkinson's 
disease. 
There is increasing evidence about the role serotonin in the pathogenesis of migraine and 
much attention has been focussed on understanding the functioning of serotonin receptors as 
its agonists have been found to alleviate the migraine pain. Keeping in view that platelets 
serves as a peripheral neuronal model, binding of ^H-ketanserin to platelet membranes known 
to label 5-HT2A receptors was investigated in clinical cases of migraine (n=33) and control 
subjects (n=30). The binding characteristics: equilibrium dissociation constant (Kj) and 
maximum number binding sites (Bmax) determined by scatchard analysis revealed a 
significant decrease in the affinity and no change in the Bmax in the cases of migraine in 
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comparison to controls. However no correlation was observed in K j and Bmax with respect to 
clinical features of migraine like duration disease, time since last attack, headache index, 
family history and type of migraine. The results of the study suggest alteration in the 
sensitivity of platelet 5-HT2a receptors in migraine. 
Conclusions 
The results of present study indicate that the availability of serotonin and dopamine at the site 
influence the sensitivity of 5-HT2a and DA-D2 receptors respectively in platelets and brain. 
Results of manganese exposure show that neurotoxicity of manganese mediates through 
increased oxidative stress and altered membrane functions as indicated by increased 
superoxide dismutase activity, membrane fluidity, intracellular calcium levels and decrease in 
catalase activity and reduced glutathione levels in both platelets and platelets. Manganese 
exposure also caused a parallel increase in dopamine receptors in platelets and brain. 
Cypermethrin a commonly used pesticide appear to exert its neurotoxic effects by altering 
membrane functions, which in turn probably, decrease the density of dopamine receptors. 
Study also shows that changes at higher dose of cypermethrin were persistent. The changes 
observed in brain were also exhibited in platelets. 
A result of 6-Hydroxydopamine lesioning in striatum shows parallel increase in dopamine 
receptors in platelets and brain. 
Parallel changes in platelets and striatum strengthened the usefulness of platelets as neuronal 
model for monitoring the changes induced by exposure to these chemicals. 
Results of clinical studies show that platelet DA-D2 receptors and monoamine oxidase-B 
(MAO-B) activity is high in Indian cases of Parkinson's disease treated with L-dopa. Results 
of clinical studies also reveal that affinity of platelet 5-HT2A receptors decreased in migraine 
patients. These studies suggest that assay of platelet DA-D2 receptor and MAO-B activity in 
Parkinson's disease and 5-HT2A receptors in migraine could be useful in monitoring the 
disease condition. 
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